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Abstract 
Astrocytes in culture display large cytosolic calcium increases upon stimulation with 
dopamine, however the mechanism and physiological significance of this calcium 
response is still unknown. In this thesis, I demonstrate that hippocampal astrocytes 
in situ respond to dopamine with similar large calcium transients. I also describe a 
novel astrocyte calcium decrease, which appears specific to dopaminergic 
stimulation. Dopamine is a potent neuromodulator of hippocampal synaptic 
activity, as are astrocytes. However, I found no evidence to suggest that dopamine-
induced calcium transients in astrocytes affect excitatory synaptic transmission and 
its short-term plasticity in the hippocampal stratum radiatum. In perforant path - 
CA1 pyramidal synapses of stratum lacunosum-moleculare, astrocytes were found 
to lessen the inhibitory effect of dopamine on evoked PTP. This work shows for the 
first time that astrocytes in situ can robustly respond to dopamine with a complex 
Ca2+ signal thus may participate in dopaminergic signalling in the brain.  
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Chapter 1: Introduction 
 
1.1 Astrocytes: structure, function and calcium dynamics 
 Virchow (1856) is commonly credited with first describing glial tissue as separate 
from the neuronal cells of the brain. Until recently, their function was considered limited to 
metabolic support of neurons and homeostatic control of the extracellular milieu. The 
difficulty of studying them has often been prohibitive (Somjen 1988), but in the last 20 
years, we have begun to uncover wide-ranging exciting new glial functions (thanks largely 
to advances in live cell fluorescence imaging technology). Glia fall into two main groups: 
microglia and macroglia – of different developmental origin, morphology and function. 
Macroglia includes astrocytes, oligodendrocyts and NG2 cells , of which astrocytes are the 
subject of this thesis. Astrocytes play a crucial role in neurodevelopment, during which time 
they are pluripotent and can differentiate into neurons, mature astrocytes or NG2 cells, as 
well as providing scaffolding for neuronal migration and regulating synaptogenesis 
(Molofsky et al. 2012). In the adult brain astrocytes regulate uptake of essential chemicals 
and ions from the blood at the glial-vascular interface, forming a part of the blood-brain 
barrier, as well as controlling the volume of blood circulation through capillary 
constriction(Cavelier and Attwell 2005). They create the microarchitecture of the brain 
tissue through their characterstic shape, separating individual synapses (Clarke and Barres 
2013) and have recently been suggested to influence synaptic transmission through the 
release of various neuroactive compounds (Perea et al. 2009). Very importantly, they 
provide metabolic support for energy-intensive neurons (Pellerin 2005) – supplying them 
with lactate. They remove glutamate from the synaptic cleft after presynaptic 
release(Danbolt 2001) and buffer extracellular potassium, keeping it at low enough 
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concentrations to avoid local neuronal depolarization (Butt and Kalsi 2006). They are widely 
implicated in the pathogenesis of mental diseases including epilepsy, Parkinson’s disease 
and Alzheimer’s disease (Verkhratsky and Parpura 2010). In this thesis I am interested in 
the role of astrocytes in the modulation of synaptic transmission – I investigate the possible 
involvement of astrocytes in the dopaminergic modulation of synaptic transmission. 
 
1.1.1 Astrocytic morphology 
Astrocytes are found throughout brain tissue and are highly heterogenous in their 
morphology (Miller and Raff 1984) – this thesis deals solely with protoplasmic astrocytes, so 
called because the fine branching of their processes forms a cloud under light microscopy, 
although many other kinds exist and differ between species (Verkhratsky and Butt 2007). 
Hereafter protoplasmic astrocytes are referred to simply as astrocytes. In the forebrain, 
astrocytes have relatively small somata (8-10μm diameter) and multiple large processes 
that are visible under light microscopy (figure 1.1a). But imaged with fluorescence 
microscopy, their processes are highly ramified, closely covering the membranes 
throughout their entire territories, around 23,000μm3, which can contain up to 600 
synapses (Bushong et al. 2002; Halassa et al. 2007) – see figure 1.1b. Their processes 
enwrap blood-vessels and individual synapses, and these astrocytic process territories 
overlap very little with each other (figure 1.1c). Astrocytes are not completely mobile 
(unlike microglia), but they can change the extent to which they enwrap neighbouring 
synapses throughout the brain (Oliet et al. 2001; Theodosis et al. 2008). Their processes are 
also mobile and can form lamellipodia and filopodia-like structures (Hirrlinger et al. 2004). 
These morphological changes can influence synaptic physiology: in the hypothalamus, the 
astrocytic morphological changes induced by changes oxytocin release during lactation 
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Figure 1.1 Protoplasmic astrocyte morphology. 
a) Human hippocampal astrocytes stained with ammoniacal silver oxide method from Ramon y 
Cajal’s original slides; b) Rat CA1 hippocampal astrocyte filled with fluorescent dye Alexa 488 and 
imaged with confocal laser microscopy; c) Two rat CA1 hippocampal astrocytes filled with 
fluorescent dyes – Alexa 488 (green), Alexa 568 (red) – from a patch pipette, do not occupy 
overlapping territories. a) adapated from Garcia-Marin et al. 2007 (Fig.3b); b) adapted from Bushong 
et al. 2002 (Fig.1b); c) adapted from Bushong et al. 2002 (Fig.3c).  
 
have been shown to decrease presynaptic transmitter release (Oliet et al. 2001) and 
modulate induction of long-term potentiation (LTP) and depression (LTD) (Panatier et al. 
2006). In striatal tissue from parkinsonian sufferers, the astroglial coverage of the synapse 
is increased (Villalba and Smith 2011). Protoplasmic astrocytes change their morphology 
upon pathological stimulation, increasing GFAP expression and the thickness and length of 
their processes (Sun and Jakobs 2012) – astrocytes that have undergone this change are 
considered ‘reactive’. Healthy astrocytes form a functional syncytium, their cytoplasmata 
are connected by gap-junctions and this allows the flow of current, ions, metabolites and 
other small molecules between cells (Sohl and Willecke 2004; Giaume et al. 2013). 
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1.1.2 Astrocytic role in homeostasis 
Astrocytes buffer extracellular K+ through inwardly rectifying K+ channels (Hertz 
1965; Higashi et al. 2001) and through the Na+/K+/2Cl- cotransporter. Astrocytic membranes 
are highly polarized, K+ with their resting potential lower than the K+ reversal potential. 
Hence K+ flows down it’s electrochemical gradient, through these membrane channels, into 
the astrocyte – here it is redistributed throughout the reservoir of the astrocytic syncytium 
along its concentration gradient, eventually to be excreted into the blood through inwardly 
rectifying K+ channels (Verkhratsky and Butt 2007). They take up glutamate released into 
the extracellular space through perisynaptically concentrated glutamate transporters, using 
the Na+ and K+ electrochemical gradients across the cell membrane (Bergles and Jahr 1997). 
Once in the intracellular milieu, glutamate is broken down into glutamine which is not 
physiologically active at the synapse and can be released into the extracellular space and 
taken up by the presynaptic terminal to be converted back into glutamate and released 
again (Parpura and Haydon, 2009). They play a very important role in metabolic support of 
neurons (that are far more energy intensive) through provision of lactate: astrocytes 
convert glucose to lactacte and then release it to be taken up by presynaptic neuronal 
terminals and converted into pyruvate and then ATP, to fuel neurotransmitter 
release.Although astrocytes play a key role in brain metabolism, I go into no further detail 
here (please see Parpura and Haydon (2009) for further information), as the focus of this 
thesis is astrocytic Ca2+ signalling and its potential effects on synaptic transmission. 
 
1.1.3 Studying astrocytic calcium dynamics 
A major turning point in the understanding of astrocyte function was the discovery 
that they exhibit both spontaneous (Cornell-Bell et al. 1990) and evoked (Porter and 
McCarthy 1996) changes in intracellular free Ca2+ (figure 1.2). Our first inklings as to  
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Figure 1.2 Astrocyte calcium signals. 
a) CA1 hippocampal astrocyte filled with cell-impermeable Alexa 594 (morphological tracer) and 
OGB-1 (calcium indicator) imaged through the Alexa 594 channel; b) Calcium-dependent 
fluorescence transients in response to HFS; i) enlarged dotted square region of a) ii) line scan of 
region indicated by dotted arrow in bi – Alexa 594 fluorescence after HFS (hollow arrow); iii) as in bii) 
but calcium indicator (OGB-1) channel; iv) normalized change in fluorescence of Alexa 594 (red) and 
OGB-1 (green) in bii) and biii) respectively. c) CA1 hippocampal astrocytes filled with AM-dye Calcium 
Green-1 AM. d) Calcium-dependent fluorescence transients in response to HFS in astrocyte regions 
indicated in c). a), b) adapted from Henneberger et al. (2010), Supp. Fig. 2a, b. c), d) adapted from 
Porter and McCarthy (1996) fig. 3a, b.  
 
the nature of cytoplasmic Ca2+ dynamics and the potential role of intracellular Ca2+ in 
astrocytes came from electrophysiology. In 1989, Barres et al. recorded inducible, voltage-
sensitive Ca2+ currents in whole-cell patch-clamped cultured astroglia. Before them, Quandt 
and MacVicar (1986) had found that Ca2+ concentration at the internal surface of excised 
astrocytic membrane could control its permeability to potassium (K+) ions. However, it was 
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the use of Ca2+-sensitive fluorescent dyes that first allowed the visualization of their 
complex intracellular Ca2+ activity. The first dyes to be used were based on acetoxymethyl 
(AM) esters (Cornell-Bell et al. 1990). These dyes are initially liphophilic and capable of 
crossing cell plasma membranes, but they are cleaved in a reducing environment (such as 
inside the cytosol) to become hydrophilic, preventing them from diffusing back out of the 
cell. Membrane-impermeable Ca2+ indicators can also be loaded into cells through patch 
pipettes (Perea and Araque 2005): both calcium-imaging methods are used in this thesis. 
 
1.1.4 Spontaneous astrocytic calcium activity 
Spontaneous changes in cytosolic Ca2+ concentrations can be witnessed in culture 
(Fatatis and Russell 1992; Shigetomi et al. 2011), in slice (Parri et al. 2001) – see figure 1.2 –  
and in vivo (Hirase et al. 2004). This activity is intracellular Ca2+ store-mediated – it can be 
triggered by Ca2+ binding to the IP3 receptor on the smooth endoplasmic reticulum (an 
intracellular reservoir of Ca2+) (Parri and Crunelli 2003). Similarly inositoltrisphosphate (IP3) 
can stimulate the opening of the IP3R and is also temperature-dependent (Wang et al. 
2006; Petravicz et al. 2008; Schipke et al. 2008) and affects neuronal activity in turn (Parri et 
al. 2001; Aguado et al. 2002; Kanemaru et al. 2007; Bonansco et al. 2011), although this is 
still controversial (Nett et al. 2002). In this thesis, spontaneous activity is taken to mean any 
changes in local Ca2+ activity visible without prior stimulation of the imaged cell(s). 
 
1.1.5 Astrocytic calcium response to neurotransmitter release  
 The astrocytic Ca2+ transients induced by released neurotransmitter have only been 
studied in depth in the last 20 years and their mechanism of action and physiological 
function are still sometimes controversial. Astrocyte Ca2+ can be increased through voltage 
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gated calcium channels (VGCCs), reverse of the Na+/Ca2+ exchanger, from mitochondria, 
from Ca2+ permeable ionotropic receptors and from metabotropic receptor-mediated 
release from the endoplasmic reticulum (ER)  (Verkhratsky et al. 2012; Rusakov et al. 2014). 
This latter form of Ca2+ increase is currently considered one of the most important in 
astrocyte signalling and is strongly potentiated by the presence of IP3, a 2
nd messenger that, 
along with Ca2+ itself, is a ligand for the IP3 receptor (type 2 in rat adult astrocytes 
(Holtzclaw et al. 2002))on the ER (Foskett et al. 2007). Knock out of the IP3R in astrocytes 
blocks both spontaneous and evoked astrocytic Ca2+ events (Petravicz et al. 2008).The 
effect of dopamine on astrocytic Ca2+, the subject of this thesis, is poorly characterized; 
however an understanding of the modes of action of other, better characterized, 
neurotransmitters on astrocyte Ca2+ will aid the elucidation of any possible dopaminergic 
action on Ca2+. 
 Much of the original work on neurotransmitter-induced astrocyte Ca2+ transients 
was carried out in cell culture systems. Exogenous application of glutamate was found to 
induce intracellular astrocytic Ca2+ transients (Cornell-Bell et al. 1990) mediated by an IP3 
increase (Pearce et al. 1986b; Jensen and Chiu 1990), via intracellular calcium stores 
(Charles et al. 1993). Similarly, ATP-induced intracellular Ca2+ activity was imaged in culture 
by McCarthy et al. in 1991, with ATP triggering intracellular IP3 release through purinergic-
2-Y receptor (P2YR) activation (Kastritsis et al. 1992; Porter and McCarthy 1995a). ACh 
application in culture also stimulates intracellular Ca2+ increases (Shao and McCarthy 1995), 
as does GABA (Nilsson et al. 1992; Nilsson et al. 1993), serotonin (Nilsson et al. 1991; 
Jalonen et al. 1997), adenosine (Marin et al. 1993), endocannabinoids (Navarrete and 
Araque 2008), TNFα (Koller et al. 1996), glucocorticoids (Simard et al. 1999); Prostaglandins 
(Bezzi et al. 1998), noradrenaline (norepinephrine) (Salm and McCarthy 1990) and, of 
course, dopamine (Parpura and Haydon 2000).  
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 However cultured astrocytes may not accurately represent astrocytic Ca2+ dynamics 
in situ: astrocytic mGluRs, through which Ca2+ transients can be stimulated (Porter and 
McCarthy 1996), are developmentally regulated – mGluR5 expression decreases and 
mGluR3 increases (Cai et al. 2000; Sun et al. 2013); as cultured cells  are often taken from 
very young animals their glutamatergic pharmacology may be different from cells in situ. 
Purinergic receptor P2Y has also been reported to be upregulated during development (Zhu 
and Kimelberg 2001) and GABAR expression changes developmentally as well, with GABABR 
responsiveness peaking at P11-15, then dropping by P33 (Meier et al. 2008). Cultured 
astrocytes show Ca2+ response to serotonin (Nilsson et al. 1991; Jalonen et al. 1997) – that 
could be modulated by mGluR activation (Haak et al. 1997) – but acutely isolated astrocytes 
have been reported to show no Ca2+ sensitivity to serotonin, developing it only after 
extended time under culture conditions (Kimelberg et al. 1997). ACh sensitivity is also 
developmentally mediated, becoming apparent only after p8 (Shelton and McCarthy 2000). 
Another important factor to consider is the very different morphology that astrocytes 
assume in culture – flat and solid instead of covering a spherical area with highly ramified 
processes (Bushong et al. 2002). These morphology of these processes creates 
compartmentalization throughout the astrocytic territory that form microdomains of Ca2+ 
events (Di Castro et al. 2011) that may well have functional importance (Rusakov et al. 
2014). Although culture systems allow for unparalled environmental control over cells, as 
well as avoiding the physical trauma associated with in situ preparations and often clearer 
conditions for live cell imaging, they suffer from the drawbacks noted above. Given this, it is 
very important to study neurotransmitter-evoked astrocytic Ca2+ dynamics in situ as a 
complementary approach to culture studies; this has been done for many of the 
transmitters listed above, as I go into below, but not yet for dopamine – the subject of this 
thesis. 
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What kinds of astrocyte Ca2+ responses have been already reported from in situ 
preparations? Bath application of mGluRI/5 agonists and ATP to hippocampal slices 
stimulated similar Ca2+ transients to those recorded from cultured cells (Porter and 
McCarthy 1995b; Porter and McCarthy 1995a) – see figure 1.5. High-frequency stimulation 
of the Schaffer collateral input to CA1, a more physiological stimulation paradigm, also 
triggered local astrocyte Ca2+ increases (Porter and McCarthy 1996; Zhu and Kimelberg 
2001; Henneberger et al. 2010). ATP can be endogenously released by both neurons and 
astrocytes (Fields 2011) but hippocampal astrocytes are thought to be the main source of 
ATP in the hippocampus (Pascual et al. 2005; Heinrich et al. 2012). It has been 
demonstrated that inhibition of tonic ATP release from astrocytes in hippocampal slices 
decreases astrocyte network Ca2+ response to glutamate stimulus (Sul et al. 2004); similarly, 
ATP application enhances glutamate-induced Ca2+ transients (Sul et al. 2004). Endogenously 
released ACh (Araque et al. 2002) and endocannabinoids (Navarrete and Araque 2010) have 
also been shown to stimulate astrocytic Ca2+ increases in the hippocampus.  
It is clear that the hippocampal astrocytes, in situ, are responsive to challenge from 
multiple neurotransmitters and many of these Ca2+ transient-evoking metabotropic 
intracellular pathways are common to dopamine receptor pathways. mGluR type I 
stimulation increases PLC and IP3, as does D2-type receptor stimulation, mGluR type II 
stimulation decreases cAMP – an effect also shared with D2-type receptors. Purinergic P2YR 
activation also activates PLC (Illes et al. 2012) and IP3 production in astrocytes.  Adenosine 
also raises intracellular IP3 and also enhances glutamate-induced astrocyte Ca
2+ signals 
(Ogata et al. 1994) and acetylcholine-induced Ca2+ signals (Ferroni et al. 2002). It can also 
raises intracellular cAMP (Ogata et al. 1996). Thus astrocytes express common intracellular 
machinery required for metabotropic dopaminergic signalling – the subject of this thesis – 
in situ and in vitro. In section 1.5, I will review in detail the current literature regarding 
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dopaminergic signalling in astrocytes, but first I will briefly discuss non-neurotransmitter-
induced astrocytic Ca2+ transients. 
 
1.1.6 Stimulating astrocytic Ca2+ signals without neurotransmitters  
Astrocyte Ca2+ transients can be triggered through other stimuli: mechanical 
stimulation (Charles et al. 1993); pH change (Gourine et al. 2010) and osmolarity change 
(Fischer et al. 1997). Transient receptor potential channels (TRPCs) are expressed in 
astrocytes (Golovina 2005; Malarkey et al. 2008) and their activation triggers calcium influx 
(Grimaldi et al. 2003; Malarkey et al. 2008) which has been implicated in refilling 
intracellular calcium stores through regulation extracellular calcium influx. Transient 
receptor potential A1 (TRPA1) channels have been reported to mediate astrocytic basal Ca2+ 
levels and also give rise to a stereotyped ‘spotty’ spontaneous calcium signal in cultured 
astrocytes (Shigetomi et al. 2011; Shigetomi et al. 2013). Similarly TRPV4 channels, 
expressed in astrocytic endfeet onto blood vessels, mediate Ca2+ transients (Dunn et al. 
2013). Depletion of intracellular Ca2+ stores by release of Ca2+ into the cytosol triggers 
relocation of the SER to the plasma membrane through interaction of the ORAI1 and STIM1 
proteins. Calcium then enters from the extracellular space, through ORA1 into the SER to 
refill it. By expressing an exogenous Gq-coupled receptor specifically on astrocytes – the 
MRGA1 receptor – it is also possible to artificially induce increases in astrocytic Ca2+ (Fiacco 
et al. 2007). There is also evidence for VGCC-mediated Ca2+ increase, one that is secondary 
to mGluR activation (Pearce et al. 1986a) and interacts with store-mediated Ca2+ signals 
(Glaum et al. 1990); astrocytes express certain VGCC subtypes (Parpura et al. 2011) and it is 
possible that the astrocyte plasma membrane may become sufficiently depolarized in 
certain places (near local hotspots of neuronal activity for example) to allow them to open 
– their activity can be modified by metabotropic receptor, and specifically by D1-type 
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receptor activation (Surmeier et al. 1995), making them a potential pathway for dopamine-
induced Ca2+ transients. However, it is important to note that, were VGCCs an important 
player in astrocytic calcium signals, one would expect that astrocytic depolarization 
(through K+ manipulation for example) would trigger widespread astroytic calcium activity 
and downstream activity – but this is not the case. That said, it is not possible 
experimentally to locally depolarize small astrocyte subregions in a physiological manner, 
which may be necessary for VGCC opening to trigger downstream cascades. 
 
1.2 Physiological relevance of astrocyte Ca2+ activity  
1.2.1 Astrocytic release of neurotransmitter: gliotransmission 
As soon as the clear astrocytic Ca2+ response to wide-ranging stimuli became 
apparent, the burning question was whether this triggered astrocytic communication with 
neighbouring neurons via release of neuroactive compounds – ‘gliotransmission’.  
Astrocytes have often been shown to contain the necessary cellular machinery for 
release of transmitter molecules: they express the vesicular docking proteins synaptobrevin 
II, cellulobrevin, syantaxin and SNAP23 (Parpura et al. 1995; Hepp et al. 1999) necessary for 
vesicular release. This release machinery is activated by the presence of intracellular Ca2+ 
and is regulated by tonic TNFα (Santello et al. 2011). Cleavage of astrocyte soluble NSF 
attachment protein receptor (SNARE) proteins with botulinum B toxin inhibits their release 
of glutamate (Araque et al. 2000) and also their release of d-serine (Henneberger et al. 
2010) and they have been shown to exhibit ‘kiss-and-run’-style vesicle secretion (Chen et al. 
2005). Astrocytic lysosomal exocytosis of ATP, mediated by intracellular Ca2+ concentration, 
has also been reported (Zhang et al. 2007), as has transmitter release from spontaneously 
opening hemi-channels (Contreras et al. 2002; Kang et al. 2008). Astrocytes can also release 
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glutamate through reversal of the Glutamate transporter, anion channel opening after cell 
swelling and action of the cysteine-glutamate antiporter (Malarkey and Parpura 2008). 
Arachidonic Acid release from astrocytes in response to ATP (Bruner and Murphy 
1990; Murphy and Welk 1990) and glutamate stimulation (Stella et al. 1994) were the first 
to be shown, and intracellular Ca2+-dependent glutamate release from astrocytes was soon 
demonstrated in culture (Parpura et al. 1994), using non-physiological agonists. Later it was 
found that more physiological stimulation of astrocytes (although still in culture) increased 
intracellular Ca2+ in excess of levels that could stimulate glutamate release (Parpura and 
Haydon 2000), although it is important to bear in mind that any external agonist applied in 
culture will not have the same spatio-temporal stimulation properties displayed in situ. In 
thalamic slices, spontaneous Ca2+ oscillations have been suggested to drive slow NMDAR-
mediated currents (Parri et al. 2001) and fast AMPAR-mediated currents in hippocampal 
slices (Fiacco and McCarthy 2004) – but this is controversial: Fiacco et al. (2007) strongly 
refute their original work, finding that artificially induced Ca2+ increases do not induce 
neuronal currents – the nature of the induced Ca2+ increase, not simply an increase in Ca2+ 
alone, has now been shown to affect whether an astrocyte will release glutamate (Wang et 
al. 2013b; Rusakov et al. 2014). 
Astrocytes control GABAergic inhibition in mouse barrel cortex (Benedetti et al. 
2011), glia in the cerebellum have been found to tonically release GABA (Lee et al. 2010) 
and cultured human astrocytes can also release GABA (Lee et al. 2011). Astrocytes can also 
release ATP – which is broken down extracellularly to form Adenosine (Cotrina et al. 1998) 
– which plays a role both in communication with neurons (Pascual et al. 2005) and between 
astrocytes themselves (Guthrie et al. 1999) – this ATP release can be stimulated by 
glutamate (Queiroz et al. 1999) and pH-sensitive ATP release from astrocytes has been 
shown to propagate astrocyte Ca2+ transients in acute and organotypic brain stem slices 
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(Gourine et al. 2010). Astrocytes have also been reported to release d-serine (Panatier et al. 
2006; Henneberger et al. 2010) this d-serine release is, SNARE-mediated, and is reported to 
be regulated by basal Ca2+ concentration mediated by TRPA1 channels (Shigetomi et al. 
2013), nitric oxide (NO) (Janigro et al. 1996), NGF and S-100B (Ciccarelli et al. 1999; Chang 
et al. 2005) 
. 
1.2.2 Astrocyte Ca2+-mediated control of gliotransmitter release 
It is well-accepted that astrocytes can release gliotransmitters, but whether such 
release is dependent on the Ca2+ dynamics reported in the literature is still controversial, as 
is the possibility of gliotransmission in vivo. The first studies to look at astrocyte 
contribution to neuronal function, were in acute hippocampal slices: Fellin et al. (2004) 
documented an increase in CA1 pyramidal cell NMDAR response synchrony upon 
stimulated Ca2+ increase in the astrocytic network – from either mGluR stimulation or 
intracellular Ca2+ uncaging; intracellular Ca2+ release into the cytosol is considered to be the 
predominant mechanism for astrocytic glutamate release (Parpura et al. 2011). IP3 uncaging 
in astrocytes has been shown to increase glutamate release probability in adjacent CA1 
pyramidal cells (Fiacco and McCarthy 2004) and in 2007, Perea and Araque showed that 
inducing large Ca2+ transients in astrocytes  (by puffing ATP or uncaging Ca2+) whilst 
simultaneously depolarizing adjacent neurons, could induce neuronal long-term 
potentiation (LTP) through mGluR activation – and the same group later showed 
endocannabinoids could trigger such a Ca2+ increase (Navarrete and Araque 2010). Cytosolic 
Ca2+ -mediated astrocytically released glutamate (Jourdain, Bergersen 2007) controls 
synaptic strength in dentate gyrus and cortical UP states (Poskanzer and Yuste 2011). 
Henneberger et al. (2010) used a subtle approach: blocking all Ca2+ activity in hippocampal 
CA1 astrocytes – by ‘clamping’ their intracellular Ca2+ – and demonstrating an astrocytic 
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control of LTP, mediated by D-serine release. Astrocytes have been found to mediate spike 
timing-dependent LTD via endocannabinoid signalling (Min and Nevian 2012). Astrocyte-
derived ATP can excite interneurons, thus inhibiting excitatory transmission, in the 
hippocampus (Bowser and Khakh 2004; Lalo et al. 2014); astrocytes also control 
chemosensory neurons through ATP release, via intracellular Ca2+ increase, in the brainstem 
(Gourine et al. 2010). Di Castro et al. (2011) show that local spontaneous astrocyte Ca2+ 
activity is necessary for synaptic transmission reliability. Knock-out of astrocytic SNARE-
dependent gliotransmission also effects sleep behaviour in mice (Halassa et al. 2009) and 
sleep loss-induced deficits via changes in hippocampal synaptic plasticity (Florian et al. 
2011). Astrocyte Ca2+ also regulates brain blood flow (Zonta et al. 2003). 
There are two major lines of argument against the physiological role of certain 
astrocyte Ca2+ activity. The first pioneered a method that artificially creates  Ca2+ transients 
within astrocytes: Fiacco et al. (2007) created a transgenic mouse expressing a extracellular 
membrane receptor to an exogenous ligand – MRGA1; these Gq-linked MRGA1 receptors, 
when activated, trigger long-lasting astrocytic Ca2+ transients via increase in intracellular, IP3 
but this group reported no effect of increasing astrocytic Ca2+ in this manner on 
glutamatergic currents in hippocampal CA1 pyramidal neurons or neuronal LTP induction 
(Agulhon et al. 2010). This conflict serves to highlight an important limitation in the 
literature – often ‘Ca2+ transients’ are reported after only having been imaged in specific 
areas of an astrocyte (in the case of Fiacco et al. (2007) the soma and large processes), 
whereas the astrocytic Ca2+ activity relevant to neuronal function may take place in the 
finer processes, neighbouring the synapses. This could explain how they report MRGA1-
induced Ca2+ transients in astrocytes, but see no change in neuronal activity. It is also 
important to note that activation of astrocytic Ca2+ transients via MRGA1 receptor 
activation does induce a phenotypic response – the mouse analogue of depression (Cao et 
al. 2013). 
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The second major line of evidence  comes from the same group, who showed that 
genetic knock-out of the astrocytic IP3 receptor 2 displayed no Ca
2+ response to g-protein 
receptor activation and showed no difference regarding neuronal baseline activity (as 
measured by spontaneous neuronal EPSCs in hippocampal CA1 pyramidal cells and tonic 
NMDAR-mediated currents)  (Petravicz et al. 2008) or potentiation (Agulhon et al. 2010). 
This mouse is a constuitive knock out, and it may be that astrocytes in this mouse have 
developmentally upregulated other Ca2+ sources – VGCCs, TRP channels, hemi-channels for 
example – and that Ca2+ signalling still exists at a low level in astrocytes. Or it may indicate 
that whilst astrocytic involvement in neuronal activity is important in normal brain tissue, 
neurons possess the homeostatic machinery to compensate in a developmental 
environment lacking astrocytic Ca2+ signalling. Recently this mouse has been found to show 
MRGA1-mediated astrocyte Ca2+ increases in vivo that stimulate ATP release and 
concomitant behavioural change related to depression (Cao et al. 2013) – further muddying 
the waters. 
Astrocytes can communicate with each other through intracellular Ca2+ waves 
(Venance et al. 1997; Scemes and Giaume 2006) and Ca2+-mediated release of 
gliotransmitters, specifically ATP. This was first postulated in 1996 (Hassinger et al. 1996) 
with the observation that astrocytes could propagate Ca2+ waves over an astrocyte-free 
space of over 100μm, propagation that could be blocked by purinergic receptor blockers 
(Guthrie et al. 1999). Imaging ATP release from cultured astrocytes confirmed that they can 
spontaneously release ATP (Arcuino et al. 2002). In vivo, Gourine et al. (2010) have shown 
that this inter-astrocyte ATP-mediated signalling controls chemoreceptor neuron activation 
in the brainstem. Astrocyte-derived ATP has also been implicated in local astrocytic Ca2+ 
activity synchronization and regulation of cortical UP states (Poskanzer and Yuste 2011). 
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1.2.3 Astrocytic Ca2+ signalling and neurological disease 
 Abnormalities in astrocyte Ca2+ signalling have been correlated with neurological 
disorders. Astrocytic intracellular resting Ca2+ concentration and synchronous activity was 
found to be higher in mice with the amyloidβ (Aβ) plaques (a symptom of Alzheimer’s 
disease) (Kuchibhotla et al. 2009) – this Ca2+ increase has been shown to act through Aβ 
stimulation of astrocytic α7 nAChRs, which in turn trigger synaptotoxic release of astrocytic 
glutamate (Talantova et al. 2013) – although a direct link between astrocyte Ca2+ 
dysfunction in Alzeimer’s and the disease initiation and progression is still controversial 
(Lim et al. 2014) Astrocytic glutamate release – triggered by intracellular Ca2+ increase – has 
also been shown to trigger the paroxysmal depolarizing shifts seen in epileptic discharges 
(Tian et al. 2005) – although this is still controversial (Hubbard et al. 2013); in vivo, 
abnormal astrocytic Ca2+ activity induced by the application 4-AP (a drug commonly used to 
model epileptic activity in tissue), was decreased by systemic administration of the 
antiepileptic drugs valproate, gabapentin and phenytoin (Tian et al. 2005). This change in 
Ca2+ activity has been suggested to affect gliotransmission (Agulhon et al. 2012) and the 
increase in astrocytic Ca2+ activity in epileptic tissue has been found to promote cell death 
(Ding et al. 2007). Astrocyte-derived ATP has recently been found to modulate depressive-
like behaviours, via P2X receptors, in an adult mouse model of depression (Cao et al. 2013). 
One must bear in mind, however, that astrocytes have a plethora of other functions and 
that abnormilties in any of these could be have as great or greater effect on epilepsy 
pathology (Hubbard et al. 2013). 
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1.3 The rodent hippocampus: structure and function 
1.3.1. Basic anatomy of the hippocampus 
The hippocampal formation is a much-studied brain region located in the medial 
temporal lobe in primates and embedded rostro-dorsal to caudocentrally under the surface 
of the cortex in rodents (figure 1.3a). Its structure is highly conserved across mammals, 
forming a trisynaptic circuit (figure 1.3b) between its three major regions: it receives its 
main input from the entorhinal cortex to the granule cells of the dentate gyrus; the granule 
cells synapse with the pyramidal cells of CA3 via the mossy fibre pathway, which synapse in 
turn with the pyramidal cells of CA1 through the Schaffer collaterals. CA1 pyramidal cells 
project to the subiculum and back into the entorhinal cortex, the main structure to which 
the hippocampus outputs. This organized structure makes the hippocampus an ideal 
structure to study synaptic transmission, as stimulation of many innervating axons and 
recording of large synaptic currents is simply done and highly reproducible in situ. This 
thesis concerns itself with the CA1 region, the ‘final synapse’ of the hippocampus. CA1 can 
be divided into four layers (figure 1.3b). Stratum Pyramidale contains the pyramidal cell 
bodies. Stratum Oriens contains the basal dendrites of the principle CA1 pyramidal cells and 
cholinergic (Fernandez de Sevilla and Buno 2003) and sparse dopaminergic (Swanson et al. 
1987) input (see figure1.3c); Stratum Radiatum contains the primary Schaffer collateral 
input – axons from the principle pyramidal cells in CA3; Stratum Lacunosum Moleculare 
contains inputs from the entorhinal cortex and sparse dopaminergic, noradrenergic and 
serotonergic inputs (Swanson et al. 1987). Each layer of CA1 is populated with various 
interneurons (Klausberger and Somogyi 2008), glial cells – of which astrocytes form a large 
proportion – and microglia. The astrocyte population is considered to be homogenous both 
in morphology and function – occupying distinct, equal and tesselating territories  
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Figure 1.3 Hippocampal anatomy of the rat. 
a) Location of the hippocampus (in pink) in the rat brain, black square indicates transverse plane. b) 
transverse slice through the hippocampus, displaying three major areas: DG – dentate gyrus; CA3 – 
Cornu Ammonis 3; CA1 – Cornu Ammonis 1; SLM – stratum Lacunosum-Moleculare; SR – Stratum 
Radiatum; SP – Stratum Pyramidale; SO – Stratum Oriens. c) Dopaminergic afferents to the 
hippocampus and surrounding entorhinal cortex. a) adapted from 
www.neuroscience.bham.ac.uk/neurophysiology/, 2007; b) adapted from Santiago Ramón y Cajal 
(1911); c) adapted from Swanson et al. 1987. 
 
 
throughout CA1 (Halassa et al. 2007) – see figure 1.1 – although these territories become 
slightly smaller in stratum Lacunosum-Moleculare (Ogata and Kosaka 2002). 
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1.3.2 Basic behavioural functions of the hippocampus 
In humans, the hippocampus is necessary for declarative memory formation (Small 
et al. 2001) (Chun and Phelps 1999) – most famously in the case of patient H.M. (Scoville 
and Milner 1957) – and memory retrieval (Eldridge et al. 2000). The hippocampus has also 
been implicated in perception – contributing to the processing of image configuration (Aly 
et al. 2013). In rats, the hippocampus is responsible for spatial memory formation (Schenk 
and Morris 1985; Li et al. 2003). Pyramidal cells of the CA1 region form a cognitive map of 
the environment (O’Keefe and Nadel 1978), with a proportion of CA1 pyramidal cells 
becoming active only in certain locations (termed ‘place cells’). There is also a population of 
‘head-direction’ cells in the subiculum that fire in relation to the position of the rat’s head 
in it’s relation to the environment (Taube et al. 1990). There is some evidence from operant 
conditioning tasks (in which rats must differentiate between rewarding and non-rewarding 
stimuli) that a small subset of hippocampal neurons are sensitive to positively reinforcing 
stimuli (Wiener et al. 1989; Otto and Eichenbaum 1992); this is interesting, given 
dopamine’s role in operant conditioning, but the proportion of cells that are reward-
valence sensitive (2%) is far smaller than the proportion sensitive to the reward-valence 
independent location of the stimuli (9%) (Wiener et al. 1989). Recording hippocampal 
network activity in vivo reveals synchronous oscillation of membrane potential at various 
frequencies – some of which display specific behavioural correlates. Theta oscillations (6-
12Hz) occur during an animal’s movement through space (Rivas et al. 1996) and during 
arousal (Sainsbury et al. 1987); gamma oscillations (20Hz) can occur during olfactory 
sensation (Vanderwolf 2001) – their concrete behavioural function is still unclear but they 
may be involved, at a network level, in synchronizing activity and biasing information 
transfer between brain regions (Akam et al. 2012); sharp ripples – short lasting (up to 
100ms) high frequency (120-200Hz) oscillations – are observed when an animal is at rest, 
which may serve to consolidate recently modified synaptic strengths (Buzsaki 1989). In this 
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thesis I am concerned less with these, broader functions of the hippocampus, but rather 
with synaptic transmission in smaller populations of synapses in the CA1 region alone. 
 
1.3.3 An overview of CA1 synaptic physiology 
Small central synapses (see figure 1.4) consist of a presynaptic axonal bouton 
juxtaposed with a postsynaptic dendritic spine, forming a synaptic cleft approximately 
20nm in width (synapses can also form between pre-synaptic boutons and the post-  
 
 
 
Figure 1.4 Basic physiology of glutamatergic synapses.  
Figure shows physical layout of the synapse: presynaptic bouton (blue), postsynaptic spine (light 
blue) and astrocyte processes (green). 1 – presynaptic depolarization induced Ca
2+ 
entry through 
voltage-gated calcium channels (VGCCs) triggers 2 – release of glutamate from presynaptic vesicles 
into the synaptic cleft. 3 – glutamate binds to AMPA and NMDA receptors in the postsynaptic 
membrane, triggering receptor opening and allowing Na
+ 
and both Na
+ 
and Ca
2+
 entry, respectively, 
leading to postsynaptic depolarization. 4 – astrocytic glutamate uptake from the synaptic cleft 
through astrocytic . 5 – metabotropic glutamate receptor activation can alter Ca
2+
 dynamics in both 
astrocytes and neurons. 
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synaptic cell soma or axon-initial segment). The presynaptic bouton contains a pool of 
readily releasable vesicles, docked to the presynaptic plasma membrane (Stevens and 
Tsujimoto 1995) that are loaded with neurotransmitter. Depolarization of the presynaptic 
membrane (for example during action potential invasion) opens voltage-gated calcium 
channels (VGCCs) (primarily P/Q and N-type at excitatory synapses onto CA1 pyramidal 
cells, (Dunlap et al. 1995)). The resulting Ca2+ influx into the presynaptic bouton triggers 
SNARE-protein dependent (Lin and Scheller 2000) exocytosis of neurotransmitter through 
the calcium sensor synaptotagmin (Geppert et al. 1994). 
After release, neurotransmitter molecules diffuse across, or out of the synaptic 
cleft. They are then either taken up through plasma-membrane bound transporters into 
neighbouring astrocytes (or the presynaptic terminal) or can bind to receptors on the post-
synaptic cell membrane. Such receptors fall into two categories: ionotropic receptors open 
upon ligand binding, allowing charged ions to travel down their electrochemical gradient; 
metabotropic receptors, when ligand bound, trigger an intracellular signalling cascade 
through dissociation of g-proteins. The main excitatory ionotropic receptors in the 
hippocampus CA1 region are glutamate receptors – the α-amino-3-hydroxy-5-methyl-4-
isoxazolepropionic acid receptor (AMPAR), which allows influx of Na+ upon opening, and 
the N-methyl-D-aspartate receptor (NMDAR) that allows Na+ and Ca2+ influx (the NMDAR 
has a voltage-sensitive Mg2+ block that requires concurrent postsynaptic depolarization and 
glutamate binding to open). Gamma-aminobutyric acid type A receptors (GABAARs) are the 
main inhibitory ionotropic receptors in the CNS, that open upon GABA stimulation to allow 
Cl- influx. Other ionotropic receptors are present, including purinergic P2X receptors, 
nicotinic acetylcholine receptors (nAChRs) and serotonergic 5HT3 receptors, but are fewer 
in number.  
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Metabotropic receptors have a slower mode of action and can also be both 
excitatory and inhibitory. Group I metabotropic glutamate receptors (mGluRs) are generally 
excitatory: they are positively linked to phospholipase C via G-proteins and their activation 
leads to an increase in both inositol trisphosphate (IP3) and diaglycerol (Fagni et al. 2000) – 
although they may become inhibitory through depletion of IP3, in turn inhibiting other IP3 
dependent excitatory channels (e.g. purinergic X receptors). Type II/III mGluRs are broadly 
inhibitory, decreasing intracellular  adenylate cyclase concentration via G-proteins, and are 
localized more presynaptically. Similarly, GABAB receptors are inhibitory and are found both 
presynaptically, where their activation has a negative effect on VGCC activity (Mintz and 
Bean 1993), and postsynaptically – triggering G protein-gated inward rectifying K+ channels 
(Andrade et al. 1986). Adenosine receptors, Muscarinic acytlcholine receptors, 
serotoninergic 5HT receptors, noradrenergic receptors and dopaminergic receptors (see 
section 1) also have neuromodulatory actions at the synapse. 
Leaf-like astrocytic processes enwrap ~60% of hippocampal synapses (although this 
is disproportionately weighted towards more active – large perforated – synapses, of which 
~80% are enwrapped), forming the ‘tripartite synapse’ (Perea et al. 2009). These astrocytic 
processes maintain homeostatic stability by rapidly taking up presynaptically released 
glutamate (Bergles and Jahr 1997), through perisynaptic glutamate/Na+ co-transporters, 
before converting it to glutamine and shuttling it back to the presynaptic neuron. 
Astrocytesas also buffer extracellular K+ (Hertz 1965) through inwardly rectifying K+ 
channels and Na+/K+/2Cl-(Verkhratsky and Butt 2007).They can thus affect synaptic 
transmission through homeostatic mechanisms: glutamatergic excitation and control of 
membrane depolarization respectively (see section 1.1.2). In the last 20 years, astrocytes 
have been found to express many kinds of receptors whose activation can trigger 
intracellular Ca2+ increases (see section 1.1.4) and glial release of neuroactive compounds – 
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but the extent to which these astrocytic actions affect physiological synaptic activity is still 
unsure (Agulhon et al. 2010; Wang et al. 2013a).  
 
1.3.4 AMPAR and NMDAR-mediated components of the Schaffer collateral and 
perforant-path synapses with CA1 pyramidal cells 
 The main excitatory input to CA1 pyramidal cells is the glutamatergic Schaffer 
collateral-CA1 synapse. Field recordings from the stratum radiatum display a voltage 
deflection (fPSP) mediated primarily by postsynaptic AMPA receptors after low-frequency 
stimulation (See chapter 2 for further detail on field recordings), with a much smaller 
postsynaptic NMDAR component (Herron et al. 1986; Morris et al. 1986; Otmakhova and 
Lisman 1999) due to the partial, voltage-dependent, Mg2+ block of the NMDA receptor pore 
at the negatively polarized membrane potentials of the CA1 pyramidal neurons. When 
these cells are voltage clamped to -70mV, this NMDAR blockade by Mg2+ is complete 
(Herron et al. 1986). Perforant path-CA1 synapses display smaller overall fPSPs in response 
to perforant-path stimulation than Schaffer-collateral-CA1 synapses (Otmakhova and 
Lisman 1999); and the NMDAR-mediated component is larger (in APV – an NMDAR blocker 
– pp. synapses display 18% reduction in response, and there is no significant APV effect at 
the S.C. synapse).  
 
1.3.5 Different kinds of potentiation of the Schaffer collateral CA1 synapses 
 Potentiation refers to the increase of the synaptic current triggered by an 
unchanged stimulus. At the Schaffer collateral synapse, this phenomenon can fall roughly 
into three categories, based on length of persistence: 
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1.3.5.1 Paired-pulse (short-term) facilitation at Schaffer collateral synapses 
of the CA1 region of the hippocampus 
After an initial electrical stimulation, a second stimulus, with an interstimulus 
interval up to several hundred milliseconds, gives a larger response. This is due to an 
increased residual Ca2+ in the presynaptic bouton, from the first stimulus, leading to an 
increased total Ca2+ concentration upon Ca2+ influx triggered by the second stimulus (Wu 
and Saggau, 1994). Change in the relative magnitude of this facilitation is evidence of a 
change in presynaptic release probability (Zucker and Regehr 2002) – important to bear in 
mind when considering the locus of all kinds of potentiation. Astrocytes can actively 
modulate facilitation by releasing ATP that, after being broken down to adenosine 
extracellularly by ectonucleotidases (Zimmermann and Braun 1996), inhibits presynaptic 
release through A1 receptors (Pascual et al. 2005); they can also modulate action-potential 
width and hence the magnitude of presynaptic Ca2+ influx from a constant axonal stimulus 
(Sasaki et al. 2011). 
 
1.3.5.2 Post-tetanic potentiation at Schaffer collateral synapses of the CA1 
region of the hippocampus 
Repeated trains of stimuli can trigger longer lasting potentiation (up to several 
minutes) that cannot be completely explained by exponential decay of Ca2+ concentration 
in the presynaptic bouton, but is still dependent on presynaptic Ca2+. This post-tetanic 
potentiation (PTP) is not fully understood, but could be mediated through presynaptic Ca2+ 
binding proteins (Zucker and Regehr 2002), metabotropic receptors (Miller 1998) and 
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ionotropic receptors (MacDermott et al. 1999). Although there is no implication in the 
literature that astrocytic Ca2+ activity is necessary for PTP, Sibille et al. (2014) have recently 
demonstrated that astrocyte K+ clearance from the extracellular space can regulate PTP – 
K+-channel 4.1 knockout in astrocytes increases PTP at Schaffer collateral synapses – a 
phenomenon that can be regulated by mGluRI activation (Devaraju et al. 2013). 
 
1.3.5.3 Long-term potentiation at Schaffer collateral synapses of the CA1 
region of the hippocampus 
A more powerful stimulus – increased frequency, current, or number of stimuli 
than trigger TBS (e.g. classic high-frequency stimulation (HFS) consisting of 100 stimuli at 
100Hz, given three times at 30s intervals) – can induce synaptic potentiation that lasts from 
hours in vitro (Bliss and Lomo 1973) to months in vivo (Abraham et al. 2002). This long-term 
potentiation (LTP) is mediated by the NMDA receptor (Collingridge et al. 1983). And can be 
divided into e-LTP, dependent on protein synthesis, and l-LTP, dependent on gene 
expression (Andersen et al. 2007). A huge amount of work has gone into demystifying the 
locus of LTP – but although it is generally agreed that at the Schaffer collateral it is primarily 
post-synaptically expressed (Andersen et al. 2007), there are studies that argue for a pre-
synaptic component (Emptage et al. 2003). Astrocytes have been shown to be necessary for 
LTP induction (Henneberger et al. 2010) and also able to trigger LTP induction themselves 
(Perea and Araque 2007). LTP can be triggered chemically as well as electrically – for 
example, application of the chemical astrocyte marker sulforhdamine 101 triggers a long 
term increase in neuronal excitability by enhancing evoked synaptic NMDAR currents (Kang 
et al. 2010). 
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1.3.6 Potentiation of the Perforant Path-CA1 pyramidal cell synapses of the 
hippocampus 
The perforant path input to CA1 pyramids in stratum Lacunosum-Moleculare does 
not display the same characteristic plasticity as the Schaffer collateral in stratum radiatum. 
LTP can only be induced in the presence of GABAAR blockers (Colbert and Levy 1993) – with 
GABA inhibition present, only short term PTP (<1min) is induced by their powerful 
potentiation protocol (8 pulses at 100Hz, delivered 8 times at 200ms intervals – repeated 3 
times at 5 minute intervals). This can be explained by powerful local GABAergic inhibition at 
the perforant path synapse to CA1 (Ang et al. 2005; Capogna 2011) and, until recently, LTP 
at perforant path-interneuron synapses had yet to be found. However Leao et al. (2012) 
published modification of LTP supposedly induced at the SLM synapse – so the literature is 
controversial. It has been reported that perforant path input has a potentiating effect on 
Schaffer collateral inputs when temporally paired (Basu et al. 2013) – a phenomenon 
mediated by endocannabinoids (Xu et al. 2012) – so it may be that long-term potentiation 
of the perforant path-SLM synapses themselves may not occur in vivo. 
 
1.3.7 Neuromodulation of hippocampal CA1 synaptic activity 
 The activity of CA1 pyramidal cells can be modulated by various neurotransmitters 
apart from the principle pair of Glutamate and GABA. Given the varied innervation that CA1 
receives from amongst others, the septum (Cholinergic), Nucleus Coeruleus 
(noradrenergic), Raphe Nuclei (Serotonergic) and Ventral Tegmental Area (dopaminergic), 
this is hardly surprising. In the following section I will focus only on the neuromodulatory 
effects of dopamine in CA1 – for a review of other neurotransmitter effects please see 
Andersen et al. (2007).  
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1.4 Dopaminergic physiology 
1.4.1 Dopamine in the mammalian brain  
The monoamine dopamine is a major neurotransmitter of the brain. The 
dopaminergic system is complex and has been the subject of great interest since its 
discovery in brain tissue, in 1957 (Montagu 1957). Dopamine acts through both synaptic 
and extrasynaptic  D1 and D2-like receptors (see section 1.1.2) – it is necessary for control 
of movement, reward processing and has been implicated in Parkinson’s disease, 
schizophrenia and addiction (Iversen et al. 2010). Dopaminergic neurons are found in two 
neighbouring nuclei in the midbrain – the Substantia Nigra (SN) and the Ventral Tegmental 
Area (VTA) (Hokfelt et al. 1984). Dopaminergic efferents project from these two subcortical 
nuclei to the striatum, the limbic system and to the frontal cortices. Dopaminergic efferents 
from the more lateral substantia nigra pars reticulata (SNr) project primarily to the basal 
ganglia, and receives return projections, forming functionally separate, parallel-processing, 
loops; this dopaminergic nigro-striatal system is involved in action initiation (Iversen et al. 
2010) – consequences of its disruption are vividly demonstrated in those suffering from 
Parkinson’s disease. Dopaminergic efferents from the VTA to the basal ganglia target the 
shell of only the ventral striatum, but also innervate other brain regions (as do projections 
from the more medial Substantia Nigra Pars Compacta (SNc)) – the orbitofrontal (OFC) and 
prefrontal (PFC) cortices – the mesocortical pathway; the amygdala (Everitt et al. 1999) and 
the hippocampus (Gasbarri et al. 1994a; Gasbarri et al. 1994b) – the mesolimbic pathway. 
The mesocortical system has been implicated in working memory in the rat (Zahrt et al. 
1997), macaque (Williams and Goldman-Rakic 1995) and human (Luciana and Collins 1997) 
and also encodes a reward signal in rat (Olds and Milner 1954) (and see Schultz et al. (1997) 
for further review), macaque (Mirenowicz and Schultz 1996) and human (Tobler et al. 
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2007). Addictive behaviour is caused by the pathological over-stimulation of this reward 
system; addictive drugs increase dopaminergic activity, assigning artificially high reward 
values to the environmental cues that conincide with drug action (Iversen et al. 2010). The 
mesolimbic pathway also controls incentive salience (Berridge 2007) – the strength of a 
conditioned response to a reward – through the amygdala (Everitt et al. 1999) and memory 
consolidation through the hippocampus (Li et al. 2003; Bethus et al. 2010; da Silva et al. 
2012). It is the role of dopamine in the hippocampus that is central to this thesis and it is 
discussed in greater detail in section 1.5.3. 
Dopamine exerts its cellular effects primarily (but not exclusively – see section 
1.7.4) through activation of metabotropic, g-protein coupled receptors. These receptors fall 
into two categories – D1-type and D2-type receptors; understanding of their two different 
downstream signalling cascades, and the potential targets for their modulation, is crucial to 
the understanding of any effect of dopamine on astrocytes. 
  
1.4.2 Dopamine receptor intracellular signalling cascades   
 The down-stream signalling cascades for D1-type and D2-type dopamine receptors 
are well described – but it is important to bear in mind that almost all the work so far has 
been done in neurons or culture expression systems (fibroblasts, HEK cells). Hence putative 
glial dopamine receptor signalling pathways may differ in some ways. 
 
1.4.2.1 D1-type receptor signalling pathways  
 D1Rs and D5Rs are both excitatory in neurons (enhancing AMPA and NMDA 
receptor conductance (Snyder et al. 1998; Flores-Hernandez et al. 2000) and L-type 
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calcium-channel currents (Surmeier et al. 1995), contributing to neuronal depolarization) 
and hence they have been classified together, as the ‘D1-type receptors’ – see figure 1.1. 
They have 7 transmembrane domains (TMDs) and they interact with Gα and Gβγ proteins 
at a point between TMD6 and their N-terminus (Mackenzie et al. 1993). D5Rs show a higher 
affinity for the endogenous ligand dopamine compared to D1Rs and also display 
constituent activity, unlike D1Rs (Demchyshyn et al. 2000). D1-type receptors can 
oligomerize with many other proteins, most notably D2Rs – forming a receptor that 
activates Ca2+ transients via PLC (Lee et al. 2004), NMDARs (Lee et al. 2002) and adenosine 
receptors (Gines et al. 2000). Binding to these receptors activates αolf/αs subunit 
containing g-proteins that dissociate to Gβγ and Gαolf/s-GTP. Gαolf/s-GTP activates the 
enzyme adenylyl cyclase (AC) which synthesises cyclic AMP (cAMP) and in turn, cAMP 
activates PKA which has many phosphorylation targets (figure 1.5). One of these is DARPP-
32 which is crucial in maintaining dopamine induced intracellular effects, by inhibiting 
dephosphorylation of downstream target proteins. D1-type receptors can potentiate 
AMPAR currents via cAMP mediated AMPAR phosphorylation (Roche et al. 1996) and 
NMDAR function through phosphorylation of the GluN1 subunit (Snyder et al. 1998); they 
can inhibit GABAARs through the cAMP signalling pathway (Flores-Hernandez et al. 2000) 
and also inhibit voltage-dependent Na+ channels (Cantrell et al. 1997). They can enhance L-
type Ca2+ channel opening, inhibit N- and P-type Ca2+ channels via cAMP (Surmeier et al. 
1995) and regulate many cellular functions, including synaptic plasticity and transcription, 
through DARPP-32 activated ERK signalling (Thomas and Huganir 2004). Of particular 
relevance to this thesis is the possible existence of a phosphatidylinositol(PI)-linked D1-like 
receptor (so called because of its high affinity to the D1R selective ligand SCH23390) which 
couples to PLC through Gαq and can increase intracellular Ca2+ (Ming et al. 2006; Hasbi et 
al. 2009). As intracellular Ca2+ dynamics are thought to be crucial to astrocytic function 
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Figure 1.5 Summary of dopamine receptor signalling pathways. 
D1-type dopamine receptors couple to Gαs/olf proteins that stimulate the AC/cAMP/PKA cascade. 
This activates DARPP-32 which can facilitate AMPARs, L-type Ca
2+
 Channels, and stimulates the ERK 
signalling cascade; it inhibits N/P-type Ca
2+ 
Channels, Na+ channels and GABAARs.  D1-like receptors 
directly promote NMDAR function through protein-protein interaction. D2-like receptors couple to 
Gαi/o proteins that inhibit the AC/cAMP/PKA cascade. The Gβγ proteins activate PLC, which 
increases IP3 production and hence Ca2+ release from the ER – this inactivates L-type Ca2+ channels 
and Na+ channels. PI-linked D1 receptors activate PLC through the Gαq protein. 
 
 
 (see sections 1.1, 1.2), this receptor could represent a plausible site of extracellular 
dopamine signal transduction into astrocytes (see section 1.1.3).  
55 
 
 
1.4.2.2 D2-type receptor signalling pathways  
 D2, D3 and D4 receptors are inhibitory in neurons (through AMPAR, NMDAR and L-
type Ca2+ channel current decrease and subsequent neuronal excitability decrease (Iversen 
et al. (2010)) and are grouped together as ‘D2-type receptors’ – see figure 1.1. They have 7 
TMDs, with the g-protein interaction occurring at intracellular loop 3. D3 shows slightly 
higher agonist affinity than D2 and D4, which are similar in this respect (Lachowicz and 
Sibley 1997). They can oligomerize with D1Rs (Lee et al. 2004) , CB1Rs (Kearn et al. 2005) 
and A2ARs (Torvinen et al. 2004; Torvinen et al. 2005). D2-like receptors are coupled to αi/o 
G-proteins that inhibit AC activation and its concomitant downstream pathways – this 
inhibition is tonically active in medium spiny neurons (MSNs) of the striatum. D2-type 
receptors activate PLC via Gβγ, increasing IP3 production – raising the probability of 
intracellular Ca2+ release from the ER – which can inactivate L-type Ca2+ channels via 
calcineurin (Hernandez-Lopez et al. 2000). They can also inhibit NMDAR transmission via 
tyrosine kinase activation (Kotecha et al. 2002). The IP3 signalling cascade is an important 
excitatory one in astrocytes (Rusakov et al. 2011) – this could amount to a large difference 
between the role of dopaminergic signalling in neurons and astrocytes. D2-like receptors 
can also inhibit phosphorylation of the NMDAR directly through formation of the D2R-NR2B 
complex (Liu et al. 2006). 
 Hetero-oligomerization of D1 and D2 receptors has been found in cells co-
expressing both receptor types in striatal neurons of the rat brain (Hasbi et al. 2011) – 
activation of this hetero-oligomer increases intracellular Ca2+ (in HEK cells) in a PLC-
dependent fashion (Lee et al. 2004), via the Gq/11 protein (Rashid et al. 2007). This D1-D2 
receptor oligomer activation has been found to modulate neuronal BDNF (Hasbi et al. 
2009), GAD67 and VGLUT1/2 (Perreault et al. 2012)  expression in the striatum. This could 
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be a neat way for existing dopamine receptor function to activate known astrocytic 
intracellular signalling pathways. 
 Dopamine’s actions have been studied in many cell types and in many regions of 
the brain. It is clear from the literature that different brain regions and different cell 
populations display heterogenous responses to dopamine. In this thesis, I study the effects 
of dopamine in the hippocampus: dopamine plays a critical role in overall hippocampal 
function (Li et al. 2003) and in individual hippocampal cellular activity (Frey et al. 1990; 
Otmakhova and Lisman 1998; Andersson et al. 2012). Next I will describe the structure and 
function of the hippocampus, as well as the physiology of the synaptic transmission that is 
studied in this thesis. 
 
1.5 Dopaminergic innervation and function in the hippocampus 
1.5.1 The role of dopamine in hippocampus-dependent behaviour 
The hippocampus is now considered an important target for dopaminergic 
innervation: novelty exposure induces hippocampal dopamine release (Ihalainen et al. 
1999); in rats, hippocampal dopaminergic infusion enhances hippocampus-mediated ‘win-
shift’ behaviour – the ability of the animal not to persevere in its response to a previously 
rewarding task, when the reward is switched to a different behavioural response (Packard 
and White 1991); lesion of the mesohippocampal afferents hinders performance in the 
Morris water maze (Gasbarri et al. 1996) – as does blockade of hippocampal dopamine 
receptor 1/5 (D1/5R), whilst D1/5R agonist infusion increases it (da Silva et al. 2012) – and 
spatial-novelty induced facilitation of hippocampal CA1 LTP could be blocked by intra-
hippocampal infusion of a D1/5R antagonist (Li et al. 2003; Lemon and Manahan-Vaughan 
2006) as could LTD (Lemon and Manahan-Vaughan 2006). Similarly VTA inhibition, through 
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baclofen infusion, decreases place cell stability (Martig and Mizumori 2011). Rossato et al. 
(2009) found that D1R activation controlled the persistence of hippocampus-dependent 
long-term memory storage and likewise, Bethus et al. (2010), found that long-term, 
location-dependent memory formation – but not short term – is mediated by hippocampal 
D1/5Rs; although a later study, using a more sensitive behavioural test has shown D1R-
blockade induced working memory (~30 minute delay) impairment. The literature clearly 
posits a role for dopamine in hippocampal behavioural function, and specifically in the 
formation of long-term memory (Shohamy and Adcock 2010) and this is mirrored at a 
cellular level in the reported effects of dopamine on hippocampal CA1 pyramidal cellular 
physiology (see below). 
 
1.5.2 Anatomy of the dopaminergic system of the hippocampus  
The hippocampus receives dopaminergic innervation from the VTA primarily in the 
subiculum and S.L.M (Swanson et al. 1987) and stratum oriens (S.O) of CA1 (Beckstead et al. 
1979; Verney et al. 1985; Gasbarri et al. 1997; Kwon et al. 2008) – see figure 1.2c – and 
these dopaminergic afferents form roughly 20% of the total innervation from both the VTA 
and the SNc (Gasbarri et al. 1994b), the rest of which is both glutamatergic and GABAergic. 
Dopamine release can be synaptic (Iversen et al. 2010) – or through volume transmission 
(Fuxe et al. 2010, Iversen et al. 2010), a form of transmission that is able to stimulate high-
affinity dopamine receptors up to 8μm away (Rice and Cragg 2008). Given the location of 
the dopaminergic afferents in the hippocampus, this suggests a role for dopaminergic 
phasic transmission in the S.L.M and the subiculum, although slower-changing, wider-
spreading tonic dopaminergic stimulation could play a role over a greater region. The 
hippocampus expresses both D1 and D2-like receptors in rat, monkey and humans in DG, 
CA3 and CA1 areas (Shohamy and Adcock 2010). In rat, D1Rs have been localized 
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histochemically in dorsal hippocampal CA1 (at higher concentrations in S.L.M) and in DG 
(Savasta et al. 1986). Likewise D2Rs have been found in dorsal and ventral CA1 (Yokoyama 
et al. 1995) and have been reported to be localized in S.L.M (Goldsmith and Joyce 1994); 
D3R mRNA is found in the hippocampus (Richtand et al. 2010); hippocampal D4Rs have 
been detected with antibody staining (Defagot et al. 1997) and D5Rs are expressed in rat 
CA1 cell bodies only (although throughout the dendritic tree in humans) (Khan et al. 2000). 
It is clear that dopamine can be released and sensed in the hippocampus – and that 
this plays a role in behaviour – but the physiological mechanisms of its action are 
controversial: it is not clear which hippocampal subregions and cell populations express the 
various dopamine receptor subtypes, the extent of their modulation of neuronal activity 
and what constitutes a physiological release of dopamine. Here I discuss only the effects of 
dopamine in area CA1 – the region relevant to this thesis. 
 
1.5.3 Dopamine’s actions on basal neural activity in Stratum radiatum 
Dopamine can have biphasic effects on CA1 pyramidal cell firing rates (recorded 
extracellularly), that are mediated by different receptors (Smialowski and Bijak 1987). This 
is indicative of the complex nature of dopaminergic modulation of the CA1 region. 
Dopamine application has a small, but highly significant inhibitory effect on basal synaptic 
transmission, mediated through NMDARs (Otmakhova and Lisman 1999) – the authors did 
not investigate through what dopamine receptors (if any) this effect is mediated in the S.R, 
although it does appear to act presynaptically. In another paper published the same year 
the same authors report that addition of the D1/5R agonist 6-Chloro-PB does not inhibit 
combined AMPAR and NMDAR-mediated synaptic transmission (Otmakhova and Lisman 
1998), this is indirect evidence that the inhibitory effect could be D-2 receptor mediated (if 
it is mediated by a dopamine receptor at all). Interestingly, they appear to see the 
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maximum inhibition at the lowest tested dopamine concentration (1μM), with inhibition 
having disappeared by 100μM application: this could be explained either by preferential 
activation of higher affinity D2-like receptors at lower concentrations (Hsu 1996) or 
activation of a different, more sensitive, inhibitory cell type: dopamine activates GABAergic 
signalling in the hippocampus (Gulledge and Jaffe 2001), and in the PFC (Trantham-
Davidson et al. 2004) which has a transient inhibitory effect on CA1 pyramidal neurons 
(Gribkoff and Ashe 1984) – although it has also been reported to decrease GABAergic 
signalling in the prefrontal cortex via D2Rs and D4Rs (Wang et al. 2002; Trantham-Davidson 
et al. 2004).  
 
1.5.4 Dopaminergic control of synaptic plasticity in Stratum radiatum 
The primary action of hippocampal dopamine has been reported on plasticity, 
where dopamine has been proposed to mediate informational saliency-induced long term 
potentiation (LTP) (Hansen and Manahan-Vaughan 2012). Frey et al. (1989), first reported 
that D2-like receptor blockade with domperidone blocked late hippocampal LTP (l-LTP) 
(reproduced by O’Carroll and Morris, 2004), and then went on to show that the D1-like 
receptor was also necessary for hippocampal l-LTP (Frey et al. 1990). This is a confusing 
result, as D1-like and D2-like receptors have opposing actions on pyramidal neurons (see 
section 1.3.2), but it could be explained by the mediation of l-LTP through a D1-D2 receptor 
oligomer, requiring activation of both D1 and D2 subunits to activate downstream 
pathways – such oligomers have been found in striatum (Rashid et al. 2007). As noted 
above, the hippocampus has been reported to express both D1 and D2-type receptors – but 
which is responsible for dopamine’s documented effects on synaptic plasticity? Below I 
discuss the evidence for D1 and D2-type receptor involvement. 
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1.5.4.1 D1-type receptor-mediated dopaminergic actions in the 
hippocampus 
There is support for both the involvement of both receptor types: pharmacological 
D1/5R activation alone can induce l-LTP (Huang and Kandel 1995; Yang 2000) – but see 
Mockett and Brooks and Navakkode et al. (2007). D1R knockout mice do not express l-LTP 
(Matthies et al. 1997). D1/5R activation can also enhance e-LTP (Otmakhova and Lisman 
1996), inhibit LTP depotentiation (Otmakhova and Lisman 1998; Kwon et al. 2008) and have 
been reported to reverse LTD (Mockett et al. 2007). Swanson-Park et al. (1999) also show 
D1/5R mediated enhanced LTP maintenance. However, counter-intuitively, they also find 
that stimulation of the cAMP pathway through which D1/5Rs act, this time by β-adrenergic 
receptor stimulation,  does not enhance LTP maintenance. Rather it enhances LTP 
induction. They suggest this dissociation could be due different location of dopamine and 
adrenergic receptors, dopamine receptors synaptically and adrenergic receptors on the cell 
body. A location-specific function of cAMP coupled receptors could explain the effects of 
dopamine on intrinsic pyramidal cell excitability: Roggenhofer et al. (2010) found that 
D1/5R agonists facilitated potentiation of intrinsic excitability in Subicular, but not CA1 
pyramidal cells (using alvear, not Schaffer collateral stimulation) and Wei et al. (2013) 
report that dopamine inhibits potentiation of intrinsic CA1 pyramidal neuron excitability. 
This could also be explained by cell location – PFC neurons, like subicular neurons, exhibit 
D1R (via NMDARs)-mediated excitability increases (Wang and O'Donnell 2001; Tseng and 
O'Donnell 2004). VTA inactivation has recently been shown to block LTP consolidation from 
a high-frequency stimulation (HFS) in CA1 in vivo (Ghanbarian and Motamedi 2013). It has 
also been found that D1-type receptors can enhance LTD at CA1 pyramidal cells in an 
NMDAR and GABA-mediated fashion (Chen et al. 1996), and Phosphatidylinositol-linked 
novel D1R (a recently described dopamine receptor type) stimulation has been reported to 
facilitate hippocampal LTD (Liu et al. 2009b), increasing the likelihood that dopamine action 
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in the hippocampus is linked to interneuronal function. Co-incident D1R activation and 
taurine uptake has been reported to potentiate l-LTP induction in the hippocampus (Suarez 
et al. 2013) – this is potentially exciting as astrocytes can release taurine (Hogerton and 
Bowser 2013; Suarez et al. 2013) and, in the NAcc in vivo, local infusion of ethanol 
simultaneously increases concentrations of both dopamine and taurine through astrocyte 
swelling (Adermark et al. 2011). Dopamine has also been reported to decrease PTP 
amplitude and enable STP induction in prefrontal cortex (PFC) pyramidal neurons in a layer 
specific, D1-type receptor-dependent fashion (Young and Yang 2005) as well as increasing 
short-term depression at recurrent inhibitory synapses in the neostriatum via D1-type 
receptors (Tecuapetla et al. 2007). 
 
1.5.4.2 D2-type receptor-mediated dopaminergic action in the 
hippocampus 
With regard to D2-type receptors, blockade of dopamine transporters, and the 
concomitant increase in extracellular dopamine, was found to enhance e-LTP induction in a 
D3 receptor-dependent manner (Thompson et al. 2005; Swant and Wagner 2006) and D3 
activation has been found to disinhibit activity at the Schaffer collateral synapses via 
GABAAR endocytosis (Hammad and Wagner 2006; Swant et al. 2008); but D4 receptor 
activation – following NRG1 induced phasic dopamine release – was found to trigger LTP 
depotentiation (Kwon et al. 2008). These different findings could be explained by the 
kinetics of the dopaminergic stimulus – tonic (slower) in the former, phasic (faster) in the 
latter – as well as the location of the dopamine release and the maximal concentration of 
dopamine reached: it is reasonable to assume that phasic application would reach higher 
concentrations than tonic, given the washout of intrinsic dopamine released by the solution 
perfusion. Interestingly, in the prefrontal cortex (PFC), tonic hyperactivation of D2 receptors 
62 
 
can erode electrically induced long-term potentiation of pyramidal neurons (Xu et al. 2009) 
– supporting an inhibitory role for D2-type receptors. This could indicate a functional 
difference between brain areas, or it could be due to the difference in the LTP induction 
protocols used by Swant and Wagner – High-frequency stimulation (HFS) – and Xu et al. – 
Theta-burst stimulation (TBS) – as TBS activates less GABAergic inhibition, due to GABAB 
autoreceptor activation (Davies et al. 1991), and so will stimulate fewer downstream 
signalling pathways and less interneuron activation. Stratum radiatum interneurons also 
respond to dopamine, which has been suggested to inhibit GABAergic transmission via 
D3Rs (Swant et al. 2008) (although see Xing et al. 2010) and to regulate gamma-oscillations 
via D4Rs (Andersson et al. 2012). 
It is worth considering that some of this controversy around dopamine function 
may be due to the in vitro nature of the recordings in many of the studies, in vivo work 
points more consistently towards D1-like receptor mediated potentiation in hippocampal 
CA1 excitatory transmission (Li et al. 2003; Ortiz et al. 2010).  
 
1.5.5 Dopaminergic physiology in Stratum Oriens of the hippocampus 
 Recording from the basal dendrites of CA1 pyramidal cells In the stratum oriens, 
there is no reported effect of dopamine on baseline glutamatergic transmission (from 
alvear stimulation), but both blockade of the dopamine transporter and activation of 
D1/5Rs with specific agonists have been reported to potentiate LTP (Stramiello and Wagner 
2010); conversely, activation of the D4 receptor reduces e-LTP, through inactivation of the 
NMDAR (Herwerth et al. 2012). 
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1.5.6 Dopaminergic physiology in Stratum Lacunosum-Moleculare of the 
hippocampus 
 In the stratum Lacunosum-Moleculare, basal glutamatergic transmission at the 
perforant path-CA1 pyramidal cell synapse is strongly inhibited (~40% decrease) by 
dopamine application (Otmakhova and Lisman 1999; Otmakhova and Lisman 2000) – 
although this was at high concentrations (20μM) of dopamine and the effect may not be 
this marked in more physiological situations. This inhibition affects NMDAR current (~60% 
drop) disproportionately compared to AMPAR current (~40% drop) and which can be 
partially blocked by either D1/5 or D2/3 receptors, mostly blocked by concurrent blockade 
of both and completely blocked by the atypical dopamine receptor antagonist clozapine – 
although clozapine is not specific to dopamine receptor subtype, and can also antagonize 
serotonergic 5HT receptors, so it is uncertain whether clozapine acts here only as a 
dopaminergic antagonist. No other action of dopamine in the SLM has been reported. 
 
The above studies have focussed on neuronal activity in the hippocampus and 
dopaminergic modulation of such activity. However the hippocampus contains a large 
population of glial cells, cells that have over the last 20 years been considered increasingly 
important to our understanding of brain function. To date, surprisingly, nothing has been 
published on hippocampal glial interaction with dopamine throughout CA1. Astrocytes are 
the glial cells I investigate in this thesis and in the next section I will describe their structure 
and functions. 
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1.6 Dopaminergic signalling in astrocytes 
 Throughout this thesis, I am concerned with the putative interaction between 
astrocytes and dopamine in situ – specifically in the hippocampus. In this section I will 
examine, in detail, the previous work that has been done trying to establish whether 
dopamine can stimulate astrocytes and whether this is physiologically relevant (figure 1.7). 
Based on the literature below, I look to test two broad hypotheses in this thesis: firstly, do 
astrocytes in situ respond to dopamine with Ca2+ transients and if so, through what 
mechanism? Secondly, do such Ca2+ transients play a role in synaptic communication? I will 
now discuss the current position of the field with regards astrocytic response to dopamine; 
in the next section I will discuss the possible physiological relevance of previously reported 
astrocytic Ca2+ signals. 
 
1.6.1 First reports of an astrocytic response to dopamine 
In 1999, cultured astrocytes were found to respond with increases in intracellular 
cAMP to application of dopamine, as well as the D1 receptor agonist SKF 38393 and the 
mixed D1/2 receptor agonist apomorphine (Zanassi et al. 1999). This cAMP accumulation 
was region-dependent, being highest in striatally-derived astrocytes, lower in cortical 
astrocytes and not present in cerebellar Bergmann glia. They also showed that striatal 
astrocytes exclusively express D1R mRNA which is translated into the D1R protein. This is an 
important result for a number of reasons – not only does it show that astrocytes can 
express functional dopamine receptors, that can activate similar pathways to those in 
neurons, but also that their expression of these receptors is heterogeneous throughout the 
brain. Heterogeneous expression could indicate situational control of the receptor 
expression in situ, arguing for a physiological role for the D1R in astrocytes. A major caveat 
when considering culture studies is the extreme responsiveness of astrocytes to their 
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surroundings and their ability to change their receptor expression patterns when shifted 
into a culture environment for more than a few hours (Shao and McCarthy 1993; Kimelberg 
et al. 1997) – and the cells studied by Zanassi et al. had most likely been cultured for over 2 
weeks – not to mention the fact that the cells for culture are harvested at a very different 
developmental stage to adult astrocytes. However the fact that tissue-related differences 
can be seen between populations of astrocytes in this study is a reassuring sign – if 
dopamine receptor expression were a methodological artefact, one would expect all 
cultured cells to respond similarly. Striatal astrocytes have since been found to respond to 
dopamine, over a 12h exposure, with a decrease in FGF-2 expression (Reuss and Unsicker 
2000) but an increase NGF and GDNF upon 24h stimulation with non-selective dopamine 
receptor agonist apomorphine (Mizuta et al. 2000). 
 
  
Figure 1.6 Change in calcium-dependent dye fluorescence in cultured 
astrocytes in response to dopamine. 
10μM dopamine application to cultured astrocytes triggers an increase in amplitude and frequency 
of somatic calcium transients. Adapted from Requardt et al. 2012, Fig 1b. 
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Dopamine application (a high concentration – 50μM) was then shown to trigger 
massive intracellular Ca2+ increase in cultured hippocampal astrocytes (Parpura and 
Haydon 2000) – an increase they argued crossed the threshold for astrocytic activation of a 
slow inward current (SIC) in neurons, thus displaying a possible physiological role for 
astrocytes in dopaminergic transmission. In fact it comprehensively smashes the threshold 
Ca2+ concentration increase required for SIC stimulation – an increase to 200nM from 
~90nM is sufficient for SIC generation and dopamine triggers an estimated (transient) 
concentration increase to 2.5mM. However the almost qualitative difference between the 
Ca2+ responses to uncaging and dopamine may indicate that they do not necessarily trigger 
the same downstream pathways (in this case neuronal SICs), and the authors fo not directly 
test the application of dopamine on SIC induction. An example of dopamine-induced 
(10μM) astrocytic Ca2+ increases is given in figure 1.6. Khan et al. (2001) identified a 
population of cortical astrocytes in monkey that expressed D2 receptors: this precise 
localization in fixed brain tissue was only possible with electron microscopy, given the 
extreme proximity of the D2- expressing astrocytic processes to the neighbouring 
interneurons. They went on to show D2R expression and agonist (quinpirole) induced 
astrocytic Ca2+ transients in freshly isolated rat and mouse cortical astrocytes – this is the 
only study reporting a D2 receptor agonists induced Ca2+ increase, but it is important to 
note that their Ca2+ fluorescence measurements are taken at low temporal resolution 
(every 3s) and their cells show heterogenous dye loading across the cytoplasm (indicating 
possible unequal loading of intracellular compartments). The small response amplitudes are 
also very small (peaking at 1.2 F/F0) and no clear link between the time-course of drug 
application and the observed Ca2+ signal.  
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1.6.2 Astrocyte dopamine physiology mediated by D2-like receptor signalling 
As mentioned above, the only study to report a D2R-mediated astrocyte Ca2+ 
increase does not provide strong evidence for a D2R-linked Ca2+ signalling mechanism. 
However, there is now considerable evidence for astrocytic expression of D2-like receptors 
in rat brain – cultured glioma cells are sensitive to D2R stimulation (Luo et al. 1999) as are 
normal cultured astrocytes taken from the whole brain (Ohta et al. 2010) and from the 
striatum specifically (Hosli and Hosli 1986; Bal et al. 1994; Miyazaki et al. 2004) – which also 
express D2R mRNA (Bal et al. 1994). Human astrocytes express D2Rs in the PFC, as assayed 
immunohistochemically and under electron microscopy (Khan et al. 2001). Rodent 
astrocytes also display D2Rs labelling under electron microscopy (Duffy et al. 2011) and 
astrocytic αβ-crystallin production is disrupted in astrocyte-specific D2R knockout mice 
(Shao et al. 2013). Astrocytic D2R activation has been linked to various downstream effects: 
increase in BDNF, GDNF and NGF mRNA expression and protein synthesis (Ohta et al. 2010); 
increased protein tyrosine phosphorylation (Luo et al. 1999); FGF-2 secretion (Li et al. 
2006); reduction of S100β secretion (Nardin et al. 2011); suppression of αβcrystallin 
mediated neuroinflammation (Shao et al. 2013) and increases in intracellular free Ca2+ 
(Khan et al. 2001; Reuss and Unsicker 2001). With the notable exception of Shao et al. 
(2013) and Nardin et al. (2011), the above studies have all been done in culture. Although 
evidence is accumulating for a physiological role of astrocytic D2Rs a convincing 
demonstration of their ability to induce astrocytic Ca2+ transients (if at all) is still lacking. 
 
1.6.3 Astrocyte dopamine physiology mediated by D1-like receptor signalling 
Classical D1-likeRs are expressed on rat striatal astrocytes (Hosli and Hosli 1986; 
Vermeulen et al. 1994; Zanassi et al. 1999; Miyazaki et al. 2004; Li et al. 2006) and may be 
expressed in cortical astrocytes (Zanassi et al. 1999; Requardt et al. 2012). Astrocytic 
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classical D1-likeRs have been reported to stimulate cAMP production and PKA activation 
(Zanassi et al. 1999), increase astrocytic GDNF and NGF expression (Ohta et al. 2010); 
increase FGF-2 expression (Li et al. 2006) and modulate NADH expression (Requardt et al. 
2012 – see below). 
Reports of astrocytic expression of novel PI-linked D1-likeRs is of great interest – 
given their interaction with IP3-mediated Ca2+ release, the major astrocytic intracellular 
signalling pathway. Increases in intracellular free Ca2+ in cultured cortical astrocytes can be 
stimulated by a specific PI-linked D1-likeR agonist (SKF83959) in a D1R and IP3 dependent 
manner (Liu et al. 2009b), this Ca2+ signal promotes ERK activation (Huang et al. 2012); in 
the striatum, this Ca2+ signal modulates astrocytic FGF-2 expression (Zhang et al. 2009).  
 
1.6.4 Astrocyte metabolic interaction with dopamine 
Recently, the DA-induced astrocytic Ca2+ signal was proposed to have a metabolic route 
(figure 1.7). Astrocytes can express the dopamine transporter (DAT) in glioma cells (Russ et 
al. 1996), cultured cortical astrocytes (Inazu et al. 1999) and in striatal tissue – although 
Kittel-Schneider et al. (2012) found no DAT expression in cultured astrocytes. The 
norepinephrin transporter (NET) has also been found in cultured cortical astrocytes (Inazu 
et al. 2003) – Takeda et al. (2002) reported that dopamine uptake was mediated by the 
NET, not the DAT. Regardless of the transporter type, it is possible for astrocytes to move 
dopamine from the extracellular space into their cytosol. Vaarmann et al. 2010 propose 
that intracellular DA catabolism triggers astrocytic Ca2+ transients. DA is one of several 
monoamines catabolized by monoamine oxidase (MAO), which is expressed in astrocytes, 
and the H2O2 produced was proposed to activate PLC and IP3 Ca signalling via lipid 
peroxidation, in a DAR-independent manner. Requardt et al. (2012) could not reproduce 
this, however, and suggest it may be an artefact from H2O2 build up from DA auto-
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oxidation. Takano et al. (2013) reported a slight increase in extracellular superoxide 
dismutase production upon stimulation of cultured cortical astrocytes with DA – so  
 
 
 
 
Figure 1.7  Summary of reported dopamine signalling pathways in Astrocytes. 
D1-type dopamine receptors can trigger NADH increase, cAMP and concomitant PKA increases, and 
it can trigger increased expression of NGF, GDNF and FGF2. D2-type dopamine receptors can 
increase NGF, GDNF, BDNF and αcrystallin expression as well as inhibiting S100B and FGF2 secretion. 
They also trigger ER Ca2+ increase through IP3, which itself can enhance ERK signalling. Dopamine 
entry into the cytoplasm, upon breakdown by MAO can stimulate IP3 production through PLC 
activation. 
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astrocytes may be involved in extracellular free radical removal. Requardt et al. (2010) 
found that DA triggers an increase in intracellular NADH, both in cortical cultures and slices; 
they later showed (Requardt et al. 2012) that DA can act synergistically with NADH (via 
D1Rs) to stimulate cultured cortical astrocyte Ca2+ activity. 
 
1.6.5 Effect of antipsychotics on astrocyte cellular physiology 
The atypical neuroleptic (a class of antipsychotic medicinal drugs) clozapine is a 
non-specific dopamine receptor antagonist (as well as a serotonergic, adrenergic and 
muscarinic receptors) that has been reported to stimulate astrocytes directly and hence is a 
source of separate interest. They have been shown to downregulate astrocytic 
dopaminergic sensitivity after a 12h exposure (Reuss and Unsicker 2001); enhance D-Serine 
and glutamate release after a 1h clozapine incubation (Tanahashi et al. 2012) and enhance 
S100β secretion in cultured astrocytic C6 glioma cells – the same is true for Haloperidol, 
another antipsychotic that also blocks dopamine receptors. However, it is important to 
note that these antipsychotics are dirty drugs, acting on all kinds of dopamine receptors to 
a degree as well as 5-HT receptors. 
Overall, the literature is clear that astrocytes can express DARs and that DA itself 
can induce astrocytic Ca2+ transients (at least in culture) – but there is still uncertainty as to 
the mechanism by which it does so. However the physiological relevance of the Ca2+ 
dynamics, from various kinds of astrocytic stimulation, is still hotly debated. I will next 
detail the one outstanding area of research regarding the role of astrocytic Ca2+ transients – 
gliotransmission – and the controversy over their physiological importance. 
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1.7 Thesis aims 
 Dopamine is a hugely powerful neurotransmitter in the brain and likewise 
astrocytes are becoming recognized as highly functional targets for neurotransmitter 
signalling – both are intimately involved with fundamental neurophysiological function and 
in pathogenesis of the brain. Hence elucidating the physiological connection between 
astrocytes and dopamine is of the great importance, with potential benefits for our 
understanding of the brain and in tackling health and disease. However, our understanding 
of astrocyte-dopamine physiology is still rudimentary – most of our knowledge comes from 
studies in culture and the literature has yet to agree on an astrocytic signalling mechanism 
for dopaminergic stimulation. Our knowledge of astrocytic Ca2+ activity and dopaminergic 
function is wide-ranging and detailed enough to allow clearer characterization of their 
possible interactions in situ – and this is the aim of this thesis. 
 To complete this aim I have split this thesis into four main objectives: 
 
1.7.1 Thesis objective 1: characterize the astrocytic Ca2+ response to dopamine in 
hippocampal slice 
 . Dopamine-induced astrocytic Ca2+ activity has only previously been recorded in 
culture conditions (see section 1.6), so the nature of the Ca2+ response recorded in situ will 
be novel because of the morphological, developmental and possibly biochemical 
differences of astrocytes in situ. This objective is split over two results chapters, organized 
by the method used to image intracellular Ca2+: chapter 3 uses AM-dye bulk-loading, 
chapter 4 uses membrane-impermeable dye loading via whole-cell patch clamp. These 
methods are complimentary, given that bulk-loading will not affect the intracellular milieu, 
whereas whole-cell patch-clamp will offer greater sensitivity and spatial resolution.I will 
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first address the simple question: Can astrocytes respond to topically applied dopamine 
with Ca2+ transients in situ? Secondly, I will investigate the intracellular signalling pathways 
that underlie the dopaminergic Ca2+ transients – this will be done primarily through 
pharmacological blockade of putative elements of the signalling cascades, but also with 
some genetic tools. 
 
1.7.2 Thesis objective 2: test for an astrocytic role in dopaminergic modulation of 
neuronal activity in the hippocampus. 
 Dopamine has various effects on the activity of neurons in the CA1 region of the 
hippocampus (see section 1.5). It has a clearly defined inhibitory effect on basal synaptic 
transmission at the perforant path synapse in Stratum Lacunosum-Moleculare – in chapter 
5, I test whether interfering with local astrocytic Ca2+ dynamics (using both fluoracetate and 
astrocytic internal calcium clamp) changes the dopaminergic inhibition of these synapses’ 
response to perforant path stimulus. 
 In Stratum Radiatum, at the Schaffer Collateral synapse, dopamine’s actions on 
neuronal activity are more controversial; but the prevailing opinion is that it positively 
modulates synaptic potentiation (as well as a slight, but significant depression of baseline 
transmission). In chapter 6, I use fluoroacetate to interfere with astrocytic metabolism and 
then probe dopamine’s ability to affect short-term potentiation and baseline synaptic 
transmission in response to Schaffer Collateral stimulation. 3 
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1.7.3 Thesis objective 3: creation of a model system to study physiologically 
released dopamine in hippocampal slice 
 A major shortcoming of work on dopamine’s action in the hippocampus is the 
inability to stimulate dopamine release from hippocampal dopaminergic terminals in a 
physiological manner (see section 5). Chapter 7 details the attempted development of 
channelrhodopsin-expressing projections from dopaminergic neurons of the ventral 
tegmental area that would innervate the hippocampus and be under light-control.  
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Chapter 2: Methods 
 
2.1 Hippocampal slice work: methods for preparation, electrophysiology and imaging in 
situ 
2.1.1 Hippocampal slice preparation 
2.1.1.1 Animals sacrificed     
Unless otherwise stated, all experiments were carried out on tissue taken from 3-4-
week-old male Sprague–Dawley rats. A series of calcium imaging experiments were carried 
out on ‘IP3-sponge’ mice: these mice express an IP3 buffer specifically in astrocytes. GST-IP3 
sponge-TetO-nls-LacZ mice, expressing doxycycline-gated glutothione-linked IP3 receptor 
fragments that are capable of buffering IP3 signalling, (Uchiyama et al. 2002), were crossed 
with GLT-1-tTA mice for specific astrocytic expression of the IP3 sponge. For details of the 
generation of this mouse line see (Tanaka et al. 2013). Control animals came from C57BL/6 
lineage. 3-4-week-old male mice were used in all experiments. All experiments were 
performed blind to genotype. All experimental protocols were carried out in full compliance 
with UK guidelines on animal experimentation or were approved by the RIKEN Institutional 
Animal Care and Use Committee.  
 
2.1.1.2 Acute excision and slicing of hippocampal tissue  
Acute hippocampal slices, 350μm thick, were obtained from 3-4-week-old male 
Sprague–Dawley rats or 3-4 week old ‘IP3-sponge’ mice. Animals were anaesthetized to 
death with a lethal intraperitoneal injection of Sodium Pentobarbitol. The skull was opened 
up and the brain excised into an ice-cold slicing solution containing (in mM): NaCl 50, 
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sucrose 105, KCl 2.5, MgCl2 7, NaH2PO4 1.25, CaCl20.5, Ascorbic acid 1.3, Sodium Pyruvate 3, 
and glucose 6 (osmolarity 304–312 mOsM), continuously bubbled with 95% O2/5% CO2. The 
whole hippocampus was dissected, placed in an agar block and transverse slices were 
prepared using a Leica VT 1200S slicer. Slices were then transferred to slicing solution kept 
at 34 °C for 15 min before being transferred to an interface or an immersion chamber 
containing Ringer solution (see below for solution recipe). For recording in the Stratum 
Lacunsom-Moleculare (SLM) and for recording NMDA receptor-mediated currents, CA3 was 
cut off from the slice. 
 
2.1.1.3 Post-slicing tissue incubation  
Slices were allowed to rest for at least 1h before recordings, in Ringer solution 
containing (in mM) NaCl 119, KCl 2.5, MgSO4 1.3, NaH2PO4 1, NaHCO3 26, CaCl2 2, glucose 
10 (osmolarity adjusted to 298–302 mOsM with glucose). All solutions were continuously 
bubbled with 95% O2/5% CO2.  
For bulk-loading slices with the astrocyte-specific morphological dye 
Sulforhodamine 101 (SR101) and Fluo-4-AM (chapter 3), the following protocol was used: 
1) Rest for 30 minutes in Ringer  
2) Incubate in 10μM SR101 for 10 minutes at 35°C 
3) Wash in Ringer 
4) Incubate in 5μM SR101 + 5μM Fluo-4-AM + 0.04% Pluronic Acid for 40 minutes at 
35°C 
5) Wash in Ringer 
6) Rest in Ringer for 30 minutes. 
7) Slices ready for recording 
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Slices were stored for up to 1h after completing this protocol before recording. 
 
2.1.2 Recording equipment preparation 
2.1.2.1 Patch pipettes and intracellular pipette solutions 
Micropipettes, pulled from borosilicate, filamented glass, were used for all 
electrophysiological recordings. For astrocyte whole-cell patching, pipette resistances were 
3-5MΩ. For field recordings, extracellular pipette resistance was reduced to 1-2MΩ, except 
for when recording fEPSPs in proximity to a patched astrocyte – here pipettes with higher 
resistance tips (3-5MΩ) were used in order to disturb the tissue less. Extracellular fEPSP 
recording electrodes are filled with the same Ringer solution as in the recording bath, 
including any additional drugs used. Pipette tips were not polished. Upon filling with 
solution, pipettes with visible blockage were discarded.  
Whole cell recording electrodes were filled with intracellular Potassium methyl-
sulphonate (KMS) solution containing (in mM): KCH3O3S 135, HEPES 10, disodium 
phosphocreatine 10, MgCl2 4, Na2ATP 4, NaGTP 0.4 (pH adjusted to 7.2 with KOH, osmolarity 
290–295 mOsM). For imaging Ca2+, two fluorescent dyes are added to the KMS solution – 
Alexa 594 (50μM) as a morphological marker and Fluo-4 (200μM) as a calcium indicator. For 
performing ‘Ca2+ clamp’ experiments, where specified, 0.45mM EGTA and 0.14mM CaCl2 
were added to the control intracellular solution, to clamp intracellular free Ca2 at a steady-
state concentration of 50–80nM (Henneberger et al. 2010). 
 
2.1.2.2. Recording bath solution and drugs used 
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For recordings, slices were transferred to a submersion-type recording chamber 
and perfused with Ringer solution saturated with 95%O2/5%CO2. For measuring NMDAR  
 
Chemical Chemical 
abbreviation 
Concentration Blocker target 
Tetrodotoxin TTX 1 μM Na+ channel  
(s) MCPG MCPG 200 μM mGluR group 
I/II   
MPEP MPEP 1 μM mGluR5  
LY 367385 LY 367385 100 μM mGluR1a  
LY 341495 LY 341495 500nM mGluR group II  
CGP 55845 CGP 1 μM GABAbR  
Picrotoxin PTX 50 μM GABAaR 
SCH23390 SCH 20 μM D1/5R 
Sulpiride Sul 20 μM D2/3R 
Selegiline Sg 20 μM MAOb  
D-AP5 AP5 50 μM NMDAR 
NBQX NBQX 100 μM AMPAR 
PPADS PPADS 100 μM P2XR 
2-APB APB 100 μM IP3R 
 
Table 2.1  Summary of pharmacological agents used throughout thesis. 
This table shows the full name of the drugs used in this thesis, their common abbreviations, the 
concentration they were used in (unless otherwise stated) and the primary locus of their effect. 
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currents, the Mg2+ concentration was decreased to 0.1mM and the GABAA antagonist 
picrotoxin (50μM) was added. This solution was either kept at room temperature (18-21°C) 
or at 33°C, as stated. Ringer pH was confirmed at 7.4. Where stated, pharmacological 
agents were added to the bath at the below listed concentrations – see table 2.1 (unless 
otherwise indicated): 
 
2.1.3 Electrophysiology: equipment, recording and stimulation technique 
2.1.3.1 Recording hardware used for electrophysiological recordings 
Electrical signals were acquired through an Axon instruments CV-7B headstage, 
connected to the pipette solution by a chlorided silver wire, and a multiclamp 700B 
amplifier. Each primary output is connected to a Humbug to reduce 50Hz background noise. 
Signals are filtered at 3–6 kHz, digitized and sampled through an analogue-to-digital 
converter, either an Axon CNS 1440A, or National Instruments BNC 2090, at 10KHz. 
Software used for acquisition was either WinCP 4.2.1 or Clampex 10.2. 
 
2.1.3.2 Extracellular electrical field recording: theory and technique 
Field excitatory post-synaptic potentials (fEPSPs) are the measurement of synaptic 
activity used in this thesis. For these measurements the recording electrode is placed in the 
extracellular space in the vicinity of the synapses of interest; it is then set to maintain a net 
flow of no current from the electrode into the extracellular space – any current flowing 
from the surrounding extracellular medium into neighbouring synapses, or cells will register 
as a change in the voltage between the extracellular medium and the recording electrode. 
The formation of voltage sources and sinks from layer specific or input specific neuronal 
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activity in the slice will also affect the local voltage change at the recording pipette. 
Stimulation of the axonal afferents in hippocampal slices leads to release of 
neurotransmitter (primarily glutamate), triggering opening of postsynaptic ionotropic 
receptors and a net influx of positive charge (in the form of Ca2+ and Na+ ions) into both 
pyramidal cells and interneurons. The voltage recorded is mostly from current flowing 
through the post-synaptic membrane – the initial gradient of the voltage recorded over 
time gives the best measure of this current. 
A stereotypical Schaffer collateral (SC) fEPSP (figure 2.1) displays a stimulation 
artefact (from the current passed into/across the stimulation electrode), a fibre volley 
(axonal sodium influx from action potentials), an initial fast, downwards voltage deflection 
and a slow decay of the initial voltage change back to baseline. All voltage deflections are 
negative, as the current flows overwhelmingly from the extracellular space into the  
 
 
Figure 2.1  Typical field Excitatory Post-Synaptic Potential (fEPSP) 
i) baseline. ii) stimulus artefact. iii) fibre volley. iv) slope. v) peak amplitude. 
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surrounding cells. This is only reversed if the stimulus is strong enough to cause the 
pyramidal cells to spike (population spike) – when recording fEPSPs in this thesis, baseline 
stimulation strength was adjusted. The baseline SC fEPSPs recorded in this thesis had an 
average slope of 0.79 ± 0.06 mV/ms (± standard error), which is similar to the published 
reported value (Otmakhova and Lisman 1999; Henneberger et al. 2010). The synaptic fEPSP 
responses recorded at the perforant path-CA1 (PP-CA1) synapse were too small (0.27 ± 0.01 
mV average amplitude) to reliably record the value of the fEPSP slopes. Hence, for PP-CA1 
recordings, amplitudes, not slopes, are reported in this thesis (chapter 5). 
 
2.1.3.3 Extracellular axonal pathway electrical stimulation 
For SR stimulation, axonal fibres were stimulated with either a monopolar 
electrode or a bipolar electrode (as stated) from a Digitimer DS3 constant current 
stimulator box. The stimulating electrode was placed in the S.R. 100-200μM closer to CA3 
then the recording electrode. The configuration was allowed to settle for up to 10 mins and 
then the stimulus intensity was gradually increased until no further increase in the fEPSP 
slope was seen. The stimulus power was then adjust to give 50-60% of the maximal fEPSP 
slope – stimulus power did not exceed 70μA and lasted 100μs.  
For SLM stimulation, the stimulating electrode was placed in the perforant path 
(pp) in SLM, 100-200μm from the recording electrode, at the CA1/Subiculum border, to 
selectively stimulate incoming perforant path afferents. Stimulation intensity was set to 
induce a fEPSP peak of 50-60% of the maximum amplitude obtainable. This required 
relatively high stimulation currents (200-500μA), consistent whith stimulation intensities in 
the literature: Otmakhova and Lisman (1998) find that, in perforant path, stimulation 
strengths of 2-5 times that needed in Schaffer collateral were required for the same fEPSP 
size and others (Judge and Hasselmo 2004) stimulated at 200μA. 
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For generating recording fEPSPs in both SR and SLM, a paired-pulse stimulation 
protocol was used, with 50ms between the two equal electrical stimulation pulses, with at 
least 200ms baseline preceding the first stimulus. For recording NMDAR-mediated fEPSPs in 
the stratum oriens (SO), the inter-stimulus interval was increased to 100ms to allow for the 
slower decay kinetics of this current. Unless otherwise stated, there was a 15s interval 
between each paired-pulse recording. 
For generating post-tetanic potentiation in both SLM and SR, a weak theta-burst 
stimulation (TBS) paradigm was used. This consisted of 100ms baseline followed by 8 pulses 
at 100Hz, given twice with a 200ms interval between the first pulse of each 100Hz train. 
 
2.1.3.4 Rejection criteria for fEPSP recordings  
For SLM fEPSP recordings, fibre volley amplitudes similar or greater than maximum 
fEPSP amplitudes are expected (Otmakhova and Lisman, 1998). Therefore, unlike at the 
Schaffer collaterals, a large fibre volley was not a rejection criterion. However, due to the 
need to measure a decrease in fEPSP amplitude and slope, recordings were rejected if the 
baseline fEPSP maximum amplitude was <0.2mV. As voltages were generally small (see 
above) recordings with a high baseline noise level were also excluded. In SR, recordings that 
required over 70μA stimulation to reach 50% slope maximum were discarded. 
For post-tetanic potentiation experiments, recordings were discarded if the fEPSP 
amplitude had not returned to baseline after 10 minutes in SR or 5 minutes in SLM. Due to 
the run-up witnessed at the SLM pp synapse (Otmakhova and Lisman 1999) some leeway 
was allowed here (up to ~5% increase). 
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2.1.3.5 Astrocyte whole-cell patch-clamp electrophysiology 
For every patched astrocyte, the membrane current-voltage (IV) relationship was 
plotted by stepped injection of current through the patch pipette, generally at 200pA 
intervals, (figure 2.2). Positive electrophysiological identification of a protoplasmic 
astrocyte required a linear IV relationship and a low input resistance (<10MΩ) as well as a 
membrane holding voltage of -80mV, or more negative – consistent with their highly K+ 
permeable membrane. 
 
 
Figure 2.2 Typical astrocytic electrophysiology 
a) Example current injection protocol. b) corresponding membrane voltage change for current 
injection in a). c) plotted IV curve. 
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2.1.3.6 Recording fEPSP through the membranes of patched astrocytes 
Given the low input resistance of patched astrocytes, fEPSPs can be recorded 
through their cell membranes by the patch pipette (Henneberger and Rusakov 2012). For 
these astrocyte fEPSP (afEPSP) recordings, the amplitude of the downward voltage 
deflection is subtracted from the eventual stable holding current 30-50ms post stimulus. 
The downward peak was sometimes masked by the upward deflection, but the fEPSP can 
be calculated post-hoc in this case, so this was not considered a rejection criteria. Stable 
access resistance is vital for these recordings: upon entering whole-cell mode the bridge 
balance was set automatically through the Multiclamp software and regularly and 
frequently reset throughout the experiment to correct for possible pipette resistance shifts.  
 
2.1.4 Two-photon excitation imaging of fluorescent dyes in situ 
2.1.4.1 Fluorescence excitation and recording hardware 
Two setups were used to record fluorescent images; either a modified Bio-Rad 
Radiance 2000 on an Olympus BW50 microscope with a 40x objective, or a Fluoview 
FV1000 MPE microscope with a 25x objective. Both were optically linked to a femtosecond 
pulse TiSapphire MaiTai laser (SpectraPhysics) emitting at 800nm. Laser power was kept 
between 5-8mW for bulk-loaded Fluo-4-AM imaging, 2-5mW for patch-pipette-loaded fluo-
4 imaging (as measured at the objective at 800nM). 
 
2.1.4.2  Visual identification and patch-clamp of astrocytes under DIC light 
microscopy 
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Astrocytes were identified for patching using the differential interference contrast 
(DIC) light image. Astrocytes are found scattered regularly throughout the CA1 region 
(Halassa et al. 2007) and cell location (regarding hippocampal subfields) was defined by the 
position of the cell soma. Subfield boundaries were defined visually as follows: astrocyte 
cell bodies on the basal dendritic side of the pyramidal cell layer were defined as being 
stratum oriens, cell bodies on the apical dendritic side, in the proximal region - appearing 
lighter under DIC image - were defined as stratum radiatum and cells in the furthest, 
darker, distil apical dendritic section were defined as being in the stratum Lacunosum-
Moleculare. Generally only astrocytic cell bodies are visible, although sometimes large 
proximal processes can also be distinguished. Astrocyte somata are characteristically round 
(although not perfectly circular), and generally around 8-10μm in diameter.  
Astrocytes were approached with a patch-pipette tip under visual control. Upon 
contact with the soma, a giga-seal (a pipette tip resistance of >1GΩ) was formed. Gigaseals 
were then broken with light suction (or occasionally the ‘zap’ function from the Multiclamp 
command window) to attain whole-cell mode. Astrocyte resting membrane potential is 
highly hyperpolarized, and cells were discarded if the membrane dropped beneath -80mV 
during an experiment; the average astrocyte resting membrane potential was -84.3 ± 
0.6mV. The pipette solution was then allowed to equilibrate with the intra-cellular milieu 
for at least 20 mins. If, after this time, no gap-junction coupled cells (GJCs) have become 
visible, the cell was discarded. For ‘calcium-clamp’ experiments, the cell was held in cell-
attach mode (seal unbroken) for a set baseline time before entering whole-cell mode. NG2 
cells and oligodendrocytes look similar under DIC and are often patched in error – however 
they can be distinguished from protoplasmic astrocytes through their electrophysiological 
(higher input resistance of >20MΩ) and morphological properties (thinner, sparser 
processes - visible under fluorescent 2P imaging). Upon identification they are discarded. 
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2.1.4.3  Fluorescence-excitation imaging of dye-loaded astrocytes 
Alexa594 normally equilibrated across the astrocyte tree within 10–15 min. The 
morphology of astrocytes loaded with fluorescence indicators (see above) was imaged in 
the Alexa emission channel (red) (540LP/700SP filter) at the end of every experiment, either 
as Kalman-averaged 512x512 pixel image or as a stack of 150-250 Kalman averaged, 
256x256 pixel, images, stacked in the z-plane with an inter-image distance of 0.5μm.  
During recordings, images were acquired simultaneously as frame scans in the 
Alexa emission channel and the fluo-4 emission channel (green) (515LP/530SP filter), at 
various pixel resolutions, depending on the sensitivity of the setup and the spatial 
resolution required for the recording. When recording from bulk-loaded astrocytes 
unreliable dye loading of processes, and relatively poor signal to noise ratio (in comparison 
to whole-cell patch-clamp loaded astrocytes), necessitated data acquisition from somata 
alone. Hence a low pixel resolution, 64x64 pixels, could be used in conjunction with a high 
image magnification, without losing useful signal. For patch-clamped astrocytes, signal to 
noise ratio is far better and simultaneous recordings from GJCs, as well as patched-cell distil 
processes in the same image frame required a higher resolution –generally around 256x256 
pixels, although the exact height and width was adjusted to best fit the features of the 
recorded cells at the zoom chosen (see below). 
Image zoom was adjusted to best capture the salient features of the imaged cells – 
somata of GJCs and visible (within resolution) patched astrocyte processes. Unless 
otherwise stated, image gain for both channels was kept the same and constant within a 
particular 2-P setup. Pixel dwell time was kept constant (4μs), as was the movement of the 
detector – recording unidirectionally.  
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Unless otherwise stated, images were acquired at 1Hz frequency. 
If cells failed to show protoplasmic astrocytic morphology after 10-15 minutes dye 
equilibration and GJCs they were discarded.  If they showed abnormally high resting fluo-4 
fluorescence signal compared to the morphological marker, they were likewise discarded.  
 
2.1.4.4  Astrocyte 'perforated patch': imaging fluorescent dyes in 
neighbouring astrocytes that have diffused in through gap junctions 
As detailed in chapter 4, this thesis incorporates a novel ‘astrocyte perforated 
patch’ method. This entails whole cell patch clamp of an astrocyte and the subsequent 
imaging of nearby gap-junction coupled astrocytes. This requires low input resistance, a 
healthy astrocyte population and some time for dye perfusion through the syncytium – all 
of which are standard for astrocyte patch clamp. Hence the success rate for ‘astrocyte 
perforated-patch’ recordings is the same as for normal astrocyte patch recordings, as all the 
criteria for a viable recording are the same. For these recordings a recording configuration 
was chosen to allow simultaneous recording from both the patched cell processes and the 
GJC somata. On some occasions, where it was impossible to achieve this, GJC somata, only 
were recorded. Recordings were only made when the diffusion of the dye from the pipette 
into the syncytium had reached a constant rate, as measured by the intensity of the 
reference dye, Alexa 594. If large fluctuations in Alexa 594 intensity in GJCs were witnessed, 
the recording was discarded. 
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2.1.4.5  Clamping intracellular astrocytic calcium through the patch pipette 
For Ca2+-clamp experiments in chapter 5, 0.45mM EGTA and 0.14mM CaCl2  were 
added to the pipette solution. Alexa 594 was also included in the intracellular pipette 
solution as a morphological marker, if astrocyte-type morphology and gap-junction 
coupling was not observed, recordings were discarded.  
 
2.1.5 Post-Hoc analysis of electrophysiological recordings and fluorescence 
images 
2.1.5.1 Electrophysiology: analysis of fEPSP voltage traces 
Raw wincp and pClamp data files were exported in ABF format, and analysed using 
clampfit 10.2. To analyse fEPSPs, baseline regions in a trace were set manually over at least 
50ms before any external stimuli given; regions of interest (ROIs) were also delineated 
manually and analysed automatically. ROIs were fibre-volley, fEPSP slope (20-60%) and 
fEPSP amplitude (as shown in figure 2.1), analysed for both stimuli in a paired-pulse 
protocol. All fEPSP data presented is baseline subtracted. To analyse afEPSPs the average 
membrane potential 30-50ms post stimulus was subtracted from the amplitude at the time 
of maximal fEPSP response amplitude – a measurement linearly correlated with the nearby 
fEPSP slope (Henneberger and Rusakov, 2012). 
 
2.1.5.2  Fluorescence imaging: raw image intensity analysis, normalization 
to dye concentration, normalization to tissue movement and 
normalization to baseline calcium indicator fluorescence 
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Raw .pic image files (Biorad imaging software) and .oib image files (Olympus 
imaging software) were analysed in ImageJ. ROIs were divided into four categories: Patched 
cell (PC) soma; PC process; PC arbour and GJC soma. Each ROI was manually outlined in the 
morphological dye channel image and saved in the ROI manager, to allow analysis of exactly 
the same area in any other channel. Only visible structures with clear astrocyte morphology 
were chosen as ROIs. An area of each image showing no fluorescence from the 
morphological marker was chosen to give a measure of average background fluorescence. 
For each ROI the average pixel fluorescence was taken for each frame and the average 
background pixel fluorescence for that frame was subtracted (to correct for instrumental 
noise). Fluo-4 signal was normalized to the morphological marker signal to correct for 
fluorescence changes due to tissue movement (giving G/R) and laser power fluctuation. 
Fluo-4 signals presented here have been normalized to the average fluorescence from each 
ROI in the baseline phase of each recording, to give ΔF/F0. The normalizing value includes 
fluorescence increases from spontaneous calcium dynamics and may therefore be higher 
than the fluorescence value at ‘resting’ calcium state.  
I consider there to be an important semantic difference between ‘resting’ and 
‘baseline’ Ca2+ states as recorded from the astrocytes in this thesis: the ‘resting’ state refers 
to the intracellular Ca2+ level (as measured by dye fluorescence) to which the cytoplasm 
returns to when not undergoing spontaneous activity, during a defined pre-stimulation 
period. This can also be thought of as the modal fluorescence value recorded from pre-
stimulation astrocytes, the one at which it can be most often found. By binning continuous 
G/R values, one can determine the modal value of a fluorescence data set. The ‘baseline’ 
Ca2+ state includes spontaneous activity – it simply takes the mean of all G/R values. Hence 
normalization of G/R to the ‘baseline’ value reports all effects relative to the amount of pre-
existing Ca2+ activity in the recorded area, whereas normalization to ‘resting’ shows change 
in Ca2+ dynamics relative to the recorded area’s preferred Ca2+ concentration. 
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It is only possible to use a modal analysis in cells with a clear ‘resting’ Ca2+ 
concentration. This is only practically possible in whole-cell recordings, when the resolution 
of spontaneous events is clear – here, the relative increase in F/F0 during a spontaneous 
event at baseline can be so great that it raises the mean baseline fluorescence noticeably 
above the ‘resting’ baseline fluorescence. If it is impossible to reliably resolve individual 
Ca2+ transients (as in many bulk-loaded slice recordings) then one cannot define the 
‘resting’ calcium level. For consistency across my experimental methods, the baseline 
fluorescence (mean G/R over 10 minutes pre-stimulation) is always used for normalization 
purposes. For all experiments involving a single dopamine application, the aim was to 
record average calcium dynamics over separate conditions; therefore all cells were included 
in the analysis regardless of the size of their calcium response. For double dopamine 
application protocols, the aim was to compare the effect of a modulator on a pre-
established dopamine response in one slice – in this case cells that did not respond to the 
first dopamine stimulus were excluded from analysis. Averages obtained for bar charts 
were taken from the average of t=13-17 minutes for each trace (unless otherwise stated) 
and error bars indicate standard error. 
Dopamine induced astrocytic calcium signals stop when the dopamine is removed 
from the environment (Otmakhova and Lisman 1999; Parpura and Haydon 2000); 
therefore, if no washout of the effect was seen (in experimental protocols featuring 
washout stage) the cells were judged to have become unhealthy (through over-stimulation 
or poor slice health), their homeostatic mechanisms failed, and the data were discarded. If 
the resting calcium dynamics was unstable during the baseline phase of an experiment, 
cells were also discarded.  
 
2.1.5.3  Novel spontaneous astrocyte calcium-oscillation analysis 
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In order to analyse the relative spontaneous fluorescence activity between 
different regions of ΔF/F0 traces a modified coastline analysis was designed to give a 
quantitative readout of relative astrocyte calcium signalling. Oscillatory activity is 
characterized by large, rapid changes in F/F0 – this is quantified by finding the range of 
ΔF/F0 for each recording minute (max-min). This readout is highly noise sensitive – large 
noise would give equal max-min values to those recorded from spontaneous oscillations –
and the coastline [the cumulative absolute difference in fluorescence between consecutive 
data points] takes the noise over each minute into account, in effect normalizing the max-
min values to the noise of the recording. So, oscillatory values were obtained by taking the 
coastline, the minimum and the maximum value for each minute and then entered into the 
following equation: 
Oscillatory activity = 
       
         
 
Averages obtained for bar charts were taken from the average of t=13-17 minutes for each 
trace (unless otherwise stated) and error bars indicate standard error. This analysis is 
further detailed in chapter 3.  
 
2.1.5.4  Novel relative frequency distribution analysis of normalized 
fluorescence change (ΔF/F0) over baseline and test epochs 
For analysing dopamine induced ΔF/F0 decreases, averaging ΔF/F0 over time is not 
possible. This is because the increase in ΔF/F0, when averaged over the whole population of 
recorded cells, is of much greater amplitude than any decrease in ΔF/F0 during any given 
minute. Therefore, as detailed in chapter 4, I plotted the ΔF/F0 relative frequency 
distribution in both baseline and dopamine conditions. These can be compared by eye in 
the main figures, but I also modelled each distribution, based on the assumption that each 
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one could be modelled as the sum of 1, 2 or 3 Guassian distributions. These are plotted in 
the supplementary figures. For each Guassian fit the following was given: the x-coordinate 
of the peak, the standard deviation, the full width at half maximum and the R2 
measurement of how well the distribution correlates with the observed data. Histograms 
are binned in divisions of 0.05, each ΔF/F0 recording, at 1Hz, is plotted on these histograms. 
‘Baseline’ distribution data is sampled from t=1-720s and ‘dopamine’ distribution data is 
sampled from t=721-1200s. 
 
2.2 Ventral tegmental area transfection with channelrhodopsin in a viral vector  
 2.2.1 Virus injection: surgery and injection parameters 
50-60g juvenile male Sprague-Dawley rats were anaesthetised with a mixture of 
ketamine (60 mg/kg) and medetomidine (250 mg/kg) intra-muscular. Additional 
anaesthesia was administered depending on the duration of the surgery. The head was 
shaved and cleaned with chlorohexidine. The head was positioned in a stereotaxic frame 
and protective ophthalmic gel was applied. A midline incision was made and the skull was 
cleaned and dried. A small craniotomy was performed within the right parietal bone. The 
surface of the brain was flushed with Ringer to remove any blood products. The virus 
(AAVsCaMKII-ChR2(H134R)-Venus YFP suspended in filtered saline (1:10) was injected into 
two sites in the Ventral Tegmental Area (VTA) (2μl per injection). The distance between 
Bregma and Lamda for these juvenile rats was measured and used to calculate the relative 
position of the VTA compared to that in adults – the recorded distance between bregma 
and lamda was divided by the value in the Rat brain atlas and the resulting ratio multiplied 
by the co-ordinates of the VTA in the atlas (x=2, y=8, z=6,7) to give approximate co-
ordinates of VTA for each juvenile rat. The injection pipette was slowly inserted and 
injections were made at two depths at 0.5mm intervals, injecting 1μl at each depth 
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followed by a 5 minute pause, then the pipette slowly removed. The skin was sutured. 
Buprenorphonine was administered (0.05 mg/kg s.c.) and the anaesthesia was reversed 
with atipemazole (1mg/kg i.m.). Post-operative care was given. The animals were allowed 
to recover for 14/21 days to allow transgene expression.  
 
2.2.2 Transfected brain fixation, VTA and hippocampal slice preparation and  
tyrosine hydroxylase immunohistochemistry 
Rats were terminally anesthatised (urethane, 1.5 g/kg i.p.) and intracardially 
perfused with saline followed by ice cold 4% paraformaldehyde. The brains were removed 
and post-fixed overnight at 4°C. The brains were soaked in sucrose (30%, 4°C) for a further 
24 hours. The brains were sliced into 60μm thick sections and serially mounted. Mounting 
medium containing DAPI (Vectashield) was applied and the coverslips secured. For 
immunohistochemical identification of dopaminergic neurons and axons, tissue was 
incubated in sheep anti-Tyrosine Hydroxylase antibody (1:250, Abcam) overnight at 4°C, 
then again in secondary donkey anti-sheep Alexa 568 (1:500, Molecular probes). 
Fluorescence of YFP and Alexa 568 were imaged on a Zeiss AX10 bright-field microscope. 
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Chapter 3: Results 1  
Dopamine triggers an increase in cytosolic calcium of hippocampal 
astrocytes in a dopamine receptor and monoamine oxidase-modulated manner. 
 
3.1 Introduction 
 Astrocytes are known to respond to application of various endogenous ligands with 
increases in cytosolic Ca2+, most notably glutamate (Cornell-Bell et al. 1990; Porter and 
McCarthy 1995b) and ATP (McCarthy and Salm 1991; Porter and McCarthy 1995a), both in 
culture conditions and in hippocampal slice preparation. These Ca2+ transients can be 
mediated by metabotropic receptors (Kastritsis et al. 1992; Porter and McCarthy 1995a), 
dependent on release of Ca2+ from the smooth endoplasmic reticulum via inositol 
trisphosphate (IP3) production (Pearce et al. 1986a; Glaum et al. 1990; Foskett et al. 2007; 
Verkhratsky et al. 2012), and also potentially by Ca2+ entry through VGCCs and the 
sodium/calcium exchanger (Rusakov et al. 2014), as well as through extracellular 
concentration of Ca2+ itself (Torres et al. 2012). Unlike neurons, individual astrocytes do not 
exhibit stereotyped Ca2+ responses to identical stimuli (Cornell-Bell et al. 1990; Bernardinelli 
et al. 2011). Ca2+ responses can be broadly divided into increases in resting Ca2+ level from 
baseline (Parpura and Haydon 2000) or changes in the frequency or nature of spontaneous 
Ca2+ oscillations (Parri et al. 2001; Shigetomi et al. 2011; Tanaka et al. 2013). Exogenous 
application of the endogenous ligand dopamine has been shown to trigger increases in 
intracellular calcium (Parpura and Haydon 2000; Requardt et al. 2012) in cultured 
astrocytes, through D1, D2 and novel D1-type dopamine receptors, as well as through ROS 
creation from dopamine metabolism (Khan et al. 2001; Liu et al. 2009a; Vaarmann et al. 
94 
 
2010; Requardt et al. 2012). In this chapter I provide evidence that exogenous application 
of dopamine can trigger calcium transients in situ in intact rodent hippocampal tissue. 
 
3.2 Methods 
Briefly, transverse hippocampal slices were taken from p21-25 male Sprague-
Dawley rats, or C57/BL6 wild-type and transgenic mice where stated, and bulk loaded with 
the specific astrocyte marker SR101 (NimmerJahn et al. 2004) and the calcium indicator 
Fluo-4-AM. All experiments were conducted at room temperature (19-21°C). Astrocyte 
somata (up to three at a time) were imaged from the Schaffer collateral region of CA1 with 
a 2P-setup at an excitation laser power of 5-8mW, at a frame rate of 1Hz. Emitted light was 
collected in two channels, 515-530nm (peak Fluo-4-AM emission wavelength = 515nm)  and 
540-700nm (peak SR101 emission wavelength = 592nm) using a modified Bio-Rad Radiance 
2000 two-photon imaging system. Fluorescence intensity for each cell, per frame, is 
calculated as the average fluorescence of all pixels in the area manually defined as the cell 
soma. Fluo-4-AM fluorescence intensity is normalized to SR101 fluorescence intensity (G/R) 
to correct for tissue movement. This normalized value (G/R) is then itself normalized to its 
baseline average value, to give a baseline-normalized time course of cytosolic calcium 
dynamics (ΔF/F0) from astrocyte somata. Cells with unstable resting calcium in the baseline 
condition (i.e. fluctuations unlike normally observed calcium transients or a constantly 
rising baseline) were discarded. Unless otherwise stated, dopamine (DA) was applied at 
100μM. Cells with no DA washout were also discarded. For single DA applications, all 
recorded cells were used in the analysis; for double DA applications only cells showing a 
clear calcium change in response to the first DA application were used. For single DA 
application, the peak response to DA was found to be between 3-7 minutes post 
application (likely due to the perfusion time of the DA through the system) and so it was 
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from t=13-17 that the average fluorescence intensity was taken for statistics. Baseline 
average fluorescence intensity was taken from the 5 minutes preceding DA application. The 
data presented in this chapter are averaged over the total number of cells and for each 
experimental minute, error bars show the SEM. For the purposes of statistical analysis, n 
was taken to be the total number of cells sampled, although total number of slices and 
animals are also given. Baseline ΔF/F was assumed to be 1 and the population of ΔF/F 
averages during dopamine application was tested for normality using the Shapiro-Wilk test, 
before using a single sample t-test; unless otherwise stated, data was normally distributed. 
Where the normality test failed the Wilcolxon signed rank test was used. To compare two 
normally distributed populations, a two-sample t-test was used. If either population was 
not normally distributed the Mann-Whitney test was used to compare both. 
 
3.3 Results 
3.3.1 Bulk-loaded astrocytes respond to dopamine with an average increase in 
cytosolic calcium concentration, in a concentration dependent manner. 
First, I tested whether astrocytes in situ could respond at all to dopamine (DA) 
application, as has been reported in culture. Hippocampal CA1 astrocytes loaded with 
SR101 and Fluo-4-AM show a clear increase in Fluo-4 fluorescence in response to a bath 
application of 100μM DA from t = 11-20 (figure 3.1a, b) – the average ΔF/F0 during DA 
application (t=13-17) is significantly increased to 1.93 ± 0.12 of baseline (figure 3.1c, d) 
(p<0.001, 1-sample t-test, n=16; data from 16 cells, 6 slices, 4 animals).  
I then went on to test the sensitivity of astrocytes to dopamine. 10μM DA 
application also elicited a significant fluorescence increase (figure 3.1d) (p=0.026, 1-sample 
t-test, n=11; data from 11 cells, 4 slices, 4 animals), but to a smaller degree – 1.46 ± 0.18.  
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Figure 3.1  Bulk loaded astrocytes respond to Dopamine with an increase in 
cytosolic calcium concentration. 
a) Representative images of SR101 channel (top row) and Fluo-4 channel (bottom row) for time 
points marked in traces in b) time course of Fluo-4/SR101 for cell A (top) and cell B (bottom) during 
100μM dopamine application.  c) Average ΔF/F0 for 100μM dopamine application. d) Summary bar 
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chart of ΔF/F0 in response to different DA concentrations; cell n-numbers shown inside bars, n.s. = 
non-significant, * = p<0.05, *** = p<0.001 – t-test (1). 
 
The population of averages during 5μM DA application is not normally distributed (p=0.001, 
Shapiro-Wilk test), and is not significant significantly different from baseline when tested 
non-parametrically (p=0.147, 1-sample Wilcolxon signed rank test, n=14). Application of 
1μM DA also shows no significant F/F0 change from baseline (p=0.14, 1-sample t-test, n=14; 
data from 16 cells, 7 slices, 4 animals). 
 
3.3.2 A modified coastline analysis of spontaneous calcium dynamics. 
Astrocytes exhibit spontaneous Ca2+ transients, visible as short, sharp increases in 
Fluo-4-AM intensity (figure 3.1b). Application of DA can decrease the frequency of these 
spontaneous oscillations recorded at baseline, but increase the average recorded 
fluorescence by increasing the resting Fluo-4 fluorescence visible at the soma. A change in 
the oscillatory activity could indicate a change in the information carried by the Ca2+ signal – 
hence it is an important feature to analyse. 
I have created a simple measure of oscillatory activity for any fluorescence signal 
over a given time interval (see chapter 2) – the interval chosen here is always 1 minute. The 
range of fluorescence intensity (min-max) is normalized to the coastline [the cumulative 
absolute difference in fluorescence between consecutive data points] (figure 3.2a). This can 
be expressed as: 
Oscillatory activity = 
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An oscillatory activity value is computed for each minute of a given ΔF/F0 trace. Unlike 
manual selection of putative astrocytic calcium transients, which is open to bias, this is a 
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truly independent measure of oscillatory activity. A high output value indicates the 
presence of a large range of fluorescence (a hallmark of astrocyte Ca2+ transients) that 
cannot be attributed to high noise (as this would increase the coastline value, bringing 
down the output value), whereas a low output value indicates a low range, and therefore 
no oscillatory activity, or high background noise – conditions where identification of Ca2+ 
transients is not possible. As the output value is highly sensitive to signal variability, this 
formula should only be used to compare baseline and test conditions in the same 
experimental setup where the background noise is similar.  
 
3.3.3 Dopamine at lower, but not higher concentrations, increases oscillatory 
calcium dynamics. 
 The same cells as were analysed for average change in fluorescence intensity in 
section 3.3.1 were now analysed for changes in oscillatory activity, comparing baseline 
conditions to during dopamine application. Oscillatory activity values were calculated for 
each minute. 1μM dopamine does not change average oscillatory activity (p=0.967, 1-
sample t-test, n=14) and neither does 5μM dopamine (p=0.202, 1-sample t-test, n=14). The 
oscillatory activity data from the application of 10μM dopamine are not normally 
distributed (p=0.025, Shapiro-Wilk test) but their median is significantly increased – 1.11 of 
baseline (p=0.001, 1-sample Wilcolxon signed rank test, n=11). However 100μM dopamine 
does not significantly increase oscillatory activity (p=0.3, 1-sample t-test, n=16). 
 
3.3.4 Dopamine can act directly on astrocytes. 
The next task was to check whether this dopamine-induced fluorescence increase 
was an indirect result of a dopaminergic effect on neurons. This was done first by blocking 
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neuronal firing: blockade of voltage-gated sodium channels with tetrodotoxin (TTX) (1μM) 
during dopamine (100μM) application had no effect on the dopamine-induced increase in 
Fluo-4 (figure 3.3a): ΔF/F0 during dopamine application is 2.06, significantly increased from 
baseline (p<0.001, 1-sample t-test, n=18) and not significantly different from the response 
to 100μM dopamine in control conditions (p=0.567, 2-sample t-test). There is however a 
change in the oscillatory activity, an increase to 1.07 ± 0.03 compared to baseline (p=0.044, 
1-sample t-test, n=18) and a significant increase of 0.12 from the oscillatory activity of 
100μM dopamine control (p=0.035, 2-sample t-test) – data not shown. There is no 
significant effect of TTX alone on the resting fluorescence, measured at t=16-20 (p=0.078,1-
sample t-test, n=18) or oscillatory activity (p=0.13, 1-sample t-test, n=18); data from 18 
cells, 8 slices, 3 animals.  
Direct dopaminergic activation of neurons could lead to TTX-insensitive glutamate 
release, which could trigger mGluR-dependent Ca2+ increases. Hence, dopamine stimulation 
was conducted the presence of MCPG, a group I/II metabotropic glutamate receptor 
(mGluR) antagonist, (200μM). 100μM did not affect the dopamine response (figure 3a): 
ΔF/F0 in MCPG and dopamine is 2.3 ± 0.21 of baseline (p<0.001, paired t-test, n=11) – not 
significantly different from the fluorescence increase in 100μM dopamine control 
conditions (p=0.131, 2-sample t-test) – and does not change oscillatory activity (p=0.612, 1- 
sample t-test, n=11); MCPG alone has no effect on baseline fluorescence (p=0.607, 1-
sample t-test, n=11) or oscillatory activity (p=0.793, 1-sample t-test, n=11); data from 11 
cells, 5 slices, 3 animals. There is no significant difference in fluorescence increase between 
100μM DA alone and in TTX (p=0.9, two-sample t-test) or in MCPG (p=0.335, two-sample t-
test). 
 
3.3.5 Dopamine acts through dopamine receptors. 
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Is this fluorescence increase mediated by dopamine receptors? When D1/5Rs and 
D2/3Rs are blocked simultaneously with SCH23390 (20μM) and Sulpiride (50μM) 
respectively, dopamine ceases to have any effect on Fluo-4 fluorescence (figure 3.3a): the 
distribution of averages is not normal (p=0.018, Shapiro-Wilk test) and there is no  
 
 
Figure 3.3 Pharmacology of the astrocytic calcium response to dopamine. 
a) Summary bar chart of fluorescence responses to 100μM dopamine in presence of various receptor 
blockers: 1μM TTX, 200μM MCPG, 25μM SCH23390 + 50μM Sulpiride, 20μM Selegiline; b) Summary 
bar chart of wild type (WT) and IP3 Sponge response to 100μM dopamine. Cell n-numbers shown 
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inside bars, * = p<0.05, *** = p<0.001 – t-test (1); n.s. = non-significant – 1-sample Wilcoxon-signed 
rank test, or Mann-Whitney test for WT/IP3 Sponge comparison. 
 
fluorescence (p=0.348, 1-sample Wilcolxon signed rank test, n=16); data from 16 cells, 13 
slices, 9 animals. significant difference between the median fluorescence response to 
dopamine in the presence of dopamine-receptor (DR) blockers – and baseline (p=0.274, 1-
sample Wilcolxon signed rank test, n=16); likewise in the presence of only DR blockers the 
data are not normally distributed (p=0.017, Shapiro-Wilk test) and there is no significant 
difference in 
Using a repetead DA application protocol (see section 3.3.7), blockade of DRs with 
SCH23390 (20μM) and Sulpiride (50μM) reduced ΔF/F0 in response to the 2
nd dopamine 
application to a level not significantly different (but approaching significance) from baseline 
(p=0.065, 1-sample Wilcolxon signed rank test, n=16; data not normally distributed, 
p=0.044, Shapiro-Wilk test) and significantly smaller than the response to the 1st dopamine 
application (0.2 difference in medians, p<0.001, Wilcoxon signed ranks test); data from 16 
cells, 12 slices, 6 animals. The ratio of 2nd/1st ΔF/F0 means was significantly different from 1 
(p<0.001, 1-sample t-test, n=16) and significantly different from the control 2nd/1st ΔF/F0 
ratio (p=0.009, Mann-Whitney test). However, when the 2nd dopamine applications are 
compared between conditions (unpaired data), there is no significant difference between 
control and dopamine application and that in SCH23390 and Sulpiride (p=0.062, 2-sample t-
test). 
 
3.3.6 There is no clear evidence that dopamine acts through the IP3 receptor 
signalling cascade  
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Blockade of intracellular IP3Rs with 2-APB (100μM) in the double dopamine-
application paradigm decreased the dopamine-induced fluorescence response upon 2nd 
application (figure 3.4d) to a level statistically indistinguishable from baseline (p=0.251, 1-
sample t-test, n=20) and significantly lower than that evoked by the 1st dopamine 
application (0.38 median difference, p<0.001, Wilcoxon signed ranks test). 2-APB alone, 
prior to 2nd dopamine, did not reach a significant increase (p=0.177, 1-sample Wilcolxon 
signed rank test, n=20; not normally distributed, p=0.016, Shapiro-Wilk test); data from 20 
cells, 7 slices, 5 animals. The ratio of 2nd/1st dopamine-induced fluorescence increases is less 
than 1 (p<0.001, 1-sample t-test, n=20), but is not significantly different from the control 
ratio (p=0.137, Mann-Whitney test). However, when the 2nd dopamine applications are 
compared between conditions (unpaired data), there is no significant difference between 
control and dopamine application and that in 2-APB (p=0.072, 2-sample t-test). 
IP3 involvement was also investigated using a transgenic mouse line expressing a 
genetically encoded IP3-buffering sponge protein – but this did not show an effect of the 
transgene (figure 3.3b). Single application of 100μM dopamine raised Fluo-4 fluorescence in 
both wild-type (WT) and IP3-sponge animals: neither averages from WT or sponge have a 
normal distribution (p=0.015 and p=0.033 respectively, Shapiro-Wilk test), both medians 
are significantly greater than baseline, 1.25 and 1.20 (p<0.001 for both, 1-sample Wilcolxon 
signed rank test, n=18 and n=16) but they are not significantly different from each other 
(p=0.283, Mann-Whitney); WT data from 18 cells, 10 slices, 8 animals; Sponge data from 16 
cells, 8 slices, 5 animals. 
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Figure 3.4 Astrocytic calcium response to a repeated dopamine application. 
a) Representative images of SR101 channel (top row) and Fluo-4 channel (bottom row) for time 
points marked in traces in b) representitive time course of Fluo-4/SR101 during 100μM dopamine 
application.  c) Average ΔF/F0 for double 100μM dopamine application. d) Summary bar chart of 
ΔF/F0 for 1
st
 (hollow bars) and 2
nd
 (hatched bars) dopamine applications, with the 2
nd
 dopamine 
stimulus in presence of various receptor blockers: 25μM SCH23390 + 50μM Sulpiride, 20μM 
Selegiline, 100μM 2-APB. e) 1
st
: 2
nd
 dopamine response ratio of ΔF/F0 means for conditions shown in 
d). cell n-numbers shown inside bars, n.s. = non-significant, ** = p<0.01, * = p<0.05 – t-test (1), 1-
sample signed wilcoxon rank test, Mann-Whitney test (see text). 
 
 
3.3.7 A repeated dopamine application triggers comparable calcium increases.  
I also used a different dopamine double stimulation paradigm for some recordings 
(two five-minute 100μM applications – the second in the presence of blockers – see figure 
3.4) in order to be sure that each astrocyte which was pharmacologically interrogated did 
originally have the ability to respond to dopamine. For each pharmacological assay using 
this protocol, I have shown the mean ΔF/F0 recorded from both dopamine applications 
(figure 3.3d) as well as the ratio of the 2nd/1st ΔF/F0 means (figure 3.3.e).  
A repeated application of dopamine (100μM) from t=6-10 and t=31-35 (figure 3.4a, 
b), with a 20 minute inter-stimulus washout period with and no pharmacological blockade 
during the second application, triggers a significant increase in ΔF/F0 from baseline during 
both the first dopamine application (figure 3.4c) – measured from t=8-10 – to a median of 
1.39 (p=0.017, 1-sample Wilcolxon signed rank test, n=14; not normally distributed, 
p<0.001, Shapiro-Wilk test) and the second dopamine application – measured from t=33-35 
– to a mean of 1.28 ± 0.06 (p<0.001, 1-sample t-test, normally distributed). The second of 
these two dopamine-induced fluorescence increases is significantly smaller than the first 
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(medians differ by 0.2, p=0.009, Mann-Whitney test). The mean ratios of the 2nd/1st ΔF/F0 
(not normally distributed, p<0.001, Shapiro-Wilk test) is significantly different from 1 
(p=0.016, Wilcoxon signed ranks test, n=14), with a median of 0.55. 
 
3.3.8 Blockade of mono-amine oxidase both increases baseline calcium 
concentration and blocks dopamine-induced calcium increase. 
Astrocytic dopamine-dependent signalling has been reported to act through DA 
break down by monoamine-oxidase B (MAOb) (Vaarmann et al. 2010). Addition of the 
MAOb inhibitor selegiline (20μM) to the bath alone significantly increases the baseline 
astrocytic fluo-4 fluorescence in a single dopamine application paradigm (figure 3.3a) 
(p=0.025, 1-sample Wilcolxon signed rank test, n=22; data not normally distributed, 
p=0.016, Shapiro-Wilk test) but not with a repeated dopamine application (p=0.176, 1-
sample t-test, n=21). Subsequent addition of dopamine, following 10 minute pre-incubation 
with selegiline, caused a significant increase in ΔF/F0 to a median of 1.19 in a single 
dopamine application paradigm (p<0.001, 1-sample Wilcolxon signed rank test, n=22; data 
not normally distributed, p=0.015, Shapiro-Wilk test) and also in a repeated dopamine 
application paradigm to a mean of 1.12 (p<0.001, 1-sample t-test, n=21). For single 
application, the dopamine-induced increase was higher than that caused by selegiline alone 
(0.06 difference in medians, p=0.03, Wilcoxon signed ranks test), but far lower than that 
recorded in control conditions (difference in medians 0.66, p<0.001, Mann-Whitney test). 
For repeated application, the increase in fluorescence from 1st dopamine application was 
larger than the 2nd (in selegiline) (median difference 0.19, p<0.001, Wilcoxon signed ranks 
test). The ratio of 2nd/1st mean fluorescence responses was significantly less than 1 
(p<0.001, 1-sample t-test), but not significantly different to the control ratio (p=0.134, 
Mann-Whitney test). When the 2nd dopamine applications are compared between 
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conditions (unpaired data), the dopamine application in selegiline is significantly smaller 
(p=0.039, 2-sample t-test). 
 
3.4 Discussion 
3.4.1 How does the average dopamine-induced astrocytic calcium increase in 
slice compare to that in the culture literature? 
  3.4.1.1 Peak amplitude of dopamine-induced astrocytic calcium increases  
The most striking result from this chapter is dopamine’s clear and consistent ability 
to increase the cytosolic calcium levels in astrocytes in situ at concentrations from 10-
100μM (figure 3.1) and for application lengths of 5-10 minutes and after repeated 
application (figure 3.2) – as measured by an increase in fluo-4-AM fluorescence. Dopamine 
itself, or agonists of the various dopamine receptors, has previously been shown to trigger 
calcium increases in cultured astrocytes (Parpura and Haydon 2000; Khan et al. 2001; Liu et 
al. 2009a; Vaarmann et al. 2010; Requardt et al. 2012).  up to a wide range of reported 
values. Parpura and Haydon (2000) show a 100-fold increase in free calcium concentration 
directly following dopamine application, although they do not give the relative 
fluorescence. In contrast, Khan et al. (2002) show only a 1.2-fold increase in fluorescence 
upon addition of the D2R agonist quinpirole. The more recent reports from Vaarmann et al. 
(2010) and Requardt et al. (2012) reliably find 2 to 3-fold calcium increases upon 
application of dopamine itself and likewise Liu et al. (2009) show a similar range of 
fluorescence increases upon astrocyte stimulation with a D1-like receptor agonist. My data 
show a two-fold average increase in cytosolic calcium upon maximal stimulation with 
100μM dopamine (see below in this section for a discussion of ‘maximal’) – in agreement 
with the more recent reports. An earlier study by Parpura and Haydon (2000) reports a 
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much shorter (~10s) and very large (~30 fold increase) Ca2+ transient upon DA stimulation – 
but this may be due to the extended length of time they cultured their cells for (up to 40 
days) before recording, allowing the cells to modify their intracellular pathways, change 
their response to DA. Conversely, the tiny increase seen by Khan et al. (2001) the result of 
stimulation of only a small proportion of the dopamine-responsive machinery in astrocytes. 
 
3.4.1.2 How do dopamine-induced astrocytic calcium increases change 
over time? 
The response of cultured astrocytes to dopamine, or dopamine receptor agonists, is 
not uniform over time – often a large initial transient is seen, followed by further smaller 
transients or a return to baseline (Parpura and Haydon, 2000; Khan et al. 2001; Liu et al. 
2009; Vaarmann et al. 2010; Requardt et al. 2012). This is different from the continued 
increase in baseline calcium concentration, throughout the presence of dopamine, that I 
report here. The difference can be explained in three ways: firstly, a fundamental difference 
in the nature of the astrocytic calcium response to dopamine between cultured astrocytes 
and those in situ, support for which is provided by Vaarmann et al. (2010) who show that 
explant cultures respond differently and more vigorously than normally cultured astrocytes; 
secondly, a change in the nature of stimulation attributed to adding dopamine to the 
perfusion solution that is unique to the in situ environment; thirdly, a switch between 
increased calcium transient frequency and sustained baseline calcium increase, dependent 
upon dopamine concentration. Support for the latter comes from the oscillation analysis I 
have performed (figure 3.2), see discussion section 3.4.2 – which shows an increase in 
dopamine-induced calcium transients at 10μM, but not 100μM dopamine. Liu et al. (2009) 
find that increasing the concentration of their D1-like agonist from 25μM to 100μM (a 
proportional similar increase) changes their calcium response from a single transient to a 
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sustained increase, but Requardt et al. (2012) show that 100μM dopamine triggers a 
qualitatively similar increase in calcium transient frequency to 20μM dopamine. The key 
difference lies in the specific stimulation of the D1-like receptor by Liu et al; Vaarmann et al. 
have shown that catabolism of the dopamine molecule (as used by Requardt et al.) can 
influence astrocytic calcium signalling – and the cortical astrocytes used by Requardt et al. 
have been shown to express functional D2-like receptors (Khan et al. 2001; Duffy et al. 
2011; Shao et al. 2013), which they did not block. Co-activation of D2-like receptors could 
modulate the intracellular calcium response to dopamine. 
 
3.4.1.3 Active dopamine concentration  required to trigger a calcium 
increase  
A dopamine-induced increase in astrocytic Ca2+ transients has been reported at 10-
20μM dopamine (Liu et al. 2009a; Vaarmann et al. 2010; Requardt et al. 2012) – I examine 
this further in discussion section 3.4.2 – as well as the sustained increase in resting Ca2+ 
reported above. Regarding the sustained increases reported by Liu et al, Vaarmann et al. 
(explant work) and myself at 100μM dopamine – it is possible that such high levels of 
dopamine are cytotoxic (see Vaarmann et al. 2010). However, the fact that the cessation of 
the effect coincides temporally with the washout of dopamine (only reported in this thesis) 
suggests that this is not a pathological effect of high dopamine concentrations, but rather 
the product of a very strong dopaminergic stimulation of astrocytes. Throughout this thesis 
I treat this exogenous application of 100μM dopamine as ‘maximal’ stimulation, as it is 
regarded throughout the dopamine literature, because it is highly unlikely that the 
concentration of dopamine would ever exceed this under physiological conditions. It is 
important to note that the concentration of dopamine added to the bath is greater than 
the concentration that eventually reaches the imaged cells in the slice, for two main 
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reasons: firstly, dopamine autoxidates in oxygenated, pH 7.4, solution (Herlinger et al. 
1995) – producing free-radicals and eventually melanin; secondly, dopamine in the 
hippocampus is taken up by the norepinephrine transporter (NET) on noradrenergic axon 
terminals (Carboni et al. 1990; Borgkvist et al. 2012) and astrocytes (Takeda et al. 2002). 
Hence a portion of any bath applied dopamine may be cleared or may degrade before it 
reaches the imaged cells, more so than in culture – making direct comparisons of dopamine 
concentration effects difficult. 
 
3.4.2 What could be the relevance for the increase in oscillatory activity 
compared to a baseline increase? 
Spontaneous calcium oscillations in astrocytes are of great interest as they can 
occur stochastically (Parri et al. 2001) or can correlate with and display properties 
dependent on the surrounding spontaneous neuronal activity (Aguado et al. 2002; Di Castro 
et al. 2011). Evoked transients do not necessarily correspond to those seen under 
physiological conditions and, when triggered, do not necessarily affect the overall astrocyte 
action (Fiacco et al. 2007; Agulhon et al. 2010). Indeed, the MRGA1-induced calcium 
increases described by Fiacco et al. are similar in amplitude and kinetics to those I have 
recorded in response to 100μM dopamine (although unlike after dopamine stimulation, 
they record no washout). Hence, identification of a dopamine-induced change in 
spontaneous activity would provide clearer evidence of a physiological role for dopamine in 
astrocyte calcium dynamics – a change that was demonstrated in this chapter (figure 3.2). 
The novel method I describe for measuring spontaneous oscillatory activity is 
designed to be entirely objective. To this end it sacrifices the manual identification of 
individual spontaneous events (for which there is, as yet, no universal classification) and all 
the potential detail that could be gained from analysis of individual events, for an overall 
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value per minute. The results, when averaged over the many recorded traces, still show a 
striking pattern – dopamine increases the relative spontaneous calcium dynamics at 10μM 
but does not at 100μM. Indeed, there are examples of cells in this chapter (figure 3.1b) that 
display decreased spontaneous activity, but increased average fluorescence, upon 
application of 100μM dopamine. This suggests either that increasing the stimulation 
strength increases the frequency of calcium transients to a point where they elide, 
appearing as a higher resting calcium level, or that an increase in resting calcium 
concentration in astrocytes (caused by high dopamine concentrations) negates dopamine’s 
previous capacity to trigger spontaneous calcium oscillations. Given that spontaneous 
events are often greater in amplitude than the 100μM dopamine-induced calcium increase, 
the latter seems more likely. This would indicate that spontaneous calcium oscillations and 
resting calcium concentration are separate, but dependent aspects of astrocytic calcium 
dynamics, both of which can be controlled by dopamine.  
 
3.4.3 A putative molecular pathway for the actions of dopamine on astrocytic 
calcium. 
3.4.3.1 Dopamine’s effects are independent of resting spontaneous 
neuronal activity in the hippocampal slice 
 Dopamine has been reported to stimulate glutamate release (Cameron and 
Williams 1993; Bouron and Reuter 1999) from presynaptic neurons – and glutamate can 
elicit astrocytic calcium dynamics via mGluRs (Porter and McCarthy 1995b; Porter and 
McCarthy 1996; Fiacco et al. 2007). However, I found that neither inhibition of neuronal 
firing, nor inhibition of mGluR signalling could block the dopaminergic initiation of astrocyte 
calcium transients (figure 3.3). Dopamine has been shown to act on interneurons in the 
pre-frontal cortex and hippocampus (Gonzalez-Islas and Hablitz 2003; Tseng and O'Donnell 
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2007; Andersson et al. 2012; Gangarossa et al. 2012), but this is largely in an inhibitory 
fashion, decreasing GABA release, thus unlikely to affect astrocytic calcium dynamics, which 
are increased by GABA stimulation (Kang et al. 1998). A decrease in GABAergic activity 
could lead to an increase in spontaneous glutamate release from neurons, due to 
decreased inhibition in the slice – however it is unlikely that this contributes to the 
astrocytic Ca2+ increase as MCPG blockade of mGluRs did not affect the nature of the Ca2+ 
increase (figure 3.3). That said, it is possible that increased astrocytic glutamate uptake 
(from increased glutamate release from neurons) could, through importing Na+ and 
reversing the activity of the Na+/Ca2+ exchanger, increase cytosolic Ca2+ (Rojas et al. 2007). 
Intriguingly, there is a small, but significant, increase in oscillatory activity when 100μM 
dopamine is applied in the presence of TTX, unlike in response to 100μM alone (which 
tends, non-significantly, downwards – figure 3.2). This could indicate that, in 100μM alone, 
dopamine stimulates neuronal activity which, in turn, interferes with the generation of 
spontaneous astrocytic calcium events normally facilitated by dopamine through one or 
several of the following: release of neurotransmitter and subsequent receptor activation; 
change in the concentration of extracellular K+, causing local depolarization and VGCC 
activation (Duffy and MacVicar 1994); change in extracellular Ca2+ concentration, triggering 
ATP mediated Ca2+ signalling (Torres et al. 2012) or change in intracellular Na+ (Rojas et al. 
2007; Reyes et al. 2012). 
 
3.4.3.2 Dopaminergic astrocytic calcium increases are mediated through 
dopamine receptors 
 Simultaneous blockade of both D1 and D2-type receptors effectively eradicates the 
astrocytic dopamine response (figure 3.3), strong evidence that it is through dopamine 
receptor activation that dopamine increases astrocytic intracellular calcium. This 
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observation is in line with both Liu et al. (2009) and Requardt et al. (2012) who both report 
D1-type receptor mediation of intracellular calcium increases as well as the D2-receptor 
mediated calcium signals reported by Khan et al. (2001), but at odds with Vaarmann et al. 
(2010) whose calcium signals persist in the presence of both D1-type and D2-type receptor 
blockers (although they did not try simultaneous blockade). It is difficult to reconcile these 
data – the concentrations of antagonists used by Vaarmann et al. are sufficient to 
effectively block any dopamine receptors. Apart from the many-fold differences between 
culture and slice data, and the fact that these cultured astrocytes had been cultured 
without the presence of neurons  (or endogenous dopamine), the most obvious difference 
is in the fluorescent calcium indicator used – fluo-4-AM for the results in this chapter, fura-
2 by Vaarmann et al. Fura-2 has a lower Kd (~224nM) than fluo-4 (~340nM). Hence it may 
be that a more sensitive measure of calcium concentration increase can pick up residual 
calcium dynamics (the responses amplitudes are halved) during dopamine receptor 
blockade in culture conditions that are far less noisy than those in slice. 
 
3.4.3.3 There is no clear evidence for the involvement of IP3 receptors in 
the dopaminergic astrocytic calcium signal 
 Many astrocyte calcium transients are thought to be primarily mediated by IP3-
mediated release of intracellular calcium from the smooth endoplasmic reticulum (Rusakov 
et al. 2011; Verkhratsky et al. 2012) – but see (Rusakov et al. 2014) – as has calcium-
mediated astrocytic glutamate release (Parpura et al. 2011). Blockade of IP3Rs produces a 
non-significant decrease in dopamine-induced Ca2+ increase (figure 3.4), suggesting IP3 is 
not involved in the signalling pathway  – although this may not reach significance due to 
incomplete blockade of the IP3R with 2-APB at high IP3 concentrations (Bilmen and 
Michelangeli 2002), such as those potentially caused by my powerful (100μM) dopamine 
114 
 
stimulus. Both D1-type and D2-type receptors have been reported to trigger release of IP3 
(Hernandez-Lopez et al. 2000; Hasbi et al. 2009) – but I could find no strong evidence to 
support this. In astrocytes, both the D1-type receptor-mediated activation of the PLC/IP3 
pathway reported by Liu et al. (2009) and the direct effect of NADH increase on IP3Rs, also 
mediated by D1Rs, reported by Requardt et al. (2012) could be responsible for this IP3R-
dependent calcium increase. It is important to note that 2-APB is non-specific in its effects 
and can act on TRP channels and connexions as well – it has also been reported to 
inconsistently block IP3R and block instead store-operated calcium entry (Bootman et al. 
2002). 
I also tested for the involvement of IP3 using a transgenic mouse model that over-
expresses an IP3 buffering protein specifically in astrocytes – that found no inhibitory effect 
on the dopamine-induced calcium increase. These data are difficult to interpret for two 
reasons: firstly, the calcium increase resulting from a 100μM dopamine application in wild-
type mouse astrocytes is less than half that evoked in rat astrocytes, hence the scale of any 
inhibitory effect would have been far smaller; secondly, to date, the IP3-Sponge mouse has 
only been reported to show very slight effects on the properties of spontaneous astrocytic 
calcium transients, not differences that would be picked up by the oscillation analysis 
described above. These differences (in duration and event area) rely on prior identification 
of Ca2+ events, a technique I have chosen not to employ in this thesis (see chapter 8). There 
are other differences between our two studies: their recorded spontaneous calcium 
transients are in response to a strong glutamate receptor agonist concentration – and these 
only in astrocytic processes from which I could not record with this method (Tanaka et al. 
2013). As with 2-APB, a possible explanation for the lack of a significant effect could lie in 
the powerful dopaminergic stimulus – such a large IP3 increase could overwhelm the 
astrocytic IP3 buffer, resulting in only a non-significant trend towards a smaller dopamine 
mediated increase in the IP3-Sponge animals (figure 3.3). 
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Given the inconclusive nature of the above data, a crucial next experiment would 
be to drain the intracellular calcium stores (through which IP3 stimulates intracellular 
calcium release) – with heparin, for example – and challenge with dopamine to see if a 
calcium increase was still visible. Another possible experiment would be to test for a 
dopamine-induced calcium response in astrocyte-specific IP3R2 knock-out mice.  
 
 
3.4.4 What role does monoamine oxidase play in the dopamine-induced calcium 
increase? 
Astrocytes express monoamine-oxidase B (MAOb) throughout the brain (Ekblom et 
al. 1993) and blockade of MAOb with selegiline has been reported to block dopamine-
induced calcium rises in astrocytes (Vaarmann et al. 2010). I tested this property of 
selegiline in both the single and double dopamine application paradigms and in both cases 
there was only a partial blockade of the astrocytic dopamine response (figures 3.3, 3.4) – 
unlike the total blockade reported by Vaarmann et al. This is perhaps unsurprising, given 
the very different nature of the slice conditions compared to culture and not necessarily at 
odds with Varmann et al. – blockade of dopamine catalysis will raise dopaminergic tonus in 
slice conditions (Heinonen and Lammintausta 1991; Huang et al. 1997) and this will affect 
neuronal activity (Hsu 1996; Huang et al. 1997) which could activate astrocytes through 
non-dopaminergic pathways. If the blockade of MAOb were incomplete (this is the same 
selegiline concentration used in culture), the concentration of dopamine could well be high 
enough to activate residual, unblocked MAOb.  
The partial blockade of the dopamine response suggests that lipid peroxidation by 
dopamine catabolytes may be involved, at least in part, in amplification of the dopamine-
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induced fluorescence signal – possibly by increasing the probability of calcium-induced 
calcium release from intracellular stores by increasing IP3 concentration through lipid 
peroxidation. Increased ROS levels (from DA breakdown) can activate transient receptor 
potential (TRP) channels (Naziroglu 2012), channels that are expressed on astrocytes 
(Shigetomi et al. 2011; Dunn et al. 2013; Reyes et al. 2013). TRPV4 channels in particular 
have recently been shown to play a role in astrocyte endfeet Ca2+ signals, mediating a small 
calcium increase that triggers calcium-induced calcium release (Dunn et al. 2013), and these 
channels are sensitive to an increase in ROS (Bai and Lipski 2010) – this is another possible 
mechanism for MAOb-mediated Ca2+-signal amplification. Another source of interest is a 
study that has suggested ROS as a means of communication between astrocytes and 
neurons (Safiulina et al. 2006) – this would imply that dopaminergic breakdown itself could 
trigger astrocyte-neuron communication. 
However, selegiline has been reported to affect astrocytes directly – stimulating 
production of FGF-2 (Riva et al. 1997) and NGF, BDNF and GDNF (Mizuta et al. 2000) – and 
hippocampal neurons (Dimpfel and Hoffmann 2011). Indeed, adding selegiline to the bath 
before dopamine stimulation induces an increase in resting calcium concentration (figure 
3.3) – one not seen upon addition of dopamine receptor blockers. This increase could be 
result of the off-target effects of selegiline mentioned above, or could be more simply 
explained by an increase dopaminergic tone (Neusch et al. 1997) stimulating astrocyte 
calcium rises through a MAOb-independent mechanism. Another possibility is that this 
slight fluorescence increase is an artefact: H202 produced by MAO activity is acidic – 
blockade of MAO could, in theory, increase cell alkalinity – fluo4 is pH sensitive, an increase 
an alkalinity of the environment would lead to greater baseline fluo-4 fluorescence. 
Additionally, if local spontaneous activity triggers local, compartmentalized astrocytic 
depolarization, voltage-gated calcium channels could be involved in generating a calcium 
signal; increased levels of reactive oxygen species (ROS) have been reported to inhibit 
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voltage-gated calcium channels (VGCCs) – selegiline would block this inhibition by 
decreasing ROS, therefore increasing VGCC activity and cytosolic calcium (Steullet et al. 
2008). However this would imply that VGCCs set astrocytic resting Ca2+ levels and there is 
no evidence yet for this. Conversely, ROS-mediated TRP channel activation (see above) 
would predict a resting Ca2+ decrease (assuming TRP channels spontaneously open at rest). 
In contrast to the data just discussed, adding selegiline in between two 
dopaminergic challenges does not increase the baseline calcium, but this could be due to an 
interaction with the residual effects of the first dopamine application and hence is a less 
reliable measure than addition of selegiline alone.  
Selegiline’s lack of selectivity of action makes concrete conclusions as to MAOb’s 
role in the dopaminergic signalling pathway in astrocytes hard to draw, but it seems clear 
that it plays an amplifying, if not a necessary role in the dopamine-induced Ca2+ increase, 
possibly via lipid peroxidation multiplying an existing calcium signal initiated by dopamine 
receptors, as discussed earlier.  
 
3.4.5 Is there a physiological relevance of a dopaminergic astrocytic calcium 
increase? 
One of the most controversial debates in the astrocyte literature is whether 
astrocyte calcium increases trigger physiologically relevant astrocyte dynamics (Fellin et al. 
2004; Ding et al. 2007; Fiacco et al. 2007; Perea and Araque 2007; Agulhon et al. 2010) and 
to what extent the nature of the calcium increase controls its function (Wang et al. 2013a). 
Astrocyte calcium increases have been found to play a necessary (Henneberger et al. 2010) 
and sufficient (Perea and Araque 2007) role in LTP induction in the hippocampus – 
dopamine is implicated in the generation of hippocampal LTP (Frey et al. 1991; Swanson-
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Park et al. 1999), so dopaminergic stimulation of astrocytic calcium increases could form a 
necessary part of the conditions required for LTP induction. 
 
3.4.6 Methodological caveats to bulk-loading recordings. 
3.4.6.1 Sulforhodamine 101 loading causes long-term excitability increases 
in hippocampal slices 
 In order both to identify astrocytes and image their morphology, slices were loaded 
with the morphological dye Sulforhodamine 101 (NimmerJahn et al. 2004) – a commonly 
used technique. However, SR101 has recently been reported to induce long-term increases 
intrinsic excitability in CA1 pyramidal cells of the hippocampus and enhanced excitatory 
input (Kang et al. 2010). Such in an increase in synaptic strength would increase the 
strength of spontaneous activity and possibly the excitability of the slice (although slice 
preparations should be relatively quiescent, given their lack of input). I have presented data 
in this chapter in strong support of dopamine’s effect on astrocytic Ca2+, but my argument 
would be more convincing if I were to replicate the data in non-SR101 loaded slices – 
methodology that I have employed in chapter 4. 
 
3.4.6.2 Somatic recordings of astrocytic calcium dynamics may not be 
representative of the calcium activity across the whole cell 
 In my recordings I have found that it is rarely possible to accurately record from 
astrocyte processes, given the low signal-to-noise ratio of recordings from bulk-loaded cells, 
hence all my recordings come from astrocyte somata. There are examples in the literature 
of recording from the large processes of bulk-loaded astrocytes (Porter and McCarthy 1996) 
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but here calcium dyes with a higher Ca2+ affinity and lower range have been used. As a 
wealth of calcium dynamics are visible in the processes that are not in the soma 
(Henneberger et al. 2010; Di Castro et al. 2011) it is desirable to image calcium dynamics in 
both in response to dopamine stimulation – this has been done in chapter 4. 
 
3.4.6.3 Spontaneous baseline calcium dynamics artificially increase the 
‘baseline’ calcium value used for normalization 
 It is also important to note that the baseline value to which each recording is 
normalized is the average fluo-4 fluorescence value. Therefore, where there is spontaneous 
activity pre-pharmacological manipulation, the normalization value will not correspond to 
what could be termed the ‘resting’ calcium indicator fluorescence – the fluorescence value 
taken between spontaneous oscillations. The advantage of this method is that it allows all 
data to be grouped and compared to a baseline of 1, a baseline that takes into account any 
spontaneous Ca2+ activity, the disadvantage is that it allows no measure of spontaneous 
calcium dynamics at baseline. As detailed in the chapter 2, it is possible to analyse G/R 
fluorescence traces with a modal analysis – this provides an average of the activity at 
baseline over a population of cells, but it may not be possible to identify the mode in traces 
with a lower signal/noise ratio. 
 
3.5 Conclusion 
 Recording astrocytic intracellular calcium changes from hippocampal astrocytes 
bulk-loaded with Fluo-4-AM reveals that astrocytes respond to dopamine with an overall 
increase in intracellular somatic calcium, in a concentration, time and repetition-dependent 
fashion. This phenomenon is independent of the resting neuronal activity in the slice, but is 
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mediated through dopamine receptors – although the intracellular signalling pathways 
remain unclear. It is apparent that the response is also amplified by the action of MAOb in 
the slice. 
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Chapter 4:  
 In addition to the reported dopamine-dependent increase in astrocytic 
cytosolic calcium, whole cell patch-clamping of astrocytes reveals a concurrent 
dopamine receptor-dependent calcium concentration decrease. 
 
4.1 Introduction 
 As described previously (Chapters 1 and 3), astrocytes can respond to 
neurochemical stimulation with changes in internal calcium (Cornell-Bell et al. 1990; Porter 
and McCarthy 1995b; Kang et al. 1998; Shelton and McCarthy 2000). Bulk-loading of dyes 
into the slice (Porter and McCarthy 1996), as was done in chapter 3, cannot achieve the 
level of image resolution possible with whole-cell patch-clamp and loading of the astrocyte 
syncytium with a cell-impermeant fluorescent indicator. Individual cell loading greatly 
improves signal-to-noise ratio, allowing for resolution of fine individual processes both 
morphologically (Bushong et al. 2002) and functionally (Henneberger et al. 2010; Di Castro 
et al. 2011), processes which display markedly more complex activity than that recorded at 
the soma: Bergmann glia display hundreds of independent Ca2+ signalling microdomains 
(Grosche et al. 1999); hippocampal astrocytes display Ca2+ transients of varying length and 
amplitude generated in their processes that may never propagate to the soma (Di Castro et 
al. 2011). It is therefore of interest to better investigate the calcium response to dopamine 
in astrocytes with both a better signal-to-noise ratio and in the astrocytic processes. Using 
whole-cell astrocyte patch, I further investigate the pharmacology of the previously 
reported astrocyte response to dopamine: astrocytes have been reported to express both 
D1-like (Liu et al. 2009a; Huang et al. 2012) and D2-like receptors (Khan et al. 2001; Duffy et 
al. 2011; Shao et al. 2013), In the following chapter, I aim to identify which receptor type is 
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responsible for the reported calcium increase and uncover a previously unreported 
dopamine-induced astrocyte calcium decrease. 
 
4.2 Methods 
In short, transverse hippocampal slices were taken from p21-25 male Sprague-
Dawley rats, allowed to rest for 1 hour and then placed in an immersion recording 
chamber. Whole cell astrocyte recordings were made with electrodes and filled with 
intracellular Potassium methyl-sulphonate (KMS) solution containing (in mM): KCH3O3S 135, 
HEPES 10, disodium phosphocreatine 10, MgCl2 4, Na2ATP 4, NaGTP 0.4 (pH adjusted to 7.2 
with KOH, osmolarity 290–295 mOsM); 200μM Fluo-4 and 50μM Alexa were added. After 
20 mins dialysis time, the astrocyte syncytium was sufficiently filled with dye to allow 
imaging of both patched and gap-junction coupled cells. All experiments were conducted at 
room temperature (19-21°C) unless otherwise stated. Astrocyte somata (up to five at a 
time) were imaged from the Schaffer collateral region of CA1 with a 2P-setup at an 
excitation laser power of 2-5mW, at a frame rate of 1Hz. Emitted light was collected in two 
channels, 515-530nm and 540-700nm using an Olympus BW50 microscope two-photon 
imaging system. Recording configuration was chosen to best concurrently image patched 
cell (AC) processes and gap-junction couple cell (GJC) somata. Fluorescence intensity for 
each cell, per frame, is calculated as the average fluorescence of all pixels in the area 
manually defined as the cell soma or process. G/R intensity is normalized to the baseline 
average to give a time course of cytosolic calcium dynamics (ΔF/F0) from astrocyte somata. 
Cells with unstable resting calcium in the baseline condition (i.e. fluctuations unlike 
normally observed calcium transients or a constantly rising or falling baseline) were 
discarded. Unless otherwise stated, DA was applied at 100μM. Cells with no DA washout 
were also discarded (in protocols including a washout step). After DA application the peak 
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response was found to be between 3-7 minutes post application (likely due to the perfusion 
time of the DA through the system) and so it was from t=13-17 that the average 
fluorescence intensity was taken for statistics. Baseline average fluorescence intensity was 
taken from the first 10 minutes of the recording, bar charts values are averaged over the 
total number of cells for a stated time frame, error bars show the standard error. For the 
purposes of statistical analysis, n was taken to be the total number of cells sampled, 
although total number of slices and animals are also given. Baseline ΔF/F0 was assumed to 
be 1 and the population of ΔF/F0 averages during dopamine application was tested for 
normality using the Shapiro-Wilk test, before using a single sample t-test; unless otherwise 
stated, data was normally distributed. Where the normality test failed the Wilcolxon signed 
rank test was used. Two compare two normal populations a two sample t-test was used. If 
either population was not normally distributed the Mann-Whitney test was used to 
compare both. ΔF/F0 data in this chapter is often presented as proportional frequency 
histograms; generally, in these graphs, bars represent baseline distribution and the 
superimposed black line represents distribution in dopamine. These two groups were 
sampled from 1-12 minutes (baseline epoch) and 3-10 minutes post-dopamine application 
(dopamine epoch). For analysis, each distribution plotted in a histogram is fitted with either 
a single or multiple Gaussian distribution: for these curves the peak x (location of Gaussian 
peak on x-axis), the standard deviation (σ), Full Width Half Max (FWHM) and R2 value is 
given, all to 2 decimal places. The fitted curves are plotted in the supplementary data, 
presented at the end of this chapter. 
 
4.3 Results 
4.3.1 The relative dopamine-induced astrocytic calcium increase is greater in 
gap-junction coupled cells than in patched astrocytes. 
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Whole-cell patch clamping of astrocytes allowed diffusion of morphological dye 
(Alexa 594) and calcium indicator (Fluo-4) into neighbouring gap-junction coupled 
astrocytes (GJCs) from the patched astrocyte (AC). Both AC processes and GJC somata could 
therefore be simultaneously imaged. A typical example of concurrent Alexa594 and Fluo-4 
imaging is shown in figure 4.1ai and figure 4.1aiii respectively. Given the previously 
reported differences in process and somatic signalling (see section 4.1), I first investigated 
any possible differences in response to dopamine between astrocyte somata and 
processes. As physical stimulation from the pipette could also trigger Ca2+ transients 
(Charles et al. 1993), I also recorded from GJC somata. Bath application of 100μM 
dopamine triggers large calcium increases in all the astrocyte syncytium, with the exception 
of the AC soma – figure 4.1aii shows this effect in the example cells. During dopamine 
stimulation (t=11-20), AC somata show no significant change in fluorescence from baseline 
(p=0.287, 1-sample t-test, n=3; data taken from 3 cells, 3 slices, 3 animals). The population 
of fluorescence averages from AC processes, in the presence of dopamine, is not normally 
distributed (p=0.002, Shapiro-Wilk test, n=15) and is significantly increased to a median of 
1.17 of baseline (p=0.018, 1-sample Wilcoxon signed ranks test, n=15; data taken from 15 
processes, 7 slices, 7 animals). GJC somata showed a significant increase in mean ΔF/F0 to 
3.1 ± 0.67 (p=0.021, 1-sample t-test, n=7; data taken from 7 cells, 7 slices, 7 animals), as did 
GJC processes, to a mean of 2.15 ± 0.15 of baseline (p<0.001, 1-sample t-test, n=8; 8 
processes, 7 slices, 7 animals). This data is summarized in figure 4.1c: GJC somata show a 
significantly greater relative increase in Fluo-4/Alexa594 fluorescence from baseline than 
AC processes (p=0.009, Mann-Whitney test), as do GJC processes from AC processes 
(p=0.031, Mann-Whitney test); GJC process responses were not significantly different to 
those from GJC somata (p=0.166, 2-sample t-test). Average time course of dopamine 
application for AC processes and GJC somata is shown in figure 4.1b.  
125 
 
 
Figure  4.1 Astrocyte ‘perforated-patch’ and regional calcium responses to 
dopamine. 
ai) Example image of Alexa594 fluorescence showing diffusion of dye into gap junction-coupled cells 
(GJC) as well as the patched cell (AC) somata and PC processes. Outlined areas indicate regions 
analysed in aii). aii) Fluo-4/Alexa594 (G/R) signal for regions indicated in ai) during application of 
100μM dopamine. aiii) Left: images from Fluo-4 channel at time point indicated with first arrow on 
G/R traces before dopamine application for regions in ai). Right: as left but during dopamine 
application (aii second arrow). b) summary time-course of GJC somatic calcium responses to 
dopamine (100μM, black bar). c) Summary bar chart of fluo-4 fluorescence changes in response to 
100μM dopamine in AC somata, processes and GJC processes and somata respectively (t=13-17); 
somata/process n-numbers shown inside bars, n.s. = non-significant, * = p<0.05, *** = p<0.001 – t-
test (1), 1-sample wilcoxon signed rank test or Mann-Whitney test (see text). 
0 0 
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Given the results from this section, I decided to record only from GJC somata and 
AC processes – therefore results for the following sections are reported from only AC 
processes and GJC somata. 
 
4.3.2 Dopamine can have a biphasic effect on astrocytic calcium concentration – 
both increasing and decreasing cytosolic calcium. 
 
As shown in the example GJCs in figure 4.2a, astrocytes can, counterintuitively, 
respond to dopamine application with both an increase and a decrease in Fluo-4 
fluorescence. As any fluorescence increase reaches far higher amplitudes than a 
fluorescence decrease, averaging ΔF/F0 over time obscures any recorded decrease. Hence, 
in order to identify fluorescence decrease in data from my previous experiments, I have 
pooled the ΔF/F0 fluorescence intensity data points from all recorded GJC somata in section 
4.3.1, shown in Figure 4.1, and from all AC processes  in section 4.3.1, separately, into two 
time epochs – ‘baseline’ (t=1-12) and ‘dopamine’ (t=13-20). These were then normalized to 
the total number of data points sampled in each condition respectively and plotted as two 
proportional frequency histograms (figure 4.2b) In the single cell examples in figure 4.2a 
there is a striking difference in the distribution of fluorescence data in dopamine compared 
to baseline conditions – two peaks are often visible in the dopamine distribution, one 
below, one above 1 (baseline average), whereas the baseline distribution peaks stay 
distributed around 1. The ‘dopamine’ population from the histograms presented in figure 
4.2a is sampled from roughly the time dopamine reaches the cells to 10 minutes post-
dopamine washout (t=13-30). These examples are taken from t=13-30 to illustrate the full 
possible decrease in fluorescence caused by dopamine application. 
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Figure 4.2 Dopamine triggers both an increase and a decrease in astrocytic 
calcium levels as revealed with histogrammatical analysis. 
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a) Four example GJC’s responses to dopamine (100μM). Left – Alexa 594 image of each cell; right 
Fluo-4/Alexa 594 fluorescence traces for each GJC with example Fluo-4 channel images, arranged 
chronologically for time-points marked with arrows; black bars indicate dopamine application, grey 
bracket indicates time-frame sampled for ‘baseline’ population in b), black bracket shows 
‘dopamine’ population for b), black arrows indicate putative ΔF/F0 decrease shoulder. b) frequency 
distributions (normalized to total frequency) of ΔF/F0 for each cell in a) for baseline epoch (t=1-12, 
grey bars) and ‘dopamine epoch (t=13-20, black line); black arrows indicate putative ΔF/F0 decrease 
shoulder. c) normalized frequency distribution of ΔF/F0 for all GJCs in presence of 100μM dopamine 
(t = 13-20) compared to baseline (t = 1-12), black arrows indicate putative ΔF/F0 decrease shoulder, 
grey bars – in dopamine, black line – baseline. d) as in c) for AC processes. 
 
In GJC somata, the proportional ΔF/F0 distribution at baseline is well fitted with a 
single Gaussian distribution (x peak=0.98, σ=0.13, FWHM=0.3, R2=0.99), but poorly during 
dopamine application (x peak=2.55, σ=2.03, FWHM=4.78, R2=0.52) – however, double 
Gaussian fitting is much closer to the observed data (x peaks=0.95/3.28, σ=0.18/1.1, 
FWHM=0.43/2.58, R2=0.93). In AC processes baseline fit with a single Gaussian is good 
(x=0.97, σ=0.21, FWHM=0.49, R2=0.98), but again, in dopamine, a single Gaussian 
distribution is a far worse fit (x=1.07, σ=0.51, FWHM=1.21, R2=0.80) than a double Gaussian 
fitting (x peaks=0.9/1.75, σ=0.25/0.87, FWHM=0.6/2.05, R2=0.98) – see supplementary 
figure S1. One feature of both distributions, that Gaussian fitting fails to capture, is the 
presence, in dopamine, of the negative going shoulder from the baseline ΔF/F0 – as marked 
by arrows in figures 4.2c, d. In both cases in dopamine, the peaks of the two Gaussians are 
either side of the baseline. 
 
4.3.3 The appearance of an intracellular astrocytic calcium decrease is 
dependent on the concentration of dopamine used. 
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4.3.3.1 10μM dopamine triggers no significant change in Ca2+ in either AC 
processes or GJC somata. 
Next I tested whether stimulation with lower concentrations of dopamine could 
replicate the astrocytic sensitive seen in bulk-loaded astrocytes (chapter 3), or separate the 
two dopamine-induced effects. Application of 10μM dopamine does not significantly 
change ΔF/F0 in either AC processes or GJC somata (Figure 4.3a). For AC processes, the 
population of means of ΔF/F0 in dopamine (t=13-17), is not normally distributed (p<0.001, 
Shapiro-Wilk test) and is not significantly different from baseline (p=0.255, 1-sample 
Wilcoxon signed rank test, n=12; data from 12 processes, 4 slices, 4 animals). Regarding the 
proportional frequency distributions, both baseline (x peak=1, σ=0.13, FWHM=0.3, R2=0.98) 
and dopamine (x peak=1, σ=0.17, FWHM=0.41, R2=0.99) epochs can be well fitted by single 
Gaussians. In GJC somata the mean ΔF/F0 is not significantly different from baseline 
(p=0.39, 1-sample t-test, n=13; data from 13 cells, 7 slices, 4 animals) and both baseline 
(peak x=0.98, σ=0.15, FWHM=0.35, R2=0.98) and dopamine (peak x=1, σ=0.18, FWHM=0.42, 
R2=0.96) ΔF/F0 proportional frequency distributions can be tolerably well fitted with single 
Gaussians– see supplementary figure S2. 
 
4.3.3.2 20μM dopamine triggers a Ca2+ increase in both AC processes and 
GJC somata, but no Ca2+ decrease. 
20μM dopamine (figure 4.3b) significantly increases fluo-4 fluorescence intensity in 
both AC processes – to 1.35 ± 0.07 of mean – (p<0.001, 1-sample t-test, n=24; data taken 
from 24 processes; 6 slices and 5 animals) and GJC somata – to 1.37 ± 0.12 of mean – 
(p<0.001, 1-sample t-test, n=12; data taken from 12 cells, 6 slices, 5 animals). The 
distribution of ΔF/F0 in AC processes in baseline conditions can be modelled by a single 
Gaussian distribution (peak x=0.99, σ=0.21, FWHM=0.49, R2=0.99) as can the distribution  
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Figure 4.3 Concentration dependent dopamine-induced fluorescence increase 
and decrease. 
a) 10μM dopamine does not affect fluo-4 fluorescence. Left: time course of dopamine application 
(black bar – dopamine application), brackets indicate time frames sampled for histograms; middle: 
fluorescence change average over t = 13-17; right: histogram of ΔF/F0 data points recorded from 
patched cell (AC) processes (above) and Gap-junction coupled (GJC) somata (below) – bars indicate 
baseline distribution (t = 1-12), line indicates distribution in presence of dopamine (t = 13-20). b) 
20μM dopamine increases fluorescence in both AC processes and GJC somata. Layout: as in a). c) 
50μM dopamine triggers both fluorescence increases and decreases in AC processes and GJC 
somata. Layout: as in a), black arrows in histogram indicate negative ΔF/F0 shoulder in the presence 
of dopamine. Hollow circles/bars – data from pc processes, grey circles/bars – data from GJC somata, 
numbers in bars indicate processes/soma n-numbers ,n.s. – not significant, ** - p<0.01, *** p<0.001, 
t-test (1).  
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upon dopamine application, although less well (peak x=1.1, σ=0.43, FWHM=1.01, R2=0.92); 
a double Gaussian distribution better captures the population shape in dopamine (x 
peaks=0.92/1.43, σ=0.23/0.53, FWHM=0.53/1.25, R2=0.99), perhaps unsurprisingly. GJC 
somata exhibit a similar proportional frequency distribution of ΔF/F0 to that shown by AC 
processes: baseline is well modelled by a Gaussian centred on 1 (peak x=1, σ=0.22, 
FWHM=0.51, R2=1) but dopamine less so (peak x=1.09, σ=0.35, FWHM=0.83, R2=0.89); the 
dopamine distribution is better modelled by a double gaussian (x peaks =0.99/1.58, 
σ=0.23/0.55, FWHM=0.54/1.3, R2=0.99) – see supplementary figure S3.  
 
4.3.3.3 50μM dopamine triggers a Ca2+ increase and decrease in both AC 
processes and GJC somata. 
In 50μM dopamine ΔF/F0 significantly increases in AC processes (figure 4.3c) to 1.29 
± 0.06 (p<0.001, 1-sample t-test, n=12; data from 12 processes, 2 slices, 2 animals), but not 
in GJC somata (p=0.17, 1-sample t-test, n=4; data from 4 cells, 3 slices, 2 animals). A single 
Gaussian models the baseline well for AC processes (peak x=0.96, σ=0.11, FWHM=0.27, 
R2=0.99) but not during the dopamine application (peak x=1.07, σ=0.35, FWHM=0.81, 
R2=0.85) – this requires a double distribution (peak x’s=0.86/1.24, σ=0.09/0.31, 
FWHM=0.21/0.72, R2=0.98) the first peak of which falls near the negative-going shoulder 
indicated by the black arrow. In GJC somata, baseline proportional distribution frequency is 
fairly well modelled by a single Gaussian (peak x=1.01, σ=0.08, FWHM=0.19, R2=0.97), but 
dopamine distribution cannot be modelled be a single Gaussian (x=1.29, σ=0.97, 
FWHM=2.28, R2=0.44); a double Gaussian models the dopamine far better (x peaks=1/2.16, 
σ=0.18/0.62, FWHM=0.42/1.47, R2=0.92), but still does not describe the negative going 
shoulder, indicated with the black arrow in figure 4.3c, which is even better modelled by a 
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triple Guassian  (x peaks=0.77/1.03/2.07, σ=0.05/0.12/0.7, FWHM=0.12/0.28/1.66, R2=0.96) 
– see supplementary figure S4. 
 
4.3.4 The biphasic dopaminergic effect is independent of neuronal activity and 
persists when purinergic receptors are blocked. 
4.3.4.1 Blocking mGluRs, Na+ channels and GABABRs does not inhibit the 
dopamine induced Ca2+ increase or decrease. 
To control for possible indirect actions of dopamine that could trigger astrocyte 
calcium dynamics through glutamate or GABA release or increase in neuronal firing, I 
blocked voltage-gated Na+ channels, mGluRs and GABABRs. First, 100μM dopamine was 
applied in a cocktail of neuronal activity blockers (figure 4.4a). This cocktail consisted of the 
mGluR5 inhibitor MPEP (1μM), the mGluR1 inhibitor LY367385 (100μM), the mGluR2/3 
antagonist LY341495 (500nM), the GABAb inhibitor CGP 55845 (1μM) and the voltage 
dependent Na+-channel blocker TTX (1μM). In this presence of this cocktail neuron action 
potential firing will be inhibited, as will metabotropic glutamatergic and GABAergic 
signalling. Under these conditions dopamine still significantly increases the astrocytic 
calcium in both GJC somata – to 3.64 ± 0.66 of baseline (p=0.016, 1-sample t-test, n=5; data 
from 5 cells, 3 slices, 3 animals) – and AC processes (data is not normally distributed, 
p<0.001, Shapiro-Wilk test) to a median of 1.3 of mean (p<0.001, 1-sample Wilcoxon signed 
rank test, n=17; data from 17 processes, 3 slices, 3 animals). These data are not significantly 
different from those recorded under control conditions (i.e. application of 100μM 
dopamine alone) in either GJC somata (p=0.594, 2-sample t-test), or AC processes (p=0.45, 
Mann-Whitney test). The proportional distribution of GJC somata data from baseline 
conditions is very well modelled by a single Gaussian distribution (x peak=1, σ=0.12, 
FWHM=0.27, R2=1), but in dopamine cannot be modelled with a single Gaussian – instead a  
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Figure 4.4 The dopamine acts directly on astrocytes and the induced 
fluorescence change is mediated through dopamine receptors. 
a) Dopamine (100μM) fluorescence increase and decrease persists in the presence of a cocktail of 
neuronal receptor/channel blockers – TTX (1 μM), MPEP (1 μM), LY367385 (100 μM), LY341495 
(500nM) and CGP (1 μM). Left: time course of dopamine application (black bar – dopamine 
application, hollow bar – blocker application), brackets indicate time frames sampled for histograms; 
middle: fluorescence change average over t = 13-17; right: histogram of ΔF/F0 data points recorded 
from patched cell (AC) processes (above) and Gap-junction coupled (GJC) somata (below) – bars 
indicate baseline distribution (t = 1-12), line indicates distribution in presence of dopamine (t = 13-
20). b) Purinergic receptor blocker PPADS (100 μM) does not block dopamine induced fluorescence 
change. Layout: as in a). c) dopamine receptor blockers – SCH23390 (20 μM) and Sulpiride (50 μM) – 
block all dopamine-induced fluroescence change. Layout: as in a). Hollow circles/bars – data from pc 
processes, grey circles/bars – data from GJC somata, numbers in bars indicate processes/soma n-
134 
 
numbers, black arrows in histogram indicate negative ΔF/F0 shoulder in the presence of dopamine, 
n.s. – not significant, ** - p<0.01, *** p<0.001, t-test (1) or Wilcoxon signed rank test (see text). 
 
double Gaussian models the effect better – displaying peaks either side of the baseline (x 
peaks=0.92/4.32, σ=0.24/0.84, FWHM=0.57/1.99, R2=0.9). In AC processes baseline is well 
modelled by a single Gaussian (x peak=1.02, σ=0.18, FWHM=0.42, R2=0.96) but dopamine 
application is not (x peak=1.25, σ=0.44, FWHM=1.04, R2=0.87) – modelling with a double 
Gaussian greatly improves the fit (peak x’s=1.02/1.45, σ=0.1/0.49, FWHM=0.24/1.15, 
R2=0.99) – see supplementary figure S5.  
 
   
4.3.4.2 Purinergic receptor blockade does not affect the dopamine-induced Ca2+ 
increase in either AC processes or GJC somata, but does inhibit the Ca2+ in 
GJC somata only. 
Astrocytes can release ATP upon stimulation to propagate intracellular calcium 
dynamics between astrocytes themselves and neurons (Fields and Burnstock, 2006). To 
ascertain if purinergic signalling played a role in the dopamine-induced calcium dynamics, I 
blocked P2X1,2,3,5 and P2Y2,4 receptors (using 100μM PPADS) in order to ascertain how much 
of this inter-astrocyte purinergic signalling made up the total dopamine-induced calcium 
signal (figure 4.4b). In AC processes, there is no significant increase in average fluorescence 
from baseline upon 100μM dopamine application in the presence of PPADS (p=0.4, 1-
sample t-test, n=3; data from 3 processes, 2 slices, 2 animals) but there is in GJC somata – 
to 1.94 ± 0.14 of baseline – (p<0.001, 1-sample t-test, n=16; data from 16 cells, 5 slices, 4 
animals). Comparing PPADS to control conditions, there is no significant difference between 
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the two sets of AC process responses (p=0.636, Mann-Whitney test), but GJC somata ΔF/F0 
is significantly greater in control conditions than in PPADS (difference in means=1.16, 
p=0.026, 2-sample t-test). Fitting Gaussian distributions to AC process responses shows a 
reasonable single Gaussian fit for baseline (x peak=0.95, σ=0.2, FWHM=0.46, R2=0.96) but 
poor for dopamine application (x peak=1.35, σ=0.47, FWHM=1.11, R2=0.42), which is well 
fitted with a double Gaussian distribution whose peaks fall either of the modelled baseline 
x peak of 0.95 (x peaks=0.65/1.49, σ=0.15/0.23, FWHM=0.04/0.54, R2=0.96) – explaining 
the lack of significance seen when averaging the data. Considering GJC somata, baseline is 
again well described by a single Gaussian (x peak=0.98, σ=0.23, FWHM=0.54, R2=0.98), but 
the dopamine response is not (x peak=1.58, σ=0.9, FWHM=2.11, R2=0.82). This requires 
either two, or even three gaussians to fit well: x peaks=0.97/1.93 (σ=0.22/0.93, 
FWHM=0.52/2.19, R2=0.95) and x peaks=0.96/1.71/2.56 (σ=0.25/0.31/0.9, 
FWHM=0.57/0.72/2.1, R2=0.98) respectively, but in neither does the first peak move far 
negative of the fitted baseline x peak of 0.98– see supplementary figure S6. 
 
4.3.5 Both increase and decrease in calcium concentrations in response to 
dopamine are blocked by simultaneous blockade of D1- and D2-type 
receptors. 
Next I sought to replicate the dopamine-receptor dependency of the dopamine-
induced Ca2+ increase recorded in bulk-loaded slices and test whether the Ca2+ decrease is 
similarly dopamine receptor-dependent. Simultaneous blockade of D1 and D2-type 
receptors with SCH23390 (20μM) and Sulpiride (50μM) blocks dopamine-induced astrocytic 
Fi and Fd (figure 4.4c). AC process ΔF/F0 data is not normally distributed (p=0.005, Shapiro-
wilk test) and in dopamine (100μM) is not significantly different from baseline (p=1, 1-
sample Wilcoxon signed rank test, n=6; data from 6 process, 3 slices, 3 animals). ΔF/F0 data 
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from GJC somata is not significantly different from baseline in dopamine (p=0.126, 1-
sample t-test, n=5; data from 5 cells, 3 slice, 3 animals). Similar single Gaussian curves fit AC 
process baseline (x peak=0.93, σ=0.32, FWHM=0.75, R2=0.98) and dopamine (x peak=0.97, 
σ=0.31, FWHM=0.73, R2=0.97) distributions well. As is the case with GJC somata baseline (x 
peak=1, σ=0.17, FWHM=0.38, R2=0.99) and dopamine (x peak=1.02, σ=0.17, FWHM=0.41, 
R2=0.98) distributions– see supplementary figure S7. 
 
4.3.6 Blockade of D1-type receptors alone can partially inhibit the Ca2+ increase 
in response to dopamine but spares the Ca2+ decrease. 
Is the effect of dopamine on astrocytes mediated by a specific dopamine receptor 
type? I investigated this through blockade of type-1 dopamine receptors alone first. 
Application of 100μM dopamine in the presence of 10μM of the D1/5R blocker SCH23390 
(figure 4.5a) stimulates only a couple of large responses in the population of AC processes –
visible as grey traces in the left panel of figure 5a – and the median ΔF/F0 for the non-
normally distributed means (p=0.004, Shapiro-Wilk test) is not different from baseline 
(p=0.97, 1-sample Wicoxon signed ranks test, n=12; data from 12 processes, 4 slices, 4 
animals). However, the proportional distribution of the ΔF/F0 data clearly shows a negative 
skew from baseline (black arrow in right, upper panel of figure 4.5a).  Both the baseline and 
the dopamine distributions can be very well modelled with a single Guassian distribution, 
but the fitted x peak for baseline (x peak=0.98, σ=0.13, FWHM=0.3, R2=1) is greater than 
that for dopamine (x peak=0.88, σ=0.16, FWHM=0.38, R2=0.98). GJC somata show a similar 
negative shift in ΔF/F0 in dopamine, but this is significant – to a mean of 0.93 ± 0.02 
(p=0.003, 1-sample t-test, n=8; data from 8 cells, 4 slices, 4 animals). This is reflected in the 
peak x of the fitted single Gaussians which show decrease in dopamine (x peak=0.94,  
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Figure 4.5 D1-type receptor blocker SCH23390 has concentration-dependent 
effects on dopamine-induced astrocytic calcium dynamics. 
a) Dopamine application (100μM) in the presence of 10μM SCH223390 primarily triggers a decrease 
in ΔF/F0. Left: time course of dopamine application (hollow bar – SCH23390 application, black bar – 
dopamine) for AC processes, black points indicate average, grey lines indicate each individual cell 
response. Middle: time course for GJC somata, grey points indicate average, light grey lines indicate 
each individual cell response. Right: histogram of ΔF/F0 data points recorded from patched cell (AC) 
processes (above) and Gap-junction coupled (GJC) somata (below). Bars indicate baseline 
distribution (t = 1-12), line indicates distribution in presence of dopamine (t = 13-20), brackets in 
time courses (left, middle) indicate time frames sampled for histograms. b) Dopamine application 
(100μM) in the presence of 5μM SCH223390 triggers a decrease in baseline ΔF/F0 but an increase in 
spontaneous events. Layout: as above. Red lines in GJC somata time course and shading in histogram 
indicate separate ‘massive responder’ two cell population. Black arrows in histogram indicate 
negative ΔF/F0 shoulder in the presence of dopamine, hollow circles/bars – data from AC processes, 
grey circles/bars – data from GJC somata. 
138 
 
σ=0.11, FWHM=0.26, R2=0.98), compared to baseline (x peak=0.99, σ=0.11, FWHM=0.25, 
R2=0.99) – see supplementary figure S8. 
 
4.3.7 Decreased blockade of the D1-type receptor results in a decrease in 
baseline calcium and an increase in spontaneous calcium events. 
Is it possible to change the ratio of Ca2+ increase to decrease without completely 
blocking either? In 5μM SCH23390, 100μM dopamine stimulation appears to have 
paradoxically opposite effects on astrocytic calcium: a decrease in baseline, upon which 
ride an increased frequency of transient high-amplitude calcium concentration increases 
(Figure 4.5b, left and middle panels). This increased variability translates to a lack of 
significant difference from baseline when examining the population of ΔF/F0 means in 
dopamine: neither AC processes (p=0.01, Shapiro-Wilk) nor GJC somata (p<0.001, Shapiro-
Wilk) are normally distributed and neither are significantly different from baseline as 
p=0.177 (1-sample Wilcoxon signed rank test, n=20; data from 20 processes, 5 slices, 3 
animals) and p=0.7 (1-sample Wilcoxon signed rank test, n=10; data from 10 cells, 5 slices, 3 
animals) respectively. 
However, examining the proportional frequency distribution of ΔF/F0 in baseline 
and dopamine conditions reveals the strikingly different possible actions of dopamine on 
astrocytic calcium in this lower concentration of SCH23390 – the negatively shifted baseline 
is clearly visible in both AC processes and GJC somata (figure 4.5b, right panel, marked with 
black arrows). For AC processes, baseline fluorescence data distribution is well fitted with a 
single Gaussian (peak x=0.99, σ=0.36, FWHM=0.86, R2=0.98), but dopamine fluorescence 
data is less so (peak x=0.89, σ=0.57, FWHM=1.34, R2=0.88) – but is well fitted with a double 
Gaussian (x peaks=0.65/1.41, σ=0.29/0.72, FWHM=0.69/1.68, R2=0.97). For GJC somata, 
2/10 recorded cells respond to dopamine with very characteristic ‘massive’ sustained 
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increases (Figure 4.5b, middle panel) hence, whilst the baseline is very well fitted by a single 
Gaussian (peak x=0.99, σ=0.22, FWHM=0.52, R2=1), the ΔF/F0 distribution in dopamine 
needs two gaussians to accommodate these two ‘massive responder’ cells (x 
peaks=0.8/3.72, σ=0.21/0.64, FWHM=0.5/1.51, R2=0.98); the peak x of the lower Gaussian 
(which accounts for most of the proportional distribution) is lower than the baseline peak 
by 0.19 – see supplementary figure S9. 
 
4.3.8 Blockade of D2-type receptors alone results in blockade of all dopamine-
induced astrocytic calcium dynamics. 
What role do D2-type receptors play? Sulpiride is a selective D2/3R blocker used 
previously in conjunction with SCH23390. Here I tested its inhibitory induced effects on 
dopamine-induced astrocytic calcium changes. 50μM sulpiride samples are small (figure 
4.6a), and the fluorescence means in dopamine show no significant difference to those at 
baseline for AC processes (p=0.332, 1-sample t-test, n=3; data from 3 processes, 3 slices, 3 
animals) or GJC somata (p=0.316, 1-sample t-test; n=3; data from 3 cells, 3 slices, 3 
animals). Fitting Gaussian distributions to AC process ΔF/F0 proportional frequency 
distributions is feasible: baseline can be well modelled by a single Gaussian (peak x=0.99, 
σ=0.11, FWHM=0.26, R2=0.98), dopamine cannot (peak x=0.99, σ=0.13, FWHM=0.31, 
R2=0.76) – but can with a double Gaussian (x peaks=0.95/1.2, σ=0.07/0.22, 
FWHM=0.16/0.52, R2=0.99), whose peaks fall either side of baseline. Modelling GJC somata 
ΔF/F0 proportional frequency distributions is possible with a single Gaussian at baseline 
(peak x=0.93, σ=0.19, FWHM=0.46, R2=0.99) and in dopamine (peak x=1.07, σ=0.19, 
FWHM=0.45, R2=0.99) – see supplementary figure S10. 
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Figure 4.6 D2-type receptor blocker sulpiride has concentration-dependent 
effects on dopamine-induced astrocytic calcium dynamics. 
a) Dopamine application (100μM) in the presence of 50μM sulpiride has little effect on ΔF/F0. Left: 
time course of dopamine application (hollow bar – sulpiride application, black bar – dopamine) for 
AC processes, black points indicate average, grey lines indicate each individual cell response. Middle: 
time course for GJC somata, grey points indicate average, light grey lines indicate each individual cell 
response. Right: histogram of ΔF/F0 data points recorded from patched cell (AC) processes (above) 
and Gap-junction coupled (GJC) somata (below). Bars indicate baseline distribution (t = 1-12), line 
indicates distribution in presence of dopamine (t = 13-20), brackets in time courses (left, middle) 
indicate time frames sampled for histograms. b) Dopamine application (100μM) in the presence of 
20μM sulpiride triggers a decrease in baseline ΔF/F0 but an increase in spontaneous events. Layout: 
as above; red shading indicates ΔF/F0 in presence of 20μM sulpiride only. Black arrows in histogram 
indicate negative ΔF/F0 shoulder in the presence of dopamine, hollow circles/bars – data from AC 
processes, grey circles/bars – data from GJC somata. 
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4.3.9 Decreased blockade of the D2-type receptor continues to block GJC calcium 
changes, but Sulpiride itself triggers activity in AC processes. 
In 20μM sulpiride, the mean fluorescence change in dopamine, from baseline, is 
significant for AC processes – to 1.34 ± 0.15 of baseline (p=0.046, 1-sample t-test, n=12; 
data from 12 processes, 3 slices, 2 animals) – but not for GJC somata (p=0.327, 1-sample t-
test, n=6; data from 6 cells, 3 slices, 2 animals). However this does not capture the nature 
of the responses well (figure 6b, left and middle panels) – for this it is better to look at the 
frequency distributions. The AC process proportional frequency distribution at baseline is 
well modelled by a Gaussian distribution (peak x=0.97, σ=0.18, FWHM=0.43, R2=0.99), but 
the distribution in dopamine, when modelled by a single Gaussian, does not capture the 
positive-going tail, (peak x=0.73, σ=0.24, FWHM=0.56, R2=0.9) – for this a double Gaussian 
is required (x peaks=0.72/2.22, σ=0.21/1.13, FWHM=0.51/2.66, R2=0.99).  In both models, 
there is a clear peak below baseline peak x from data in dopamine as indicated by the black 
arrow in figure 4.6b. However in GJC somata both the baseline (peak x=0.99, σ=0.16, 
FWHM=0.38, R2=0.98) and dopamine (peak x=1.02, σ=0.24, FWHM=0.57, R2=0.98) 
distributions are well captured by similar Gaussian curves. 20μM Sulpiride on its own, 
before dopamine application, appears to affect AC process calcium – but the difference of 
the means from baseline is not significant (p=0.339, 1-sample Wilcoxon signed rank test, 
n=12; not normally distributed, p=0.044, Shapiro-Wilk test). However, fitting the 
distribution of ΔF/F0 in sulpiride alone with a single Gaussian gives a very good fit (peak 
x=0.78, σ=0.19, FWHM=0.46, R2=0.99) and peak at x=0.78, well below baseline – see 
supplementary figure S11. 
 
4.3.10 Specific, coincident activation of D1 and D2 receptors stimulates a small, 
biphasic calcium signal in AC processes only. 
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Can the dopamine-receptor dependent effects reported above be replicated 
through dopamine-receptor activation alone? When 100μM SKF38390 (a specific D1R 
agonist) and 100μM quinpirole (a specific D2R agonist) are added to the bath, no significant 
change in ΔF/F0 was found in either the processes (p=0.421, 1-sample Wicoxon signed ranks 
test, n=15; data not normally distributed, p=0.002, Shapiro-Wilk test; data from 15 
processes, 5 slices, 4 animals) or the GJC somata (p=0.158, 1-sample t-test, n=12; data from 
12 GJCs, 5 slices, 4 animals). Although the proportional frequency distribution of GJC ΔF/F0 
can be modelled equally well with a single Gaussian in both baseline (peak x=0.99, σ=0.29, 
FWHM=0.67, R2=0.99) and dopamine (peak x=1.04, σ=0.29, FWHM=0.68, R2=0.99) 
conditions, AC process ΔF/F0 in dopamine is worse approximated by a single Gaussian 
distribution (peak x=0.9, σ=0.26, FWHM=0.61, R2=0.93) than AC process baseline ΔF/F0 
(peak x=0.94, σ=0.26, FWHM=0.61, R2=0.99). The dopamine distribution is better modelled 
by a double Gaussian (x peaks=0.87/1.58, σ=0.22/0.77, FWHM=0.51/1.82, R2=0.98). 
 
4.3.11 Activation of D2Rs alone triggers a small bidirectional calcium signal in AC 
processes alone, similar to D1/D2 agonist application 
When 100μM quinpirole alone is added to the bath, there is a significant increase in 
ΔF/F0 was found in AC processes (p=0.021, 1-sample t-test, n=16; data from 16 processes, 3 
slices, 1 animal) but not in GJC somata (p=0.857, 1-sample t-test, n=6; data from 6 GJCs, 3 
slices, 1 animals). The proportional frequency distribution of GJC ΔF/F0 can be modelled 
equally well with a single Gaussian in both baseline (peak x=0.99, σ=0.14, FWHM=0.34, 
R2=1) and dopamine (peak x=1, σ=0.13, FWHM=0.38, R2=0.99) conditions. AC processes 
display spontaneous activity in baseline conditions, leading to a ΔF/F0 distribution that can 
be adequately modelled by a single Gaussian distribution (peak x=0.9, σ=0.25, FWHM=0.59, 
R2=0.97) but better modelled with a double Gaussian (x peaks=0.86/1.26, σ=0.21/0.39, 
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Figure 4.7 Specific dopamine receptor agonist application triggers small, 
biphasic calcium dynamics in astrocytic processes. 
a) SKF38390 (100μM) and Quinpirole (100μM) has a small effect on process ΔF/F0. Left: time course 
of dopamine application (black bar – SKF and QPR application), brackets indicate time frames 
sampled for histograms; middle: fluorescence change average over t = 13-17; right: histogram of 
ΔF/F0 data points recorded from patched cell (AC) processes (above) and Gap-junction coupled (GJC) 
somata (below) – bars indicate baseline distribution (t = 1-12), line indicates distribution in presence 
of dopamine (t = 13-20). b) Quinpirole alone (150μM) has a similar, small effect on process ΔF/F0. 
Layout: as in a).  
 
 
FWHM=0.49/0.91, R2=1) – see supplementary figure S12. Similarly, AC process ΔF/F0 in 
dopamine can be modelled with a single Gaussian (peak x=0.96, σ=0.35, FWHM=0.83, 
R2=0.96) but is better fitted with a double Gaussian (x peaks=0.83/1.36, σ=0.28/0.47, 
FWHM=0.66/1.1, R2=0.98) – see supplementary figure S13. 
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4.4 Discussion 
4.4.1 Why is the response to dopamine different between the patched cell and 
gap junction-coupled cells? The creation of an astrocyte ‘perforated-patch’. 
The first aim of this chapter is to assess whether dopamine has similar effects on 
astrocytic calcium in non-treated slices to those that have been bulk-loaded with SR101 and 
fluo-4-AM (as in chapter 3). I achieved this by whole-cell patch-clamping single astrocytes 
and loading them with cell-impermeant calcium-indicator (Fluo 4). The greatly improved 
dye-loading and signal to noise ratio afforded by this technique allowed me to image 
astrocyte processes – key to understanding dopamine induced calcium dynamics. AC 
process calcium dynamics in response to dopamine stimulation have yet to be studied 
(given all previous studies have been in culture). A striking, if well-known phenomenon that 
occurs upon whole-cell patch-clamp of an astrocyte is the appearance of nearby, non-
patched astrocytes when viewed under fluorescence excitation imaging. Astrocytes are 
intimately linked to each other by gap junctions, channels formed primarily from connexin 
43 and connexin 30 proteins (Giaume and Theis 2010) in situ. These gap-junctions are 
permeable to molecules up to around 1-1.2kDA in size, including important intracellular 
signalling ions (Na+, K+ and Ca2+) (Ransom and Ye 2005) and some second messangers and 
amino acids (Tabernero et al. 2006; Theis and Giaume 2012). These inter-cellular pores are 
permeable to both the morphological dye and calcium-indicator that I am using: Alexa 594 
(MW: 909 Da) and Fluo-4 (MW: 737 Da) respectively and it is the diffusion of these dyes 
into neighbouring astrocytes that makes them visible (see figure 1a). Indeed this 
phenomenon is so robust that its presence is used as an indicator of patched cell health, as 
undesirable intracellular conditions (high calcium, pH change) interfere with gap junction 
coupling (Crow et al. 1994; Giaume and Venance 1998; Rackauskas et al. 2010). I have 
decided to put this phenomenon to use throughout this thesis by imaging concurrently 
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from both patched astrocyte (AC) processes and gap-junction coupled astrocyte (GJC) 
somata. The patched astrocyte can be regarded as a filter between the patch pipette and 
the GJCs – both limiting the size of molecules dialysing into, or washing out from GJCs 
(through gap-junction pores) and limiting the diffusion rate between the pipette and GJCs, 
by increasing the spatial distance and environmental complexity (proteins, cell-membrane, 
etc.) between the patch-pipette and the imaged cell. This recording configuration can be 
likened to electrophysiological perforated-patch recordings (Horn and Marty 1988), as both 
methods seek to leave the recorded cell’s intracellular milieu as close to its original state as 
possible – hence the ‘astrocyte perforated patch’. 
As is clear from figure 4.1, in all but AC somata, dopamine triggers average 
intracellular cytosolic free calcium increases. The lack of response in the AC somata is to be 
expected – it is a relatively small structure (8-10μM diameter) which will dialyse rapidly 
with pipette solution, washing out most small endogenous signalling molecules that could 
be vital for dopamine-induced calcium increase. The mechanical stimulation from pipette 
tip vibration could also trigger calcium signalling (Charles et al. 1991), further confounding 
any possible calcium response recordings. Therefore, for the remainder of this thesis I have 
not reported fluorescence changes at the AC soma. 
AC processes are currently considered the most interesting area of inquiry 
regarding astrocytic calcium signalling, given their proximity to the synapse and the 
compartmentalization of their calcium responses (Di Castro et al. 2011). Here, I discuss the 
large processes imaged in the above results – smaller, synapse-ensheathing processes are 
too small to contain the endoplasmic reticulum required for internal calcium release upon 
dopamine stimulation. Unlike the AC soma, they show an effect of dopamine on cytosolic 
free Ca2+ – the fact that this is proportionally smaller than both the average fluorescence 
increase recorded in bulk-loaded cells (chapter 3) and in GJCs, suggests that there is a 
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residual effect of the nearby patch-pipette on the AC processes. The effect is not due to 
functional difference in process vs. soma calcium signalling: there is no significant or 
obvious difference between the calcium response in GJC somata and GJC processes (figure 
4.1). Dopamine-induced calcium changes are reported relative to average baseline 
fluorescence so two, non-exclusive, explanations are possible: firstly, dialysis of the AC with 
the patch-pipette solution and washout of the existing intracellular milieu decreases the 
sensitivity of the AC to dopamine-induced calcium increase; secondly, the mechanical 
stimulation and dialysis of the AC with residual patch-pipette Ca2+ increases the baseline 
free calcium levels and spontaneous calcium dynamics. Thus, even if the same absolute 
concentration of calcium is reached upon dopamine stimulation, the relative increase from 
baseline will be reported as lower. Of the two, the second seems more likely: baseline 
spontaneous activity in AC processes was often observed to be higher than in GJCs (see 
example in figure 1a) and even than that observed in bulk loaded cells; this activity would 
increase the baseline average and is also indicative of a greater probability in intracellular 
CICR, itself increased by a higher resting free cytosolic calcium concentration. Whilst it is 
tempting to speculate that washout of small molecular components of the dopamine 
receptor-linked intracellular signalling cascade (e.g. cAMP, IP3) decreases AC process 
sensitivity to dopamine, whilst sparing GJC somatic sensitivity, it has been shown that IP3-
mediated spontaneous activity is still present in patched astrocytes (Di Castro et al. 2011; 
Sun et al. 2014), arguing against a strong effect of washout on the intracellular signalling 
milieu.  
 Overall, the data from this initial result shows a startling effect of patch-clamping 
on the astrocytic dopamine response. Although the effect of dopamine is the subject of this 
thesis, the implications of this result are not limited to investigations of dopamine’s effects 
on calcium. Whole-cell patch-clamping of astrocytes dramatically interferes with the nature 
of their intracellular calcium dynamics, a result which is supported by more data coming out 
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of our group (Zheng and Bard – personal communication). This is problematic as it is only 
the processes of patched astrocytes that can be imaged for calcium dynamics with 
sufficient spatiotemporal resolution. When studying the effect of long-lasting, global 
dopamine stimulation, as used in this chapter, it is possible to take calcium dynamics 
recorded from the soma as a general indication of the effects of stimulation. Highly 
localized events of a short time-period, for example synaptic stimulation and spontaneous 
activity (Henneberger et al. 2010; Di Castro et al. 2011; Panatier et al. 2011), that are only 
visible in astrocyte processes, are generally a result of more spatially and temporally precise 
stimuli – hence the viability of the ‘astrocyte perforated-patch’ as a recording method for 
this chapter. This method relies on the gap-junction coupling of astrocytes across the 
syncytium. These gap-junctions are pores, created by connexin proteins, which allow small 
molecules (~1.2kDa) across the astrocytic plasma membrane into neighouring astrocytes. 
Alexa594 molecules have a molecular weight of 820 Da and fluo-4 of 930 Da, allowing them 
to diffuse from the patched astrocyte into the surrounding astrocytes, allowing them to be 
imaged. 
 
4.4.2 A novel astrocytic calcium decrease.  
Perhaps the most surprising finding of this chapter is dopamine’s ability to decrease 
astrocytic cytosolic free calcium concentration (Ca2+-decrease) as well as increasing it (Ca2+-
increase) (figure 4.2). Such Ca2+-decrease in response to dopamine is not unprecedented, 
but has not been discussed in detail in the literature. Khan et al. (2001) report Ca2+-
decrease upon stimulation of the D2R with quinpirole, in the presence of the D2R 
antagonist raclopride. This is a surprising result – given that quinpirole alone is reported to 
increase calcium – that Khan et al. explain via raclopride blockade of constitutive D2R 
pathway activity (although such constitutive activity has not been reported in the literature 
148 
 
and could also be explained by hetero/homomeric receptor expression – see section 4.3.6). 
Zhang et al. (2009) show example traces of Ca2+-decrease in individual striatal astrocytes 
following stimulation with both SKF38393 and quinpirole – although they do not comment 
on it. Dopamine-induced Ca2+-decrease is not reported by Vaarmann et al. (2010) or 
Requardt et al. (2012).  Hence it is fair to say that this is the first detailed report of 
dopamine-induced Ca2+-decrease in astrocytes – although this is not to say that the addition 
of dopamine is not simply interfering with underlying Ca2+ homeostasis, by blocking Ca2+ 
entry, or stimulating Ca2+ extrusion. In neurons, dopamine has been reported to decrease 
intracellular free calcium levels in snail neurons (Gerschenfeld et al. 1989), lactotrophs of 
the hypothalamus (Malgaroli et al. 1987) do so via decreased voltage-gated Ca2+ channel 
activity and cone-photoreceptors via D4 receptors (Ivanova et al. 2008). In the rodent 
prefrontal cortical neurons, D4Rs decrease NMDAR mediated calcium-currents (Wang et al. 
2003). Astrocytes express VGCCs (Barres et al. 1989; D'Ascenzo et al. 2004; Burgos et al. 
2007; Padmashri and Sikdar 2007) so it is possible that dopamine receptor activation could 
modulate resting calcium through interference with VGCC opening from spontaneous 
neuronal activity-induced local depolarization. In astrocytes, excepting the above results, 
the only report of inducible Ca2+-decrease is from Shigetomi et al. 2011, who report that 
TRPA1 channels regulate astrocyte basal calcium, and that specific blockade of these 
channels decreases resting calcium levels. Very interestingly, in peripheral neurons, 
apomorphine – a non-selective dopamine receptor agonist with a slight preference toward 
D2-type receptor activiation – triggered concentration-dependent activation (low 
concentrations) or inhibition (higher concentrations) of the TRPA1 channel (Schulze et al. 
2013) – although see (Aman et al. 2007). This novel site of potential dopamine action could 
be another explanation for the Ca2+-decrease reported here from dopamine application.  
Are Ca2+-decrease and Ca2+-increase inter-dependent? This can be resolved by 
answering two questions: are decreases always preceded by transient increases – i.e. are 
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they some kind of extended negative rebound? And do large increases only occur riding on 
small, obscured decreases? Calcium decreases almost always follow dopamine-induced 
increases – although this trend can be reversed with the application of the D1/5R blocker 
SCH23390, arguing against dopamine autoxidation as the cause (table 4.1): AC processes 
and GJC somata can exhibit dopamine-induced calcium decreases without concomitant 
increases, as can be seen in D1-type receptor blockers (figure 4.5) and in some 100μM 
recordings not shown in the single cell examples in figure 2. Given that the ratio of cells 
exhibiting a decrease before an increase can be shifted (though D1/5R blockade – it seems 
that Ca2+-decrease is not solely a knock-on effect of a  
 
 
Protocol 
Figure data 
taken from  
cell 
population 
First DA-induced Ca2+ 
response direction 
 
 
 
+ - 
100μM DA 4.2 
AC process 13 2 
GJC somata 7 0 
50μM DA 4.3c 
AC process 12 0 
GJC somata 4 0 
20μM DA 4.3b 
AC process 21 3 
GJC somata 9 2 
 100μM DA + 
10μM SCH23390 
4.5a 
AC process 7 4 
GJC somata 1 7 
    100μM DA +        
5 μM SCH23390 
4.5b 
AC process 14 6 
GJC somata 7 3 
 
Table 4.1 Direction of first clear effect of dopamine on astrocytic Ca2+ in 
protocols where a Ca2+ decrease has been recorded 
Table indicates the number of cells responding to dopamine either first with an increase (+) or a 
decrease (-) in either AC processes or GJC somata, which protocol was used to elicit the Ca
2+ 
changes, 
and which figures the data are displayed in. 
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Ca2+-increase. As the Ca2+-decrease has slower kinetics and smaller amplitude than the Ca2+-
increases, is seems likely that a Ca2+-increase often appears first because it more easily 
distinguished from baseline F/F0, whereas a Ca
2+-decrease may have already begun but not 
be visible under these recording conditions. As discussed later, it is certainly possible to 
induce Ca2+-increase without a visible Ca2+-decrease – although given the small amplitude 
of Ca2+-decrease, it may be present, but not sensed with the fluorescent indicators used. 
This possible lack of sensitivity is discussed below, but it could be remedied in future by the 
use of higher sensitivity dyes (e.g. OGB-1). The reason for continued use of Fluo-4 is that it 
provides the high dynamic range required to record all of the calcium increase. 
The dopamine-induced Ca2+-decrease is not always clearly visible, but can occur at 
any point after the initial addition of dopamine to the perfusion solution. It constitutes a far 
smaller relative shift in fluorescence intensity than the dopamine-induced Ca2+-increase – 
but this could be because the recording configuration is set up to best record calcium 
increases (Fluo-4 has a high dynamic range, but lower sensitivity than OGB-1; the laser 
power for each recording is adjusted to make the resting fluo-4 fluorescence only very 
slightly greater than background). The kinetics of Ca2+-decrease are very different from 
Ca2+-increase – Ca
2+-decrease onset is very slow (minutes) compared to Ca2+-increase, which 
has a sharp onset (1-2 seconds), whether it is the beginning of a sustained increase or many 
shorter transients. On the basis of these features the dopamine-induced Ca2+-decrease can 
be classified as a change in the resting calcium concentration, whereas the Ca2+-increase 
are more transient signals, riding on top of the baseline decrease. The fact that Ca2+-
decrease persists after the washout of dopamine and takes 10s of minutes to return to 
baseline indicates that it is working through a different, slower system to the Ca2+-increase. 
This might be a concentration-dependent effect, stimulation by residual dopamine, post-
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washout, of high-affinity receptors or other highly sensitive pathways – but this was not 
found to be the case when concentration effects were directly investigated (figure 4.3). 
Apart from the examples in figure 4.2a, b I have chosen not to analyse the fluorescence 
from the washout period with regard to dopamine-induced calcium decrease: this is 
because the potential interaction of both residual dopamine in the slice and longer lasting, 
previously stimulated, intracellular mechanisms affecting astrocytic calcium, make clear 
inferences as to the mechanism and function of Ca2+-decrease hard to draw. It is important 
to note that Fluo-4 is highly pH sensitive – an increase in alkalinity of ~0.2 could account for 
the decrease in recorded fluorescence described here – however there are no reports in 
the literature of dopamine triggering such an increase in alkalinity.  
Given the much larger ΔF/F0 value that Ca
2+-increase command over Ca2+-decrease, 
and their stochastic nature, averaging the fluorescence data over time would eradicate any 
recorded decrease in fluorescence, even when they spend most of their time at decreased 
fluorescence (see figure 4. 5b and figure 4. 2a, c3 for a good example). Presenting the 
proportional frequency distribution of ΔF/F0 values gathered at both phases of dopamine 
application experiment (baseline vs. in the presence of dopamine) allows the pooling of all 
data points from all the recorded cells for each epoch, and visualization of all general shifts 
in ΔF/F0 caused by dopamine. The distributions of the decrease and the increase can be 
well modelled by the sum of two Gaussians – one with the peak x location below the mean, 
one with peak above – this implies the presence of two biological processes, one 
responsible for Ca2+-decrease, one for Ca2+-increase. In fact, this Gaussian analysis may 
slightly underestimate the amplitude of Ca2+-decrease: the sampling area for the 
‘dopamine’ epoch shown in all the histograms has an arbitrary start point (the beginning of 
the 3rd minute post addition of dopamine to the perfusion solution), which may not 
correspond perfectly to the beginning of the dopamine effect – hence each histogram will 
display some proportion of baseline ΔF/F0, which will slightly positively skew the peak of 
152 
 
the first Gaussian. The negative going ‘shoulders’ on each histogram in figure 2 indicated 
that there may in fact be an even greater negative-going component, not completely 
captured in these Gaussian fits. 
 
4.4.3 Why does changing dopamine concentration affect the relative proportion 
of decreasing and increasing fluorescence? 
 To distinguish between stimulation of dopamine-induced decreases and increase, I 
gradually increased the concentration of applied dopamine (figure 4.3), starting at 10μM – 
which elicits neither an increase nor a decrease in fluorescence. Interestingly, 20μM 
dopamine has different effects on GJCs compared to AC processes: in GJCs, only Fi visible, 
but in AC processes both Ca2+-increase and Ca2+-decrease are apparent. This could be 
explained by two obvious differences between AC process recordings and GJC somata 
recordings: better signal to noise ratio from AC processes, and increased resting calcium in 
AC processes compared to GJC somata. Thus, with respect to a decreased signal to noise 
ratio, an overall reduction in both dopamine-induced calcium increase and decrease 
processes, from decreased dopamine stimulation, would lead to smaller ΔF/F0 for Ca
2+-
increase and Ca2+-decrease (see the average time course in figure 3b): given the higher 
concentration of dye in the AC processes and the better signal to noise ratio, the decrease 
might only visible here and not in the GJC somata. If initial resting calcium is the cause, it is 
possible that an increased resting cytosolic calcium concentration in the AC processes could 
potentiate dopamine’s ability to decrease astrocytic calcium. An ideal experiment to test 
this would be to artificially increase the resting calcium in GJCs (by increasing external Ca2+ 
concentration, for example) and see if that mimics the dopamine-decreasing effect of 
20μM dopamine in GJCs.  
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 At 50μM, dopamine induces an even clearer decrease in AC processes (the 
Gaussian modelling decrease shifts from x peak 0.9 in 20μM to 0.86 in 50μM) and a 
decrease in GJCs (when modelled with a triple Gaussian, x peak of decrease is 0.77). This is 
consistent with a calcium decrease in GJCs at 20μM dopamine being present, but out of 
sensitivity range, especially as the observed decrease in AC processes is larger in 50μM than 
20μM dopamine – but does not rule out a potentiation of the dopamine-induced decrease 
at higher intracellular resting calcium levels. At 100μM dopamine, both AC processes and 
GJC somata show populations of decreased fluorescence, but not to the same extent as at 
50μM (first fitted Gaussian peaks are at 0.9 and 0.95 respectively) – indicating that, at 
higher concentrations, the dopamine-induced fluorescence increase begins to overwhelm 
the decrease.  
 A biphasic concentration-dependent response such as seen in these data is 
consistent with the biphasic activation of TRPA1 channels – activated at lower DAR agonist 
concentrations and antagonized at higher ones (Schulze et al. 2013). Another possible 
explanation is astrocytic D2-type receptor inhibition of baseline-activatied VGCCs. The 
concomitant calcium increase could be triggered by D2R-mediated IP3 increase (Hernandez-
Lopez et al. 2000) in conjunction with other DA-sensitive pathways (see below). 
 
4.4.4  Pharmacological dissection of the calcium increase and decrease. 
 Interestingly, simultaneous blockade of mGluRs, GABABRs and Na
+ channels during 
100μM dopamine application blocks the calcium decrease but not the increase (consistent 
with the similar result in TTX alone from bulk-loaded slices – see chapter 3). This implies a 
dopaminergic activation of neuronal activity and a concomitant release of a glioactive 
substance that decreases astrocytic calcium. To date, there are no reports of mGluR or 
GABABR-mediated astrocytic calcium decreases in the literature, so the candidate substance 
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is likely to be released by dopamine-induced hippocampal neuronal activity itself. An 
intriguing possibility is that Ca2+ itself is the active extracellular signalling molecule: Torres 
et al. (2012) recently reported that increasing neuronal calcium dynamics (as dopamine has 
been reported to do – (Gulledge and Jaffe 2001; Lezcano and Bergson 2002) – decreases 
extracellular calcium concentration. This was reported to trigger astrocytic calcium 
increases via ATP release – a result that is consistent with the partial blockade of Ca2+-
increase by PPADS discussed below – but over an extended time-period could decrease 
astrocytic intracellular calcium through decreased calcium entry from the extracellular 
space and slow draining of the intracellular stores. The alternative is a dopamine-induced 
release of endocannabinoids, acetylcholine or serotonin (none of which have been reported 
in hippocampal slices) and their subsequent induction of a Ca2+ decrease. Neither of these 
phenomena have been reported – in fact, regarding the latter, the opposite has (Cai et al. 
2000; Araque et al. 2002; Navarrete and Araque 2008). 
In GJCs, blockade of P2 purinergic receptors eliminates the calcium decrease whilst 
sparing part of the calcium increase (there is a strong negative going peak in AC processes – 
but the sample size is small and more prone to random variation). Therefore ATP, either 
through tonic activation or through dopamine-induced release is responsible for part of the 
astrocytic calcium rise – a well-described phenomenon (McCarthy and Salm 1991; Koizumi 
et al. 2002; Fumagalli et al. 2003; Navarrete et al. 2013). ATP has been reported to 
stimulate dopamine release in the striatum (Zhang et al. 1995) raising the intriguing 
possibility of a positive feedback mechanism between local dopamine release and 
astrocytes via astrocytic release of ATP. More puzzling is the blockade Ca2+-decrease by 
PPADS – calcium reduction through a direct action of P2 receptors would contradict the 
consensus in the literature that P2R activation invokes only calcium increases in astrocytes. 
It also argues against the involvement of TRPA1 channels in the calcium decrease – and 
there are no reports of PPADS affecting TRPA1 channels. The PPADS data do bear a striking 
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resemblance to those from 20μM dopamine application. P2Y receptors are Gq-coupled, 
operating through PLC activation (Pirotton et al. 1996), as do D2Rs (Hernandez-Lopez et al. 
2000) and the PI-linked D1-like receptor (Hasbi et al. 2009); it is possible that PPADS 
depresses the activity of this D2R pathway through P2YR antagonism, thereby indirectly 
decreasing the effects of dopamine on astrocytic calcium: the reverse has been shown 
(dopamine receptor modulation of ATP-evoked calcium increase) in striatal neurons, 
indicating a functional link between the two receptor pathways (Rubini et al. 2008). This 
could push the dopamine-induced Ca2+-decrease out of the recording sensitivity range (as 
discussed above) in GJCs, leaving a Ca2+-increase visible – this would account for a Ca2+-
decrease visible in AC processes but not GJC somata. Another possibility is that PPADS, in 
blocking the P2YR, blocks tonic ATP-induced reactive oxygen species-generation in the 
recorded astrocytes (Kahlert et al. 2007), which blocks part of the calcium increase; this 
would be consistent with the partial inhibition of the calcium response seen in the presence 
of selegiline in bulk-loaded cells (chapter 3). PPADS has been reported to interfere with 
amphetamine-like psychostimulant administration-induced behaviour (Kittner et al. 2001) – 
as these drugs increase dopamine concentration in the brain, it may be that there exists a 
previously undocumented interaction between dopamine, dopamine-receptors and PPADS. 
As with bulk-loaded slices, strong, simultaneous blockade of both D1 and D2-type 
receptors completely inihibits both the Ca2+-decrease and Ca2+-increase. As this includes the 
PPADS-insensitive portion of Ca2+-increase (an increase also insensitive to neuronal blocker 
cocktail), it can be assumed that astrocytically localized dopamine receptors can trigger a 
calcium increase – as has been reported previously (Khan et al. 2001; Liu et al. 2009a; 
Requardt et al. 2012). Inhibition of Ca2+-decrease by dopamine receptor blockers could be 
explained by the inhibition of neuronal calcium response to dopamine – stopping 
extracellular calcium decrease, the blockade of TRPA1 activation by non-selective action 
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dopamine receptor blockers (although this is yet to be reported in the literature) or by a 
previously unreported calcium-decreasing action of dopamine receptors. 
 
4.4.5 How does stimulation of individual dopamine receptor types change the 
nature of the astrocytic calcium response? 
Blockade of D1/5Rs alone inhibits dopamine-induced Ca2+-increase – consistent 
with Requardt et al. (2012) and Liu et al. (2009) – but spares the Ca2+-decrease (figure 5). 
This strongly implies not only a D1-mediated mechanism of calcium increase, but also 
separate mechanisms of calcium increase and decrease. Decreasing the concentration of 
SCH23390 used to block D1/5Rs increased the excitatory effect of dopamine, without 
affecting the scale of the fluorescence decrease from baseline (the rough x-co-ordinate of 
the peak) i.e. only changing the proportion of time spent at decreased baseline – consistent 
with the above hypothesis. From these data one would assume therefore, that Ca2+-
decrease is mediated by D2Rs – but the data from D2R blockade indicates a more complex 
picture. 
Addition of the D2/3R blocker sulpiride to the bath (figure 6) has no direct effect on 
AC process cytosolic calcium or GJC somatic calcium at 50μM. However, at 20μM, it seems 
to trigger massive spontaneous calcium dynamics in AC processes, but not GJC somata. 
Sulpiride can block D2 inhibitory autoreceptors in the striatum (el Mestikawy et al. 1986), 
leading to increased dopaminergic tonus (Tanaka et al. 1996). Hence it is possible that this 
triggered calcium dynamics in astrocytes, which was visible only in the more sensitive AC 
processes – however the dopamine-induced Ca2+-increase was entirely blocked by Sulpiride 
at both concentrations and in both GJC somata and AC processes (as the distribution of AC 
process activity in 20μM sulpiride and 100μM dopamine simultaneously was similar to that 
in 20μM sulpiride alone), implying that any effect of increased tonus would be blocked. The 
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blockade of both dopamine-induced calcium increase and decrease in GJC somata at both 
sulpiride concentrations might be considered the stronger evidence, given the sensitivity of 
AC process recordings to mechanical stimulation and cytosolic solution exchange from the 
patch-pipette. Examining only the data GJC recordings suggests that Ca2+-decrease and 
Ca2+-increase are both under the control of D2-type receptors, whereas Ca2+-increase is 
under the control of D1/5Rs. There is evidence for this function of D2-type receptors in the 
literature: the non-selective dopaminergic receptor agonist apomorphine can decrease 
calcium in chromaffin cells through PLC (a recognized downstream signalling molecule of 
D2/3Rs) inhibition and calcium entry into the cell (Sontag et al. 1990); D2/3 receptor 
activation has been shown to decrease calcium dynamics through modulation of L-type 
VGCCs in rat Nucleus Accumbens neurons (Perez et al. 2011), rat and frog pituitary 
melanotropes (Desrues et al. 1993; Fass et al. 1999) and neuroblastoma cells(Vallar et al. 
1990; Brown and Seabrook 1995). The consensus from this literature is that D2/3R-
mediated calcium decrease operates through inhibition of VGCC activity – as astrocytes are 
known to express functional VGCCs (Barres et al. 1989; D'Ascenzo et al. 2004; Burgos et al. 
2007; Padmashri and Sikdar 2007), this could well be the mechanism of dopamine-induced 
calcium decrease. Interestingly, the level of oxidative stress in cultured neurons has been 
found to control the effect of dopamine on calcium levels, with higher oxidative stress (such 
as may be found in the presence of high concentrations of dopamine – see Vaarmann et al. 
2010) – which could trigger D2/3R-dependent inhibition of local VGCC opening (Steullet et 
al. 2008), although higher oxidative stress also triggers TRP channel opening (Kim and 
Hwang 2013). Given dopamine receptor blockers’ ability to completely eradicate the 
astrocytic calcium response, the actions of selegiline as a partial blocker of the calcium 
increase seen in chapter 3 have not been investigated further here.  
Very interestingly, specific co-stimulation of both D1 and D2 dopamine receptors 
with the D1 agonist SKF83983 and the D2 agonist quinpirole triggers both a slight Ca2+ 
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increase and decrease, only visible in the astrocytic processes. One possibility to explain 
this, in conjunction with the finding that large astrocyte Ca2+ dynamics are SCH23390-
sensitive (figure 4.5), is that astrocytes preferentially express D5 receptors – astrocytes 
have been found to express D5Rs in culture (Brito et al. 2004) – and these are partially 
activated by SKF38393. Another, more intriguing, possibility is that activation of dopamine 
receptors alone is necessary but not sufficient to trigger the magnitude of the dopamine 
responses seen upon stimulation with dopamine itself – it requires non-receptor signalling 
as well. This is consistent with MAOb blockade-induced inhibition seen in chapter 3 – it is 
possible that, while D1/2 activation provides a calcium ‘spark’, the IP3 generated by MAO 
activity (through PLC activation) amplifies the Ca2+ released from intracellular stores. This 
idea of a dopamine receptor mediated calcium ‘spark’ is also consistent with only seeing 
dopamine receptor agonist activity in the AC processes – it is possible that dopamine 
receptor-mediated signalling is spatially localized, whilst MAOb-mediated large-amplitude 
Ca2+ signalling is a more synchronous whole-cell Ca2+ discharge (Rusakov et al. 2014). 
The Ca2+ response seen upon dual dopamine receptor agonist stimulation is 
consistent with both a solely D1-type receptor mediated dopamine-induced calcium 
increase, and a heteromeric D1/D2 receptor activation (Hasbi et al. 2010). However more 
results seem to rule out a large, solely D2R mediated response (although D3 and D4 
activation is still a possible route) – as discussed below. 
I have found that astrocytic stimulation with the specific D2 dopamine receptor 
agonist quinpirole does not change astrocytic calcium levels from their baseline (figure 4.7) 
– unlike the results reported from Khan et al. (2001). This could be due to stimulation of 
hippocampal astrocytes in this study as opposed to PFC astrocytes in theirs, or due to the 
nature of the culture conditions. I used the same concentration of quinpirole as was used in 
their study (150μM) however it is difficult to know what the necessary concentration 
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required to stimulate astrocytes in situ is, given that I have no positive control. Hence it 
may be that there was an astrocytic effect but I could not pick it up – given the small nature 
of the original reported effect (a 10s increase of 20% ΔF/F) in low noise culture recording 
conditions, this is a definite possibility.  
 
4.4.6 A putative model of astrocytic dopaminergic signalling 
 The fact that both D1-type and D2-type receptor blockers can separately inhibit the 
dopamine-induced calcium increase suggests the presence of a D1-D2 or D2-D5 heteromer 
(Hasbi et al. 2010; Hasbi et al. 2011) activation of which leads to calcium increase, but 
which can be inhibited through blockade of either subunit. There is evidence for these 
types of receptor in HEK cells (Lee et al. 2004; Rashid et al. 2007) and striatal neurons 
(Verma et al. 2010). Simultaneous blockade of both D1 and D2-type receptors has also been 
found to be necessary to block dopaminergic modulation of ATP-evoked calcium increase in 
striatal neurons (Rubini et al. 2008). This is consistent with the reported inhibition of 
calcium signal through D1R blockade reported by Requardt et al. (2012). Co-expression of 
both D1-D2, or D2-D5 receptor heteromers and D2R homomers – or differential activation 
of the dopamine heteromer (Hasbi et al. 2010) – could account for the dopamine-induced 
calcium increases and decreases (through VGCC inhibition) reported in this chapter, 
although part of the reported calcium decrease may be due to TRPA1 activation, changes in 
external calcium through neuronal activity and ATP signalling. An excellent further 
experiment would be to test for a dopamine-induced Ca2+ decrease in the presence of 
TRPA1 receptor blockers – occlusion of the Ca2+ decrease would strongly suggest that it was 
TRPA1 mediated. 
 How does this fit with the selegiline-induced amplification of the Ca2+ increase seen 
in chapter 3? Requardt et al. (2012) suggest that D1R activation increases the ratio of NADH 
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to NAD+ in astrocytes, changing the redox state of the cell (as does MAOb-mediated ROS 
production) and increasing the likelihood of Ca2+ transients through IP3R signalling (Raturi et 
al. 2013). D2-type receptors also increase intracellular IP3 (Hernandez-Lopez et al. 2000), 
but not through changing the redox state of the cell. Hence, another possible explanation 
of the receptor-sensitivity of this response is that blockade of D1-type receptors could 
decrease the IP3 concentration in the cell (as does MAOb blockade) through a shift in the 
redox state (Raturi et al. 2013), thus decreasing the probability of a Ca2+ increase but not a 
Ca2+ decrease. However blockade of D2-type receptors could both inhibit TRPA1-mediated 
Ca2+ decrease and Ca2+ increase through inhibition of IP3 production. 
 Another possibility is on off-target effect of dopamine (not directly on astrocytic 
D1/2 type receptors) triggering a complex metabolic change within the astrocytic 
syncytium, leading to the observed calcium decrease. Simultaneous direct astrocytic 
dopamine receptor activation could account for the two observed calcium signals. Whilst 
such a complex metabolic effect could be difficult to unravel, the experiments listed in the 
discussion above would test more thoroughly if the calcium decrease is indeed through a 
direct effect on astrocytes. Additionally, it would be informative to assay the astrocytic 
response to dopamine during the blockade of the homeostatic calcium machinery (e.g. 
SERCA pumps) – and even in the presence of 0mM extracellular Ca2+ bath solution – to 
ascertain whether the calcium decrease is due to an interference with homeostatic 
processes. 
 
 4.4.7 Physiological relevance of an astrocyte calcium decrease 
Shigetomi et al. (2011) report that astrocyte resting calcium decrease through 
TRPA1 activation, or through buffering of internal calcium with BAPTA, decreases 
interneuronal miniature IPSC (mIPSC) amplitude via an increase in extracellular GABA 
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concentration. Dopamine has been reported to have similar inhibitory effects on 
interneuron activity (Gribkoff and Ashe 1984; Swant et al. 2008; Tierney et al. 2008; Paul 
and Cox 2013), hence astrocytic modulation of GABAergic inhibition could be another route 
of dopamine function in the hippocampus.  
 
 4.5 Conclusion 
As in chapter 3, dopamine was found to increase astrocytic intracellular free 
calcium through D1/D2 receptor stimulation – although here measured in a novel ‘astrocyte 
perforated-patch’ configuration. A previously unreported effect of dopamine was also 
reported in the slice preparation: a decrease in astrocytic calcium through D2 receptor 
activation, in a neuronal activity-dependant fashion. The exact mechanism of this decrease 
remains unclear. 
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Chapter 5: Results 3 
 
Astrocytic calcium dynamics play only a small role in dopaminergic 
modulation of synaptic communication in the Stratum Lacunosum-Moleculare. 
 
5.1 Introduction  
Dopamine has a strong inhibitory effect on baseline excitatory transmission in 
Stratum Lacunosum-Moleculare (SLM), mediated by D1/2Rs and working, at least partially, 
through decrease of pre-synaptic release probability (Otmakhova and Lisman 1998). Given 
that this inhibition is D1/2R mediated, as are the dopamine-induced astrocyte calcium 
transients reported in chapters 3 and 4, and astrocyte calcium transients have been 
proposed to modulate neuronal activity (Perea and Araque 2007; Henneberger et al. 2010), 
I investigated the possibility that dopamine-induced astrocytic calcium transients were 
responsible for the dopamine-induced inhibition of SLM synapses. Similarly, dopamine has 
been implicated in post-tetanic potentiation (PTP) induction (Young and Yang 2005) – a 
form of short term potentiation that has been found at the perforant path-CA1 synapse 
(Colbert and Levy 1993; Leao et al. 2012) – so I investigated the involvement of astrocytes 
in a dopaminergic modulation of SLM PTP. 
 
5.2  Methods 
Transverse hippocampal slices were taken from p21-25 male Sprague-Dawley rats. 
All experiments were conducted at 32°C. Astrocytes from the Stratum Lacunosum-
Moleculare (SLM) region of CA1 were identified under DIC and patched-clamped (figure 1a-
c). For ‘calcium-clamp’ experiments (Henneberger et al. 2010), cells were held in cell attach 
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mode for the indicated time before break-in. The patched cell (PC) processes and nearby 
gap-junction coupled cell (GJC) somata were imaged with a 2P-setup at an excitation laser 
power of 2-5mW, at a frame rate of 1Hz. Emitted light was collected in two channels: 515-
560nm (peak Fluo-4 emission wavelength = 515nm) and 590-650nm (peak Alexa594 
emission wavelength = 618nm). Fluorescence intensity for each cell, per frame, is calculated 
as the average fluorescence of all pixels in a manually defined region of interest (ROI). 
Fluorescence data is from GJCs (see results chapter 2). G/R intensity is normalized to 
baseline, to give a time course of cytosolic calcium dynamics (ΔF/F0) from ROIs. Cells with 
unstable resting calcium in the baseline condition – i.e. fluctuations unlike normally 
observed calcium transients (Parri et al. 2001; Aguado et al. 2002) or a constantly rising 
baseline – were discarded. Cells with no DA washout were discarded.  
To record fEPSPs from perforant path (pp)-CA1 synapses, a recording pipette was 
placed in SLM of CA1 and a monopolar stimulating electrode in pp, closer to subiculum. 
Stimulus strength was adjusted to give 50-60% of maximal fEPSP amplitude and recordings 
were made at 0.067Hz (every 15s).  Astrocytic fEPSPs (afEPSPs) can be recorded from the 
astrocyte patch pipette, and they provide an accurate readout of the local fEPSP 
(Henneberger et al. 2010) – although peak afEPSP amplitude has to be computed from 
subtracting afEPSP peak from the following upwards deflection of the voltage trace. 
Simultaneous afEPSP and fEPSP (from a locally positioned recording pipette) were made 
during ‘calcium-clamp’ experiments (figure 5.2c). Theta-burst-stimulation (TBS) consisted of 
8 stimuli at 100Hz delivered twice at 5Hz. 
The fluorescence data presented in this chapter are all from GJC somata, 
averagered over the total number of cells and for each experimental minute – error bars 
show the standard error. For the purposes of statistical analysis of imaging experiments, n 
was taken to be the total number of GJCs sampled, although total number of slices and 
164 
 
animals are also given. For electrophysiology data, n is the number of slices, although 
animal numbers are also given. To compare two normally distributed data populations, a 
two sample t-test was used.  
 
5.3 Results 
5.3.1 Unlike astrocytes from stratum radiatum, stratum lacunosm-moleculare 
astrocytes do not show a visible calcium response to 20μM bath-applied 
dopamine.  
Are astrocytes throughout CA1 homogeneous in their response to dopamine? 
Interestingly, they do not seem to be: 20μM bath-applied dopamine does not significantly  
 
 
Figure 5.1  Unlike in stratum radiatum, 20uM Dopamine does not evoke 
astrocytic calcium transients in stratum lacunosum-moleculare  
a) Time courses of astrocytic AC process (hollow circles) and GJC somata (grey circles) calcium 
changes in response to 20μM dopamine (black bar). b) Summary bar graphs showing average 
response in stratum lacunosm-moleculare astrocytes (white and grey) compared to stratum 
radiatum astrocytes (blue and blue cross-hatched) in both GJC somata (white and blue) and AC 
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processes (grey and blue cross-hatched). n.s. – not significant, ** - p<0.05, ** - p<0.01, *** p<0.001, 
t-test (1), Wilcoxon signed rank test, 2-sample t-test or Mann-Whitney test (see text). 
 
 
change ΔF/F0 in either AC processes (p=0.29, 1-sample t-test, n=6; data from 6 processes, 2 
slices, 2 animals) or GJC somata (p=0.232, 1-sample Wilcoxon signed rank test, n=10; not 
normally distributed, p=0.029, Shapiro-Wilk test; data from 12 cells, 4 slices, 4 animals) of 
the stratum lacunosum-moleculare (SLM) – see figure 5.1. ΔF/F0 of SLM AC processes is 
significantly less than SR AC processes (p=0.041, 2-sample t-test; SR data from figure 4.3), 
similarly the difference ΔF/F0 of SLM GJC somata from SR GJC somata approaches 
significance (p=0.052, Mann-Whitney test; SR data taken from figure 4.3) 
 
5.3.2 Ca2+-clamp blocks the dopamine-induced Ca2+-decrease, but not the 
increase. 
Ca2+-clamping of astrocytic intracellular milieu has been used to block astrocyte-
dependent processes (Henneberger et al. 2010); in order to inhibit astrocytic Ca2+-dynamics 
directly I will use this method later in the chapter. But first I tested whether it can block 
dopamine-induced astrocyte Ca2+-dynamics. Astrocyte Ca2+-clamp does not block 
dopamine-induced Ca2+ increases, but it does block dopamine-evoked decreases. Thus, use 
of the Ca2+-clamp can be used to test whether a dopamine-induced astrocytic Ca2+ decrease 
is necessary for a given electrophysiological effect. In section 5.3, although 20μM dopamine 
does not trigger Ca2+ increases, any Ca2+ decreases (not visible in this configuration) would 
be blocked. Although calcium dynamics were not imaged during the Ca2+-clamp data in 
figure 5.3, this control experiment is displayed here (figure 2.4). In AC processes (data from 
25 processes; 3 slices, 3 animals), baseline can be fitted with a single Gaussian (x peak=0.98,  
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Figure 5.2 Calcium-clamp solution in astrocytes blocks dopamine-induced 
calcium decreases but not increases in stratum radiatum astrocytes. 
 a) time courses of astrocytic PC process (hollow circles) and GJC somata (grey circles) calcium 
changes in response to 20μM dopamine (black bar) whilst patched with a calcium-clamp solution; 
grey bracket indicates region sampled for ‘baseline’ in b), black bracket indicates region sampled for 
‘dopamine’. b) histogram of ΔF/F0 responses in baseline (t=1-12, grey bars) and dopamine (t=13-20, 
black line) conditions, for AC processes (upper right panel) and GJC somata (lower right panel). 
 
FWHM=0.93, R2=0.92), but requires two (x peaks=1.07/1.74, σ=0.27/0.7, FWHM=0.68/1.66, 
R2=0.99) – see figure S1. GJCs were not analysed as they were beyond the distance that 
could be affected by the Ca2+-clamp. This methodological finding is discussed further in the 
general discussion. σ=0.24, FWHM=0.6, R2=0.99), dopamine cannot be well fitted with a 
single Gaussian (x peak=1.16, σ=0.39,  
 
 
5.3.3 Dopaminergic inhibition of the perforant path-stratum lacunosum-
moleculare synapse is unaffected by local clamp of astrocytic intracellular 
calcium. 
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Figure 5.3  Dopaminergic inhibition of perforant path fEPSPs persists with 
astrocyte calcium dynamics clamped. 
a) Recording configuration: above, relative positions of patch pipette (green), field electrode (blue) 
and stimulating electrode (red) in the hippocampal slice; below, DIC image of patch and recording 
pipettes, pp – perforant path, SLM – stratum lacunosum-moleculare, SR – stratum radiatum, scale 
bar – 50μm. b) example of simultaneous fEPSP (above) and afEPSP (below) recordings (averaged 
over 80 traces). c) Time course of normalized fEPSP slope (hollow circles) and normalized afEPSP 
peak (grey circles) for cell attach (i), whole cell equilibrating (ii) and whole cell recording (iii) followed 
by dopamine (20μM) application (black bar). d) paired-pulse ratios (50ms interval) for recordings 
shown in c). 
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Now, I tried to inhibit dopamine-dependent synaptic inhibition in the stratum lacunosum-
moleculare (Otmakhova and Lisman 1999) with the astrocyte Ca2+-clamp. The protocol for 
the Ca2+-clamp experiment was as follows: astrocyte fEPSPs (afEPSPs) and nearby fEPSPs 
were simultaneously recorded (figure 5.2a, b); for the first 10 minutes, astrocytes were held 
in cell-attach mode; then whole-cell mode was achieved and the cell allowed to fill for 20 
minutes; finally 10 minutes baseline (t=32-41) was recorded, followed by 10 minutes 
dopamine (20μM) application (t=42-51) and then 20 minutes washout (t=52-71). Baseline 
was taken as the period 10 minutes before dopamine application. There was no significant 
difference from baseline of fEPSP slopes in cell-attach mode (t=6-10) (p=0.316, 1-sample t-
test, n=3). The inhbitory effect of DA at t=47-51 was clear (figure 5.2c): a decrease of fEPSP 
slope to 0.44 ± 0.05 of baseline (p=0.001, 1-sample t-test, n=4). The afEPSP showed a 
similar DA induced decrease (figure 5.2c), 0.56 ± 0.07 baseline (p=0.03, 1-sample t-test, n = 
3). The fEPSP PPR (figure 5.2d) does not change significantly upon cell dialysis (p=0.077, 1-
sample t-test, n = 3), nor upon DA application (p=0.253, 1-sample t-test, n = 4). This is 
consistent with the afEPSP recordings (figure 5.2d) – they show no significant PPR 
difference from baseline (p=0.461, 1-sample t-test, n = 3). 
 
5.3.4 Dopamine inhibits PTP in the stratum lacunosum-moleculare. 
Astrocytes are not necessary for dopaminergic inhibition of baseline fEPSPs in SLM 
– could they be involved in short-term plasticity? First I looked to establish an effect of 
dopamine on short-term plasticity. In the presence of 50μM picrotoxin (PTX), a short theta-
burst stimulus (TBS) induces post-tetanic potentiation (PTP) – as shown in the example in 
figure 5.4a and the averaged data in figure 5.4b. Recording rate is 0.067Hz, starting at 5 
seconds post-TBS. There is an interaction between control and dopamine peak amplitudes 
(figure 5.4i, upper panel) (2-way repeated measures ANOVA, F(19,171) = 2.01, p=0.01, table  
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Figure 5.4 Inhibition of post-tetanic potentiation in the Stratum Lacunosum-
moleculare by dopamine is enhanced after inhibition of glial Krebs’ 
cycle with fluoroacetate. 
a) Left: example experiment – peak fEPSP amplitude sampled every 15s – showing effect of 
dopamine (black bar) on PTP induction in fluoroacetate (FAC – hollow bar), lightning bolts indicate 
theta-burst stimulus (TBS), blue dashed lines indicate baselines taken for normalization of each PTP. 
Right: example fEPSPs recorded before (black trace) and 5s after (grey trace) TBS. b) i) Time course of 
PTP following TBS in 20μM dopamine (grey circles) normalized to control (hollow circles). Above: 
Peak amplitudes normalized to average peak amplitude of previous minute. Below: time course of 
paired-pulse ratio (2
nd
/1
st
 amplitude peaks) following TBS. ii) Time course of PTP after 50 minutes in 
control conditions (hollow circles) and after 50 mins FAC incubation (pink circles). Layout: as in i). iii) 
effect of dopamine on PTP in control (grey circles) and FAC pre-incubation conditions (red circles). 
Layout: as in i); statistics compare dopamine and FAC+dopamine data sets, * = p < 0.05, Fisher’s test 
– see text. 
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S1) and it is clear from figure 5.4b that the control data are more greatly potentiated than 
the dopamine data. Comparing individual time points between the two conditions using 
fisher’s test, all points were significantly different (p<0.05) except at 5, 155, 170, 215, 245, 
260 and 290 seconds (see figure 5 S1). PPR changes post-TBS (figure 5.4i, lower panel) also 
interacted (2-way repeated measures ANOVA, F(19,171) = 1.74, p=0.034, table 5 S2), with 
smaller PPR. From 125s onwards, only 215s and 275s were significantly lower in control 
than dopamine; data taken from 10 stimuli, 5 slices, 5 animals. changes in visible in 
dopamine. At all time-points up to and including 110s – apart from 35s – dopamine PPR 
was significantly less than control using fisher’s test, at the p<0.05 level.  
 
5.3.5 Astrocytes are not required for PTP but partially alleviate dopaminergic 
inhibition of PTP. 
Finally: are astrocytes involved in this dopaminergic modulation of PTP? Pre-
incubation with 5mM of the glial poison fluoroacetate (FAC) does not significantly affect the 
TBS-induced PTP amplitude (figure 5.4i) (2-way repeated measures ANOVA, F(19,133) = 
0.753, p=0.758, table S3) – only three time points are significantly different at p<0.05, using 
fisher’s test:  185s, 215s and 230s (see figure 5 S3). However, although there is no 
significant interaction between the PPRs (2-way repeated measures ANOVA, F(19,133) = 
0.864, p=0.628, table S4), when examining individual  time points the difference in PPR 
reaches p<0.05 significance (using fisher’s test) for the first three recordings, i.e. 5s, 20s and 
35s – as well as at 185s, 215s and 230s. 
Dopaminergic inhibition of TBS-induced PTP amplitude persists in FAC and there is 
no significant interaction between dopaminergic inhibition in FAC pretreated slices and 
inhibition observed under control conditions (2-way repeated measures ANOVA, F(19,133) 
= 1.14, p=0.138, table S5) – however upon individual comparison with Fisher’s test, at the 
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p<0.05 level, amplitudes following TBS in dopamine at 20s, 35s, and 65s are significantly 
lower in FAC pre-treated slices. Regarding PPR, there is no interaction between FAC-
pretreated and control slices in dopamine (2-way repeated measures ANOVA, F(19,133) = 
0.642, p=0.868, table S6), nor do any of the individual time points show a significant 
difference at the p<0.05 level when tested with Fisher’s test. Control data taken from 10 
stimuli, 5 slices, 5 animals, Dopamine data taken from 8 stimuli, 4 slices, 4 animals. 
 
5.4 Discussion 
5.4.1 Heterogeneity in the astrocytic response to dopamine – distinct 
subpopulations. 
Unlike the calcium responses recorded from astrocytes in stratum radiatum (S.R.) 
(chapter 4), there is no cytosolic calcium increase in stratum lacunosum-moleculare (SLM) 
astrocyte GJCs from 20μM dopamine stimulation. Given that SLM astrocytes can respond to 
dopamine (figure 5.3), this may indicate a sensitivity difference to dopamine between 
astrocytes from different hippocampal strata. Morphological differences between S.R. and 
SLM astrocytes have been reported before, SLM astrocytes occupying smaller synaptic 
territories (Ogata and Kosaka 2002). Similarly astrocytic K+ buffering in SLM has been 
reported to be more gap-junction dependent than in S.R. (Wallraff et al. 2006; Hewett 
2009). Subpopulations of hippocampal astrocytes have also been reported in their 
expression of GFAP and NPY (St-Pierre et al. 2000) and RNA expression (Yeh et al. 2009). 
Cortical astrocytes display population-specific volume changes (Benesova et al. 2009) and 
also subpopulations that are responsive to Sonic Hedgehog (Garcia et al. 2010). 
 Very interestingly, (Reuss et al. 2000) describe a subpopulation of cortical 
astrocytes, functionally distinct in that they respond to D1R stimulation with calcium 
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transients – and they show that incubation with FGF-2 increases the proportion of these 
cells. FGF-2 is present in the hippocampus (Ernfors et al. 1990; Zechel et al. 2010), involved 
in memory formation (Preissler et al. 2007), is known to modulate astrocytic response to 
different ligands (Song and Ghosh 2004) and has been found to be modulated by the 
dopaminergic system in rat hippocampus and prefrontal cortex (Turner et al. 2008; 
Giannotti et al. 2013) A decreasing gradient of FGF-2 expression from SR to SLM could be 
responsible for this observed change in astrocyte sensitivity to dopamine – but such a 
gradient has yet to be reported. It is also intriguing that this astrocytic sensitivity difference 
occurs between two CA1 strata with such different functional responses to dopamine: 
whereas dopamine is strongly inhibitory at SLM synapses (Otmakhova and Lisman 1998) – 
suggested to gate information flow from the entorhinal cortex – in the SR it is far less 
inhibitory (Otmakhova and Lisman 1998) and promotes synaptic l-LTP formation (Frey et al. 
1989; Matthies et al. 1997; Kwon et al. 2008). As astrocytes are necessary for e-LTP 
formation (Henneberger et al. 2010), this increased SR sensitivity could well suggest a role 
for astrocytes in the functional division of dopamine action across CA1. 
 
5.4.2 Astrocytes are not involved in dopaminergic inhibition of the perforant 
path-stratum lacunosum-moleculare synapse. 
Although no calcium responses were recorded at 20μM dopamine in SLM 
astrocytes, one cannot be sure of the calcium dynamics in the fine, synapse-enwrapping, 
processes. Hence, I ‘clamped’ the calcium through intracellular dialysis of both Ca2+ and 
calcium buffers in order to deactivate astrocyte-calcium mediated processes at nearby 
synapses – a technique that has been shown to work for LTP induction in stratum radiatum 
astrocytes (Henneberger et al. 2010). This has no clear effect on the inhibitory action of 
dopamine (figure 5.2), as reported by Otmakhova and Lisman (1998) – whereas they report 
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a decrease to 60% of synaptic strength in dopamine, I observe a decrease to 45 ± 5%. 
However, Otmakhova and Lisman (1998) also report high variability in the strength of the 
inhibition and it seems likely that, with the relatively small sample size in my experiments, 
the inhibitory effect I see is comparable to theirs. Ideally, now that I have shown that 
afEPSPs are an accurate measure of the fEPSP changes due to dopamine, I would repeat 
these experiments with the fEPSP electrode over 200μM away. At this distance the calcium 
clamp no longer has traction – at least over LTP induction (Henneberger et al. 2010). Here I 
would record non astrocyte calcium-clamped synaptic responses to verify. This would 
identify the presence of any small contributory action of astrocytic on this dopaminergic 
inhibition. This experiment does not rule out dopamine affecting synaptic inhibition 
through non-calcium mediated astrocyte pathways. The calcium-clamp protocol was tested 
for its effectiveness in chapter 2: it was found that it inhibited dopamine-induced calcium 
decreases but not increases. Hence it is possible that the dopamine induced inhibition is 
still due to astrocyte invoked calcium increases, but the massive change in calcium 
conditions within the cell should have had some effect on the inhibition if they were 
important for it. 
 
5.4.3 Dopaminergic inhibition of post-tetanic potentiation. 
As discussed in chapter 1, potentiation at the perforant path-SLM synapse is 
controversial in the literature, having been reported as possible only under GABAR 
blockade by Colbert and Levy (1993), but possible under normal conditions by Leao et al. 
(2012). I could only induce very short potentiation under strong repetitive TBS (data not 
shown), but in the GABAR blocker picrotoxin, it was possible to induced both PTP and LTP. 
In fact, many of the recordings were discarded because long-lasting potentiation was 
induced (fEPSP amplitude did not return to baseline after 5 minutes), hence only a weak 
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version of TBS was used to induce PTP (figure 5.4). This PTP had a strong presynaptic 
component, demonstrated by the PPR change, similar to other reported short term-
potentiation (Zucker and Regehr 2002). Consistent with dopamine’s inhibitory, presynaptic 
effect on baseline transmission (Otmakhova and Lisman 1998), it inhibited the amplitude 
(post 5s) and duration of PTP induction through (at least partial) inhibition of the 
presynaptic component – as witnessed by the inhibition of the PTP evoked PPR decrease. 
This all fits with an overall inhibitory function for dopamine at this synapse.  
 
5.4.4 What role do astrocytes play in both control and dopamine-modulated 
PTP? 
Inhibition of the astrocytic Krebs cycle with fluoroacetate (FAC) does not change 
the relative amplitude of TBS evoked PTP (although the responses tend to be non-
significantly smaller) but it marginally increases the duration of the PTP by ~1 minute 
(figure 5.4bii). Interestingly, there is a clear difference in PPR change evoked by TBS – a PPR 
significantly closer to baseline for the first three recordings (5s, 20s and 35s). It appears that 
astrocytes secrete a presynaptically active excitatory signalling molecule upon TBS (Agulhon 
et al. 2008), release of which could be triggered through extracellular K+ build-up and 
subsequent astrocytic cAMP increase (Choi et al. 2012). Another possibility is that FAC is 
interfering with astrocyte K+ conductance (Largo et al. 1997) and hence with short-term 
potentiation (Sibille et al. 2014). If the effect is due to gliotransmission, the signalling 
molecules released could include glutamate (Fiacco and McCarthy 2004; Perea and Araque 
2007) or ATP, acting on presynaptic A2 receptors after extracellular breakdown to 
adenosine, as previously reported by Panatier et al. (2011); this would explain a FAC-
induced inhibition of the TBS-induced PPR decrease. Astrocytic calcium has been reported 
to be necessary for short-term plasticity at the Schaffer collateral synapse (Andersson and 
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Hanse 2010) – but this was short-term depression – and astrocyte control of both short-
term facilitation and depression has been postulated (De Pitta et al. 2011). A decrease in 
presynaptic release probability would predict a smaller amplitude response to TBS – but I 
did not observe this; a possible explanation is compromised astrocytic glutamate buffering 
in the synaptic cleft from FAC poisoning, this would increase the amplitude of the post-
synaptic response, potentially obscuring the decrease in amplitude from decreased 
presynaptic release. 
Addition of dopamine to FAC-incubated slices completely inhibits PTP past 5s, 
remaining smaller than PTP in dopamine from control slices for ~1min (at 20s, 35s, and 
65s). However there is not the significant inhibition of the PPR decrease that we would 
expect from FAC-incubated slices compared to control. The PPR result is perhaps 
unsurprising, as dopamine in control conditions has such a strong inhibitory effect on post-
TBS PPR decrease that it may completely obscure any further significant PPR shift (for 
example, the normalized PPR at 20s is at 1 for FAC slices already). The further depression of 
the PTP by dopamine in FAC pre-treated slices is the most exciting result: it suggests that, 
upon TBS in the presence of dopamine, astrocytes release an excitatory neuroactive 
compound that moderates the inhibitory effect of dopamine – possibly an increase release 
of the presynaptically active molecule postulated above – an effect not present in FAC pre-
treated slices.  
 A methodological caveat to this result is the function of FAC: although in this 
chapter it is assumed that FAC has disrupted astrocytic function and normal Ca2+ dynamics, 
it is important to note that this disruption is not complete. FAC inhibits the Krebs’ cycle by 
binding to coenzyme A, which reacts with citrate synthase to produce fluorocitrate which 
inhibits aconitase function and therefore aerobic respiration. However, astrocytes could 
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still respire anaerobically and there is no data to suggest whether, in this state, they could 
still respond with similar calcium changes to dopamine. 
Although astrocytes are clearly not involved in dopaminergic modulation of 
baseline synaptic transmission – they are in transient synaptic potentiation. Is this 
phenomenon dependent on astrocytic calcium? Although no calcium responses are seen in 
SLM astrocytes in response to the 20μM dopamine used throughout this chapter, it may be 
that only synergistic stimulation with both synaptically released glutamate and bath applied 
dopamine triggers visible astrocytic calcium responses in this astrocyte population – this 
would be a fruitful area for further study. It has been reported that SLM synaptic inputs at 
theta frequency, when coupled with Schaffer-Collateral stimulation (preceding by half a 
theta-cycle), can preferentially stimulate the pyramidal cell soma (Ang et al. 2005): this 
presents another potential area for astrocytic involvement and would certainly be worth 
investigating. 
 
5.5  Conclusion 
 Astrocytes of the stratum lacunosum-moleculare form a functionally distinct 
subset, in regard to their response to dopamine, in comparison to astrocytes of the stratum 
radiatum – they display decreased dopamine sensitivity. Although stratum lacunosum-
moleculare astrocytes do not mediate the established dopaminergic inhibition of the 
perforant path input to CA1, their health is necessary to achieve the full degree of 
potentiation when post-tetanic potentiation is induced at this synapse. 
  
177 
 
Chapter 6: Results 4 
Astrocytes are not necessary for either dopaminergic modulation of baseline 
transmission or post-tetanic potentiation in stratum radiatum. 
  
6.1 Introduction 
Dopamine is now recognized as an important neuromodulator in Stratum Radiatum 
(SR) of the hippocampus – it can moderately inhibit basal transmission (Otmakhova and 
Lisman 1998) and is necessary for l-LTP induction (Matthies et al. 1997) and also for spatial 
memory formation (Li et al. 2003). Dopamine has been reported to modulated cortical PTP 
in an input frequency-specific manner (Young and Yang 2005) and may be involved with 
hippocampal PTP deficiencies in the Mecp2-disrupted mouse model of Rett syndrome 
(Weng et al. 2011). Given astrocytes’ increased sensitivity to dopamine in CA1 stratum 
radiatum, compared to stratum oriens (chapter 5), I decided to test whether dopamine’s 
effects on baseline transmission were astrocyte-mediated. I then tested for a dopaminergic 
modulation of PTP at schaffer-collateral synapses and for an astrocytic component to any 
such modulation. 
 
6.2 Methods 
Transverse hippocampal slices were taken from p21-25 male Sprague-Dawley rats. 
All experiments were conducted at 32°C. To record fEPSPs from Schaffer collateral 
synapses, a recording pipette was placed in stratum radiatum of CA1 and a bipolar 
stimulating electrode also in stratum radiatum, but closer to CA3 (>200μm apart). To record 
NMDAR-mediated fEPSPs in stratum oriens, the field electrode was placed in stratum 
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oriens, among the basal dendrites, and the stimulation electrode in the alveus, toward the 
subiculum; for these recordings, CA3 was removed from the slice, picrotoxin (50μM) and 
NBQX (100μM) were added and 0.1mM Mg2+ recording solution was used. Stimulus 
strength was adjusted to give 50-60% of maximal fEPSP slope and recordings were made at 
0.067Hz (every 15s). fEPSP slope was measured either from 20-60% of the upward phase or 
from 30-70%, depending on the nature of the fEPSP. Theta-burst-stimulation (TBS) 
consisted of 8 stimuli at 100Hz delivered twice at 5Hz. Recordings were discarded if 
baseline was unstable or fEPSP slope did not return to baseline after 10 minutes recording 
from the first TBS. Unless otherwise stated, all data was normally distributed (as measured 
with the Shapiro-Wilk test). Paired-pulse ratio (PPR) refers to the ratio of the second slope 
compared to the first. fEPSP are reported after normalization to baseline, as were PPRs – 
traces were discarded if the PPR of the first recording post TBS (15s) was not beneath the 
antecedent value. 
 
6.3 Results 
6.3.1 Glial poisoning with fluoroacetate does not affect the dopaminergic 
inhibition of stratum radiatum fEPSPs. 
In the previous chapter I found that inhibiting astrocytes in stratum lacunosum-
moleculare (SLM) with fluoroacetate did not affect dopamine’s ability to inhibit fEPSPs – 
but I have also shown that astrocytic Ca2+ responsiveness to dopamine is different between 
SLM and stratum radiatum (SR): could there also be a difference in astrocytic involvement 
in dopaminergic signalling? I tested this here. Bath application of 20μM dopamine 
transiently inhibits excitatory synaptic communication (figure 6.1). At t=16-20, fEPSP slope 
– as normalized to baseline – is significantly decreased to 0.8±0.03 (p=0.028, 1-sample t-
test, n=3), but PPR is not significantly changed (p=0.327, 1-sample t-test, n=3). Hippocampal  
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Figure 6.1 Glial poisoning with fluoroacetate does not affect the inhibition of 
Stratum Radiatum fEPSPs by dopamine. 
a) Stratum Radiatum fEPSP slopes in response to 20μM dopamine. Left: time courses normalized to 
baseline (t=1-10) in control conditions (hollow circles) and after 50 mins fluoroacetate (FAC) 
incubation (red circles), dopamine application indicated by black bar. Right: summary bar chart of 
dopamine effect  on fEPSP slope (average of t=16-20). b) Paired-pulse ratio  of Stratum Radiatum 
fEPSP slopes in response to 20μM dopamine. Layout: as in a); * - p < 0.05, n.s. – non-significant, 1-
sample t-test (1). 
 
 
slices pre-incubated with 5mM fluoroacetate (FAC) still displayed dopamine-induced 
inhibition, to 0.86±0.04 (p=0.04, 1-sample t-test, n=4) and no PPR change (p=0.103, 1-
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sample t-test, n=3). The dopamine-induced slope decreases in control and FAC were not 
significantly different (p=0.284, 2-sample t-test). 
 
6.3.2 Description of a reproducible form of transient post-tetanic potentiation at 
Schaffer collateral synapses. 
Given the lack of a clear involvement of astrocytes in dopaminergic modulation of 
basal transmission, I next wanted to investigate whether astrocytes were necessary for 
dopaminergic modulation of short-term potentiation – but first I needed to describe a 
reliable short-term plasticity protocol in slices, one that could be used twice at the same 
synapses to control for variation between synaptic populations. A short TBS protocol can 
induce transient, reproducible PTP at Schaffer collateral synapses (Figure 6.2): normalized 
fEPSP slope 15s post-TBS is significantly larger – 1.6 of baseline – for 1st TBS (p=0.004, 1-
sample t-test, n=8) and also – to 1.73 of baseline – for 2nd TBS (p=0.01, 1-sample t-test, 
n=8). These two TBS-induced increases are not significantly different (p=0.368, paired t-
test). This coincides with a decrease in PPR: PPR 15s post 1st TBS is not significantly 
decreased (p=0.107, 1-sample t-test, n=8), but 30s post TBS is (p=0.009, 1-sample t-test, 
n=8); PPR 15s post 2nd TBS is significantly lower than baseline (p=0.004, 1-sample t-test, 
n=8) as it is at 30s (p=0.048, 1-sample t-test, n=8). There is no significant difference in PPR 
between 15s post 1st and 2nd TBS (p=0.114, 1-sample t-test, n=8) or 30s (p=0.824, 1-sample 
t-test, n=8). By 16-20 minutes post-1st TBS (t=21-25) the fEPSP had returned to baseline – it 
was not significantly different (p=0.75, 1-sample t-test, n=8); likewise PPR had returned to 
baseline (p=0.705, 1-sample Wilcoxon signed rank test, n=8; not normally distributed, 
p=0.003, Shapiro-Wilk). There is no interaction between 1st and 2nd PTP fEPSP slopes (2-way 
repeated measures ANOVA, F(19,133) = 0.68, p=0.836, table S7), nor between 1st and 2nd 
PTP PPRs (2-way repeated measures ANOVA, F(19,133) = 0.61, p=0.894, table S8), for 5  
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Figure 6.2 TBS induced PTP reproducibly returns to baseline and has a pre-
synaptic component. 
a) Example fEPSP traces from double stimulation; black trace – baseline, red trace – first recording 
(15s) after theta-burst stimulation (TBS). b) Above: time course (average per minute) of Stratum 
Radiatum fEPSP slopes in response to two TBSs (lightning bolts), 20 minutes apart. Below: paired-
pulse ratios (PPR) for the above fEPSPs. Both time courses normalized to baseline (t=1-5). c) Above: 
fEPSPs recorded 5 minutes either side of both TBS at higher time resolution (1 rec / 15s), normalized 
to the 5 minutes preceding each TBS respectively; hollow circles – 1
st
 TBS, grey circles – 2
nd
 TBS. 
Below: PPRs of the above fEPSPs. d) Summary bar charts for fEPSP slopes (left) and fEPSP PPRs 
(right), showing average baseline for 2
nd
 TBS and first recording (15s) post-TBS of both 1
st
 and 2
nd
 TBS 
(grey bars) normalized to 1
st
 baseline, and first recording post-2
nd
 TBS normalized to 2
nd
 baseline 
(grey hatched bars); n.s. – non-significant, 1-sample t-test (1) or 1-sample wilcoxon signed rank test – 
see text. 
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minutes post-TBS; no single time-points are significantly different – fisher test. 
 
6.3.3 In the presence of dopamine receptor blockers fEPSPs at 2nd baseline are 
larger than the original baseline average, but not larger than fEPSPs 
recorded at the 2nd baseline in the previous control experiment 
Does blockade of dopamine signalling affect fEPSPs recorded at baseline? When 
20μM SCH23390 (D1R antagonist) and 50μM Sulpiride (D2R antagonist) are added to the 
bath solution at t=16, the 2nd baseline fEPSP slope (figure 6.3) – before the 2nd TBS (t=21-25) 
– is significantly larger than the average fEPSP at the experiment start (t=1-5) – it is 1.12 ± 
0.05 of the baseline (p=0.035, 1-sample t-test, n=9); PPR is significantly decreased from 1 at 
t=21-25 to 0.95 ± 0.01 of baseline (p=0.005, 1-sample t-test, n=9). The average fEPSP slope 
at 2nd baseline in dopamine antagonists is not significantly different to that recorded at the 
2nd baseline in control conditions (p=0.204, two-sample t-test), although the average PPR 
was significantly lower in DR antagonists (p=0.024, Mann-Whitney test) – figure 6.4c. 
 
6.3.4 Blockade of dopamine receptors occludes initial, pre-synaptic component 
of relative post-tetanic potentiation, but does not affect the latter 
components. 
Is this PTP dopamine-dependent? Is it dependent on tonic dopamine in the slice? 
To check this I induced PTP in the presence of dopamine-receptor blockers. Comparing 
fEPSP slopes of the 1st and 2nd TBS-evoked PTPs (Figure 6.4), both normalized to the 
baseline taken at the start of the recording (1-5mins), shows no significant interaction (2-  
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Figure 6.3 Dopamine receptor blockade potentiates baseline fEPSP 
presynaptically which partially occludes PTP. 
a) Dopamine blockade raises post-TBS baseline transmission. Above: time course (average per 
minute) of stratum radiatum fEPSP slopes in response to two TBSs (lightning bolts), 20 minutes 
apart; hollow bar indicates SCH23390 (20μM) and Sulpiride (50μM) application. Below: paired-pulse 
ratios (PPR) for the above fEPSPs. Both time courses normalized to baseline (t=1-5); hollow circles –
SCH23390 and Sulpiride added, blue circles – data from previous control experiment (figure 6.3a). b) 
Above: fEPSPs recorded 5 minutes either side of both TBS at higher time resolution (1 rec / 15s), 
normalized to the 5 minutes preceding each TBS respectively; hollow circles – 1
st
 TBS, grey circles – 
2
nd
 TBS (in SCH23390 and Sulpiride), light grey line – 2
nd
 TBS normalized to 1
st
 TBS baseline. Below: 
PPRs of the above fEPSPs. c) Summary bar charts for fEPSP slopes (left) and fEPSP PPRs (right), 
showing average baseline for 2
nd
 TBS and first recording (15s) post-TBS of both 1
st
 and 2
nd
 TBS (grey 
bars) normalized to 1
st
 baseline, and first recording post-2
nd
 TBS normalized to 2
nd
 baseline (grey 
hatched bars); n.s. – non-significant, 1-sample t-test (1). 
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way repeated measures ANOVA, F(19,152) = 1.28, p=0.203, table S9); comparing individual 
time points, with the fisher test, shows some significant difference at specific time points, 
more in the final 2.5 mins. Examining only the first recording post-TBS (15s), there is no 
difference between evoked 1st and 2nd TBS (p=0.819, paired t-test, n=9). When each 2nd TBS 
is renormalized to the 5 minute baseline preceding it, there is a significant interaction 
between 1st and 2nd TBS fEPSP (2-way repeated measures ANOVA, F(19,152) = 1.74, 
p=0.034, table S10), but only one significant difference when individual points are 
compared (with fisher test), at 15s. At 15s, the fEPSP post-2nd TBS (in dopamine receptor 
blockers) is significantly smaller than the fEPSP post-1st TBS (p=0.001, paired t-test, n=9) 
Comparing PPRs in the same fashion, there is a significant interaction between 1st 
and 2nd TBS-evoked PTP PPRs, when both normalized to the beginning baseline (2-way 
repeated measures ANOVA, F(19,152) = 1.8, p=0.027, table S11) – there are some 
significantly different individual differences (fisher test), but none in the first minute (see 
table S12); at 15s, the 1st and 2nd PPRs are not significantly different (0.668, paired t-test, 
n=9). When the 2nd PPR is normalized to the previous 5 minutes, there is still a significant 
interaction (2-way repeated measures ANOVA, F(19,152) = 1.72, p=0.038, table S6) – there 
are no significant individual differences apart from at 270s post-TBS; at 15s, the PPR is 
significantly different (p=0.026, paired t-test, n=9). 
 
6.3.5 Prolonged recording after post-tetanic potentiation results in fEPSP 
rundown. 
FAC takes 50 minutes incubation to have an effect on glial activity – is it possible to 
record PTP before FAC application and again after FAC incubation? Unfortunately fEPSPs 
exhibit significant rundown after such a long time: fEPSP slopes (figure 6.4a) recorded at 
t=61-65 (56-60 minutes post-TBS) approach a significant decrease to 0.76 ± 0.08 of baseline  
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Figure 6.4 FAC incubation does not affect the size of PTP proportional to 
recent baseline, but rundown is apparent 50 minutes post-TBS in 
both control and FAC conditions. 
a) Prolonged recording post TBS decreases baseline fEPSP slope and increases PPR both in 
control conditions and after incubation with fluoracetate (FAC). Above: time course 
(average per minute) of Stratum Radiatum fEPSP slopes in response to two TBSs (lightning 
bolts), 60 minutes apart; hollow circles – control conditions, red circles – FAC added at t=16, 
orange bar indicates FAC (5mM) application. Below: paired-pulse ratios (PPR) for the above 
fEPSPs. Both time courses normalized to baseline (t=1-5). b) Above: fEPSPs recorded 5 
minutes either side of both TBS at higher time resolution (1 rec / 15s), normalized to the 5 
minutes preceding each TBS respectively; hollow circles – 1st TBS, red circles – 2nd TBS (in 
FAC). Below: PPRs of the above fEPSPs. c) Summary bar charts for fEPSP slopes (left) and 
fEPSP PPRs (right), showing average baseline for 2nd TBS (t=61-65) in control (hollow bar) 
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and FAC incubation (red bar) conditions, and first recording (15s) post-TBS for both 1st (red 
bar) and 2nd (grey bar) TBS normalized to previous 5 minutes; * - p < 0.05, n.s. – non-
significant, 1-sample t-test (1). 
 
(p=0.052, 1-sample t-test, n=4), the PPR values are significantly higher – 1.08 ± 0.01 
– than baseline (p=0.013, 1-sample t-test, n=4). 
 
6.3.6 Relative post-tetanic potentiation before and after fluoroacetate 
incubation is unchanged. 
I go on to FAC to isolate and inhibit astrocytic Krebs’ cycle function – but first I 
checked to see if glial poisoning alone would affect fEPSPs. In control conditions, the 2nd 
baseline period (61-65 mins) has approached a significant decrease in fEPSP slope to 0.76 ± 
0.08 of baseline (p=0.052, 1-sample t-test, n=4) and has a significantly increased PPR to 
1.08 ± 0.01 of baseline (p=0.013, 1-sample t-test, n=4). In slices where fluoroacetate (FAC) 
was added at t=15 mins, the 2nd baseline fEPSP was significantly decreased to 0.7 ± 0.06 of 
baseline (p=0.035, 1-sample t-test, n=3) and PPR was increased to 1.15 ± 0.03 (p=0.041, 1-
sample t-test, n=3). The fEPSP changes were not different between control and FAC 
conditions (p=0.582, 2-sample t-test), although PPR approached a significant increase 
(+0.08) in FAC compared to control conditions (0.062, 1-sample t-test) 
When each 2nd TBS (in FAC) is renormalized to the 5 minute baseline preceding it, 
there is no significant interaction between 1st and 2nd TBS PPR (2-way repeated measures 
ANOVA, F(19,57) = 0.75, p=0.748, table S13), but only one significant difference when 
individual points are compared (with fisher test), at 135s; there is no significant difference 
between the two at 15s (p=0.662, paired t-test, n=4). When the 2nd PPR is normalized to the 
previous 5 minutes, there is still no significant interaction (2-way repeated measures 
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ANOVA, F(19,57) = 0.84, p=0.658, table S14) – there are some significant individual 
differences occurring after 2.5 minutes post-TBS; at 15s, the PPR is not significantly 
different (p=0.721, paired t-test, n=4). 
 
6.3.7 Glial poisoning increases the modulation of baseline by dopamine receptor 
blockers, but does not affect post-tetanic potentiation by dopamine 
receptor blockers.  
Does glial poisoning with FAC change the way in which dopamine receptor blockade 
affects baseline fEPSPs, or reveal an effect on PTP? The average 2nd baseline fEPSP slope, 
after addition of DR antagonists (20μM SCH23390, 50μM Sulpiride) in slices pre-incubated 
in FAC (5mM) (figure 6.5) before the 2nd TBS (t=21-25) is significantly larger than that at the 
experiment start (t=1-5) – its median (it is not normally distributed – p=0.019, Shapiro-Wilk 
test) is 1.18 of the baseline (p=0.035, 1-sample Wilcoxon signed rank test, n=11). This 
average fEPSP slope increase at 2nd baseline is significantly greater than that recorded in 
control conditions (no FAC or DR antagonists – figure 6.3) (p=0.023, Mann-Whitney test) 
but not than that recorded in DR antagonists alone (figure 6.4) (p=0.362, Mann-Whitney 
test). It is important to note that there is a significant interaction between the 1st PTP 
recorded in control conditions and that recorded in FAC pre-incubated slices (2-way 
ANOVA, F(1,19) =38.7, p<0.001), although there is no significant difference between both 
fEPSP slopes at 15s (p=0.24, 2-sample t-test). The average PPR at the 2nd baseline is 
significantly decreased from 1 to 0.9 ± 0.03 of baseline (p=0.007, 1-sample t-test, n=11). 
This is significantly lower than that recorded in control conditions (p=0.009, Mann-Whitney 
test) but not lower than that recorded in antagonists alone (p=0.191, two-sample t-test). 
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Figure 6.5 Pre-incubation with FAC does not interfere with the effect of 
Dopamine blockers on baseline transmission or PTP. 
a) Glial poisoning with FAC does not significantly modify the effect of dopamine receptor blockade in 
stratum radiatum fEPSPs. Above: time course (average per minute) of Stratum Radiatum fEPSP 
slopes in response to two TBSs (lightning bolts), 20 minutes apart; hollow bar indicates SCH23390 
(20μM) and Sulpiride (50μM) application, orange bar indicates presence of FAC (5mM). Below: 
paired-pulse ratios (PPR) for the above fEPSPs. Both time courses normalized to baseline (t=1-5); 
hollow circles – FAC pre-incubation and SCH23390 and Sulpiride added, blue circles – data from 
previous control experiment (figure 6.3a). b) Above: fEPSPs recorded 5 minutes either side of both 
TBS at higher time resolution (1 rec / 15s), normalized to the 5 minutes preceding each TBS 
respectively; hollow circles – 1
st
 TBS, grey circles – 2
nd
 TBS (in SCH23390 and Sulpiride), light grey line 
– 2
nd
 TBS normalized to 1
st
 TBS baseline. Below: PPRs of the above fEPSPs. c) Summary bar charts for 
fEPSP slopes (left) and fEPSP PPRs (right), showing average baseline for 2
nd
 TBS and first recording 
(15s) post-TBS of both 1
st
 and 2
nd
 TBS (grey bars) normalized to 1
st
 baseline, and first recording post-
2
nd
 TBS normalized to 2
nd
 baseline (grey hatched bars); * - p < 0.05, ** - p < 0.01, *** - p < 0.01, n.s. – 
non-significant, 1-sample t-test (1) or wilcoxon signed ranks test – see text. 
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Comparing fEPSP slopes of the 1st and 2nd TBS-evoked PTPs (Figure 6.5), both 
normalized to the baseline taken at the start of the recording (1-5mins), there is no 
significant interaction (2-way repeated measures ANOVA, F(19,171) = 1.25, p=0.227, table 
S15); comparing individual time points, with the Fisher test, shows some significant 
difference at specific time points, more in the final 2.5 mins. Examining only the first 
recording post TBS (15s), there is no difference between evoked 1st and 2nd TBS (p=0.272, 
paired t-test, n=11). When each 2nd TBS is renormalized to the 5 minute baseline preceding 
it, there is no significant interaction between 1st and 2nd TBS PPR (2-way repeated measures 
ANOVA, F(19,171) = 1.3, p=0.187, table S16), but only one significant difference when 
individual points are compared (with fisher test), at 255s. At 15s the normalized fEPSP 
slopes are not significantly different (p=0.079, paired t-test, n=11). Comparing PPRs in the 
same fashion, there is no significant interaction between 1st and 2nd TBS-evoked PTP PPRs, 
when both normalized to the beginning baseline (2-way repeated measures ANOVA, 
F(19,171) = 1.26, p=0.219, table S17) – there are some significantly different individual 
differences (fisher test), but none in the first minute; at 15s, the 1st and 2nd PPRs are not 
significantly different (0.833, Kolmogorov-smirnov). When the 2nd PPR is normalized to the 
previous 5 minutes, there is still no significant interaction (2-way repeated measures 
ANOVA, F(19,171) = 1.24, p=0.228, table S18) – there are no significant individual 
differences; at 15s, the PPR is not significantly different (p=0.075, Kolmogorov-smirnov). 
 
6.3.8 Blockade of putative tonic dopaminergic activity does not affect astrocyte-
derived-d-serine-modulated NMDAR-mediated fEPSPs. 
Bath application of SCH23390 (20μM) whilst recording NMDAR-mediated fEPSPs (in 
presence of low Mg2+ (0.1mM), NBQX (100μM) and picrotoxin (50μM)) had no significant 
effect on NMDAR-mediated fEPSP slopes (p=0.528, 1-sample t-test, n=5) – see figure 6.6. 
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Figure 6.6 Blockade of D1-type receptors does not affect NMDAR-mediated 
currents in the stratum radiatum. 
NMDAR-mediated fEPSPs normalized to baseline (t=1-10), recorded from stratum oriens in low 
(0.1mM) Mg
2+
,10μM NBQX and 50μM picrotoxin; SCH23390 (20μM) added at t=11 mins (hollow 
bar). 
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6.4 Discussion 
6.4.1 I find no evidence to suggest that astrocytes play role in dopaminergic 
modulation of baseline synaptic transmission in stratum radiatum.  
Investigation of different types of baseline synaptic activity that could be 
dopamine-modulated has revealed a possible role for astrocytes in baseline transmission 
(figure 6.1) but not in NMDAR-mediated currents (figure 6.6). Bath application of 20μM 
dopamine has a small but highly significant inhibitory effect on baseline, primarily AMPAR-
mediated, currents at the Schaffer collateral synapse (Otmakhova and Lisman 1999). 
Consistent with the lack of an astrocyte component in this dopaminergic inhibition in the 
stratum lacunosum-moleculare (Chapter 5), astrocyte metabolic poisoning does not affect 
the inhibition of fEPSP slopes in CA1 (figure 6.1). This reliably repeats Otmakhova and 
Lisman’s result (1999): although I see no significant change in PPR, their reported increase 
may be due to a constantly rising PPR, as it is not washed out with dopamine, whereas my 
PPR values are still at baseline after dopamine washout. 
 
6.4.2 What role does dopamine play in PTP? 
Given the lack of astrocytic interaction with dopamine at basal activity levels, I next 
investigated their involvement in synaptic potentiation. Surprisingly, studies of 
dopaminergic modulation of post-tetanic potentiation (PTP) are scarce, only Young and 
Yang (2005) in the cortex and the possibility of a dopaminergic involvement in the PTP 
deficit in a mouse model of Rett syndrome – given that dopamine tonus is increased in 
these mice (Weng et al. 2011). This is the first investigation I am aware of into 
dopaminergic modulation of PTP at the CA1 synapse. PTP in the hippocampus is very well 
studied (Zucker and Regehr 2002) and my PTP phenomenon is at the longer lasting end of 
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potentiation that qualifies as ‘PTP’ and not ‘STP’ (short-term potentiation) – a phenomenon 
defined by the stimulation of protein production. Given this, I will discuss two facets of the 
PTP described here: early PTP (ePTP) (<30s) that will contain a fast acting, presynaptic 
component – controlled by calcium concentration-dependent release probability increase 
at the presynaptic bouton (Zucker and Regehr 2002) – and late PTP (lPTP) that I postulate is 
primarily post-synaptic. Evidence for the validity of this classification comes from the faster 
return to baseline of the PPR than of the fEPSP slope (figure 6.3), indicating a proportion of 
the potentiation is not reliant on increased release probability. It is likely that there is also a 
post-synaptic component to the ePTP as a post-TBS increase in the 2nd fEPSP slope is visible 
(see example in figure 6.3a). After 20 minutes the fEPSP slope has returned to baseline and 
a second TBS can be given, which displays identical characteristics. This experimental 
protocol controls for variability in slice quality, animal differences and stimulation and 
recording electrode placement, making it sensitive to slight changes caused by 
pharmacological interrogation. Blockade of D1/2Rs has two effects: firstly, it decreases the 
baseline paired-pulse ratio, and secondly it partially occludes ePTP (when normalized to the 
new baseline. I will discuss each of these phenomena in turn.  
 
6.4.2.1 Putative dopaminergic modulation of baseline transmission 
Although dopamine receptor blockade alone significantly decreases only PPR 
(figure 6.3) from control, when dopamine receptors are blocked after FAC incubation both 
baseline fEPSP slope and PPR are significantly different from baseline. Hence it is possible 
that FAC enhances a pre-existing action of dopamine receptor blockers – an idea supported 
by the fact that the direction of the effect is the same for both manipulations and additive 
(increasing fEPSP slope and decreasing PPR) – see figure 6.5c.  
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If this is the case, then could the non-significant increase in baseline fEPSP under 
dopamine receptor blockade be indicative of a real effect? Such an increase in baseline 
could potentially be due to either blockade of tonic dopaminergic inhibition in stratum 
radiatum, or could possibly be an effect of dopaminergic blockade on the decaying tail of 
the 1st PTP. To answer the latter first – there is little evidence to suggest that increasing the 
decay rate of potentiation is a function of tonic dopamine in the hippocampus (although 
there is in Aplysia (Newlin et al. 1980)) ; given that many studies have reported that 
dopamine enhances hippocampal lLTP (Frey et al. 1990; Swanson-Park et al. 1999) and 
inhibits low frequency stimulation induced depotentiation (Otmakhova and Lisman 1998), 
one would in fact expect the opposite. One group has, however, demonstrated a direct 
depotentiating effect of phasically released dopamine (Kwon et al. 2008) after LTP 
induction, if this effect could be caused by tonic dopamine, or by dopamine release from 
the 1st TBS, this could provide a potential mechanism – although their phenomenon is D4R 
mediated and my blockade of D1/2-type receptors should leave D4Rs unblocked (although 
the concentrations of antagonist are high – potentially high enough to block all dopamine 
receptors). High-frequency stimulation has been shown to trigger dopamine release in the 
hippocampus (Frey et al. 1990), so it is possible that the 1st TBS triggers a dopamine release 
that depotentiates the induced PTP, although the stimulus I used is far weaker than that 
used by Frey et al. and the time between any putative dopamine release and the start of 
dopamine receptor blockade is long (~15 minutes) – probably long enough for full 
dopamine clearance from the extracellular space. This, coupled with the apparent dip 
towards baseline at t=18-19 (figure 6.4a) and subsequent rise at t=21-23 (if depotentiation 
were being inhibited, one would expect a constant decay as seen in figure 6.3), makes a 
direct effect of D1/2-type receptor blockade on baseline transmission more plausible. 
Regarding tonic dopaminergic inhibition of baseline, addition of D1-type receptors 
blockers alone has not been reported to increase baseline transmission (Frey et al. 1991; 
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Huang and Kandel 1995), but there is no report yet of a disinhibitory effect of combined 
D1/2-type receptor blockade on baseline transmission in CA1. Such a result is consistent 
with studies that report an inhibitory effect of dopamine application on Schaffer collateral 
synapses (Hsu 1996; Otmakhova and Lisman 1999); these studies have both found evidence 
for a presynaptic locus – as I have with the PPR decrease upon D1/2-type receptor 
blockade. Hsu (1996) reports D2R-mediated inhibition of presynaptic transmitter release 
(although D2R mediated increase in CA1 pyramidal firing rate was previously reported 
(Smialowski and Bijak 1987), such a presynaptic D2 receptor, tonically activated, could 
explain the antagonist-induced transmission potentiation. In PFC, D2R activation triggers 
GABA-mediated EPSP inhibition in deep layer pyramidal neurons from superficial but not 
deep layer stimulation – raising the possibility of layer specific effects of D2R activation on 
inhibition (Tseng and O'Donnell 2007); alleviating such inhibition through D2 blockade 
could contribute to baseline potentiation witnessed. However this D2R could also be 
astrocytic – D2R activation could trigger release of presynaptically inhibitory 
gliotransmitter, such as adenosine (Halassa et al. 2009) or ATP (Panatier et al. 2011).  
The ideal and simple experiment to test whether simultaneous D1/2-type receptor 
blockade can potentiate baseline synaptic transmission is to add D1/2R antagonists to the 
slice whilst recording fEPSPs at baseline, without giving any kind of TBS. 
 
6.4.2.2 Increased early PTP  
When renormalized to the observed baseline increase, D1/2-type receptor 
blockade attenuates the slope increase and PPR decrease seen on the first recording post-
TBS, an effect which then slips away. This is a clear effect on the relative presynaptic ePTP 
(figure 6.3). This result has two interpretations: the first is that tonic dopaminergic 
inhibition of presynaptic release is transiently overcome by TBS-induced ePTP, acting 
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through the same presynaptic pathways – alleviation of this tonic inhibition through DR 
blockade decreases the relative possible TBS-induced ePTP increase; the second is that TBS-
induced dopamine release transiently potentiates presynaptic release, a potentiation 
blocked by DR antagonism. 
There is some evidence for both possible mechanisms in the literature – both Frey 
et al. (1991) and Huang and Kandel (1996) see a decrease in mean fEPSP response at 1 
minute post LTP induction during D1/5R blockade compared to control (although this does 
not reach significance); given their greater stimulus strength (100 stimuli at 100Hz), it is 
plausible that more dopamine would be released and any presynaptic excitatory effect of 
released dopamine would last longer than the 15-30s observed in this chapter. The work of 
Hsu (1996), however, would support a relative occlusion of ePTP by blockade of tonic D2R 
activation. 
What is striking is the lack of effect on relative PTP that dopamine receptor blockers have. 
Given the importance of dopamine in the hippocampus for synaptic plasticity and 
behaviour (Li et al. 2003), and its reported role in PTP in the PFC (Young and Yang 2005), 
one might have expected some effect of dopamine blockade on hippocampal PTP, but this 
highly sensitive double TBS protocol uncovers very little difference made by DR antagonism. 
This result is consistent with the bulk of the literature in suggesting the dopamine is 
important for the later stages of LTP, possibly via translation and transcription through ERK 
signalling (Kaphzan et al. 2006; Sarantis et al. 2009). 
 
6.4.3 What role do astrocytes play in PTP? 
Given that FAC takes 50 minutes to affect astrocytes (Henneberger et al. 2010), this 
protocol required a 60 minute interval from the 1st to the 2nd TBS to measure the effect of 
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astrocyte poisoning at the same set of synapses. This had the unexpected effect of 
decreasing fEPSP slopes and increasing PPR at baseline stimulation rate. This could 
constitute synaptic rundown, always a potential hazard in slice recordings, or it could be 
due to the 1st PTP – it is possible that this short term potentiating stimulus could cause LTD, 
via a decrease in presynaptic release probability, and it would be interesting to 
pharmacologically probe this phenomenon further. However it is clear, comparing control 
and FAC traces, that the ability of TBS to induce relative PTP is unchanged without 
astrocytes (figure 6.5). Healthy astrocyte K+ uptake decreases the magnitude of PTP in 
control conditions (Sibille et al. 2014), so one might expect a PTP increase after FAC 
incubation – which I do not see – but the exact effect of FAC on K+ transport is still 
unknown. 
 
6.4.4 Could compromising astrocyte function have changed the dopamine-
receptor-mediated effects on post-tetanic-potentiation? 
The putative additive effect of glial poisoning on DAR blockade-induced baseline 
fEPSP increase and PPR decrease, this would suggest either that tonic dopaminergic 
stimulation of astrocytes causes an astrocytic release of presynaptically active inhibitory 
gliotransmitter – adenosine for example (Florian et al. 2011). Another possibility is that FAC 
incubation itself changes the post-TBS return to baseline synaptic transmission in the slice. 
Given there is a significant interaction between the control 1st PTP and the pre-incubated 
FAC and DAR antagonist 1st PTP, this may indicate the latter (although the 1st fEPSP 
amplitude post TBS, at 15s, was not significantly different between the two) – if this is the 
case, then although the effects of DAR blockade and FAC incubation are both similar, they 
may be independent i.e. astrocytes are not affected by tonic dopamine.  
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If astrocytes were modulating baseline activity through tonic dopamine activation, 
such a change would be consistent with astrocytes having a moderating effect on the 
dopaminergic inhibition of Schaffer collateral synapses at baseline – consistent with the 
moderating effect they were found to have post-PTP in SLM (chapter 5). More recordings 
would have to be made to be confident of such a delicate effect.  
As commented on in Chapter 5, section 5.4.4, FAC is not a complete inhibitor of 
astrocytic function (although in this chapter it is assumed to inhibit the astrocytic calcium 
response to dopamine). FAC inhibits aerobic respiration (through creation of fluorocitrate 
and the inhibition of aconitase) – but there is no data to show whether astrocytes could still 
respond with normal calcium signals whilst respiring solely anaerobically. 
 
6.4.5 NMDAR-mediated currents are not regulated by tonic D1/5R activation. 
D1 receptor activation has been strongly linked to NMDAR activity, having been 
reported to both increase and decrease NMDAR-mediated currents (Chetkovich and Sweatt 
1993; Castro et al. 1999; Seamans et al. 2001; Lee et al. 2002; Chen et al. 2004; Pei et al. 
2004) , modulate ERK signalling (Kaphzan et al. 2006; Sarantis et al. 2009), control NMDAR-
mediated LTP (Stramiello and Wagner 2008; Roggenhofer et al. 2013)  and  NMDAR-
mediated behaviour (Li et al. 2003; Roggenhofer et al. 2010; Xing et al. 2010; Zarrindast et 
al. 2012). Given dopaminergic calcium increases in astrocytes are D1-mediated (Chapter 3, 
4) and the astrocytic control of NMDAR responses via D-serine release (Panatier et al. 2006; 
Oliet and Mothet 2009; Fossat et al. 2012) is mediated by astrocytic calcium (Henneberger 
et al. 2010) and similarly that D1R blockade blocks Ca2+ dependent processes in neurons 
(Chen et al. 2007) – I tested whether baseline NMDAR-mediated transmission was sensitive 
to D1-blockade. The lack of a significant effect of SCH23390 on NMDAR-mediated fEPSPs 
suggests that any astrocytic activation by tonic dopamine release in the hippocampal slice 
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does not control tonic release of D-serine (consistent with the data from chapter 4) or 
activate D1R/NMDAR interaction on neurons. Recently, it has been reported that D4Rs 
modulate NMDAR-mediated currents during LTP induction in stratum oriens (Herwerth et 
al. 2012) – where the above data is recorded –a repeat of this experiment with D4R 
blockade would be an interesting further investigation. 
 
6.5 Conclusion 
As has been previously shown, direct application of dopamine can inhibit Schaffer 
collateral synapses. However, this is the first time it has been reported that blockade of 
tonic dopamine in the hippocampal slice can potentiate baseline synaptic transmission at 
the Schaffer collaterals. Similarly this is the first study to show that dopamine receptor 
blockade can interfere with the early phase of PTP in the hippocampal slice, although the 
later phase is unaffected. It is clear, however, that none of these dopaminergic phenomena 
are mediated by astrocytes. 
When this chapter is taken into account with the previous chapter, apart from the 
small role of astrocytes in PTP-modulation at the pp-SLM synapse, the data indicate no role 
for astrocytes in the dopaminergic modulation of synaptic transmission in CA1 of the 
hippocampus. This suggests that the robust dopamine induced Ca2+ changes in astrocytes 
are not obviously linked to synaptic activity – although whether they have any physiological 
function is still unsure.  
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Chapter 7: Results 5. 
 Viral delivery of a channelrhodopsin transgene to dopaminergic 
hippocampal afferents the does not work if under the control of a CaMKII promoter. 
 
7.1 Introduction 
Dopaminergic projections from the ventral tegmental area (VTA) innervate the 
hippocampus in rat (Swanson 1982; Gasbarri et al. 1994a; Gasbarri et al. 1994b) and in 
mouse (Herwerth et al. 2012) in the Stratum Oriens and Stratum Lacunosum-Moleculare. 
Although bath application of dopamine has been shown to affect hippocampal slice activity 
(Frey et al. 1990; Huang and Kandel 1995; Otmakhova and Lisman 1999), we can only be 
sure of the physiological relevance of dopamine action in vivo (Li et al. 2003) because only 
here is dopamine released from dopaminergic terminals at a physiological level. Although it 
is possible to release dopamine by LTP-inducing electrical stimuli (Frey et al. 1989), it is not 
possible to do so without this extremely powerful stimulus.  
Over the last ten years, optogenetic control of neuronal activity has become the 
most versatile and powerful tool to selectively control specific populations of cells (Fenno 
et al. 2011). Channelrhodopsins are light-sensitive proteins that, upon activation, create an 
ion-permeable pore in the plasma membrane. CaMKII has been reported to be expressed in 
the dopaminergic neurons of the VTA (Fog et al. 2006; Padmanabhan and Prasad 2009) as 
well as in most principal neurons of the brain (Griffith 2004; Wayman et al. 2011). In order 
to selectively control dopaminergic projections to the hippocampus, I injected the VTA with 
a viral vector that would express excitatory channelrhodopsin under the CaMKII promoter: 
transport of the channelrhodopsin protein throughout the axonal arborisation of 
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dopaminergic cells should allow release of dopamine in a physiological manner upon 
stimulation with light. 
 
7.2 Methods 
50-60g juvenile male Sprague-Dawley rats were anaesthetised with a mixture of 
ketamine (60 mg/kg) and medetomidine (250 mg/kg) intra-muscular. Additional 
anaesthesia was administered depending on the duration of the surgery. The head was 
shaved and cleaned with chlorohexidine. The head was positioned in a stereotaxic frame 
and protective ophthalmic gel was applied. A midline incision was made and the skull was 
cleaned and dried. A small craniotomy was performed within the right parietal bone. The 
surface of the brain was flushed with aCSF to remove any blood products. The virus 
(AAVsCaMKII-ChR2(H134R)-Venus YFP suspended in filtered saline (1:10) was injected into 
two sites in the Ventral Tegmental Area (VTA) (2μl per injection). The skin was sutured. 
Buprenorphonine was administered (0.05 mg/kg s.c.) and the anaesthesia was reversed 
with atipemazole (1mg/kg i.m.). Post-operative care was given. The animals were allowed 
to recover for 14/21 days to allow transgene expression. For immunocytochemistry, rats 
were terminally anesthatised (urethane, 1.5 g/kg i.p.) and intracardially perfused with 
saline followed by ice cold 4% paraformaldehyde. The brains were removed and post-fixed 
overnight at 4°C. The brains were soaked sucrose (30%, 4°C) for a further 24 hours. The 
brains were sliced into 60μm thick sections and serially mounted. Mounting medium 
containing dapi (Vectashield) was applied and the coverslips secured. For 
immunohistochemical identification of dopaminergic neurons and axons, tissue was 
incubated in sheep anti-Tyrosine Hydroxylase antibody (1:250, Abcam) overnight at 4°C, 
then again in secondary donkey anti-sheep Alexa 568 (1:500, Molecular probes). 
Fluorescence of YFP and Alexa 568 were imaged on a Zeiss AX10 bright-field microscope. 
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Figure 7.1 Principle cells of the Ventral Tegmental Area that express the ChR2-
CamKII virus are not from the dopaminergic cell population. 
a) ChR2-YFP protein expression in VTA cells (green), small vertical white arrows indicate principle cell 
somata. Above: animal sacrificed 2 weeks post-injection. Below: 3 weeks post-injection. b) anti-
tyrosine-hydroxylase reactivity (red) in the same area of tissue, large horizontal white arrows 
indicate principle cell somata. Layout as in a). c) red and green images merged to show no overlap in 
fluorescence (yellow). Layout: as in a). d) DAPI staining shows cell nuclei – DAPI staining is weak, but 
present in principle cells indicated in a) – c). 
 
 
7.3 Results 
7.3.1 Principle cells of the Ventral-Tegmental Area can express ChR2-YFP under 
the CaMKII promotor, but these are not the dopaminergic cells. 
In PFA-fixed midbrain slices, large cell bodies are visible at ~535nm light wavelength 
in the animal sacrificed at 2 weeks and that at 3 weeks (figure 7.1a). Staining with 
antibodies for tyrosine hydroxylase (TH) reveals large numbers of dopaminergic neurons in 
the same imaging field as the YFP –positive cells (figure 7.1b), but no cells are positive for 
both TH and YFP (figure 7.1c). DAPI staining shows weak but positive staining for nuclear 
material in all YFP and TH-labelled cells  (figure 7.1d. 
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Figure 7.2 Both dopaminergic and ChR2-CamKII expressing axons from VTA 
innervate Stratum Lacunosum-Moleculare of the hippocampus but 
dopaminergic axons do not express ChR2-CamKII. 
a) ChR2-YFP protein expression in axons in Stratum Lacunosum-Moleculare of the hippocampus 
(green), small vertical white arrows indicate axons. Left: animal sacrificed 2 weeks post-injection. 
Right: 3 weeks post-injection. b) anti-tyrosine-hydroxylase reactivity (red) in the same area of tissue, 
thin, horizontal white arrows indicate axons;,thick, vertical white arrows indicate groups of 
fluorescent puncta. Layout as in a). c) red and green images merged to show no overlap in 
fluorescence (yellow). Layout: as in a). 
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7.3.2 Both cell types project from VTA to hippocampus, but the populations do 
not overlap.  
In hippocampal slices taken from the same animals, thin YFP-positive structures, 
identified as axons based on their sparse distribution and characteristic morphology, 
innervate stratum Lacunosum-Moleculare (figure 7.2a). Similarly axonal structures and 
large amounts of punctate staining (putative axonal terminals) are TH-positive in the same 
regions of the hippocampus (figure 7.2b). However, as with the neuronal cell bodies, there 
is no overlap in the fluorescence (figure 7.2c) 
 
7.4 Discussion 
 7.4.1 Which neurons were transfected?  
The expression of channelrhodopsin in cell bodies in the VTA (identified by the 
presence and characteristic distribution of TH positive cells and baso-medial location) of 
both animals, none of which co-express tyrosine hydroxylase, is strong evidence to suggest 
that this specific CaMKII promotor AAV vector does not transfect dopaminergic neurons. 
The VTA contains both GABAergic (Bonci and Malenka 1999; Koyama et al. 2005; Cohen et 
al. 2012; Tolu et al. 2013) and glutamatergic (Yamaguchi et al. 2007; Yamaguchi et al. 2011). 
GABAergic neurons in rat striatum and cortex do not express CaMKII (Benson et al. 1992; 
Jones et al. 1994; Liu and Jones 1996; Wang et al. 2013b), but those in rat cerebellum 
(Borodinsky et al. 2003) and nucleus accumbens (Liu et al. 2009c; Avalos-Fuentes et al. 
2013) can – so it is unsure whether these could be GABAergic cells transduced. VTA 
glutamatergic cells express CaMKII throughout the brain, so these form a likely potential 
target for viral infection. 
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Given that there is clear innervation of the hippocampus by axons transfected with 
ChR2, then the transfected VTA cell types must be those that project to the hippocampus. 
There is no evidence to suggest a GABAergic projection to the hippocampus in the 
literature; there is evidence for both dopaminergic (Gasbarri et al. 1994a) and 
glutamatergic (Yamaguchi et al. 2011) innervation of the hippocampus from VTA. This is 
consistent with the results from this chapter – I have found TH-positive axonal innervation 
of the hippocampus, which could correspond to dopaminergic innervation from the VTA (or 
noradrenaline from the locus coeruleus, which also sends many projections to the 
hippocampus (Swanson et al. 1987), and non-TH-positive axons in very close proximity, 
suggesting they belong to the same fibre tract. I suggest that the results show ChR2 
transfection of glutamatergic cells of the VTA, not dopaminergic cells, and their projections 
to the hippocampus. Although I did not test whether these projections could be 
functionally activated by light, this result shows that, in principle, it is possible to specifically 
transfect VTA inputs – up to and including the axonal terminals – to the hippocampus with 
channelrhodopsin.  
 
 7.4.2 Why were no dopaminergic neurons transfected? 
It is possible to transduce dopaminergic neurons with adeno-associated viruses 
(AAV) such as used here (Oh et al. 2009; Bass et al. 2013), similarly CamKII can be used as a 
promotor for transgenic expression of channelrhodopsins (Land et al. 2014). So why did I 
observe no transfected dopaminergic cells? One possibility is that dopaminergic cells were 
transfected, but died before the animals’ brains were sliced: the viral injection may be 
slightly cytotoxic, either through the immune response (Martino et al. 2011) or through 
protein overexpression in the infected cells. Dopaminergic cells are more vulnerable to 
cytotoxic stimuli than the surrounding cell types (Gonzalez-Hernandez et al. 2010) – hence 
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they may not have survived while the glutamatergic cells did. Another possibility, given that 
Oh et al. (2009) use AAVs to transfect dopaminergic neurons, is that the CaMKIIα promoter, 
the specific CaMKII subtype in this virus, is not in fact suited to transfecting dopaminergic 
neurons. Although there is evidence from cultured dopaminergic neurons to support 
CaMKIIα expression (Fog et al. 2006), other studies have found expression of other CaMKII 
subtypes, but not CaMKIIα (Kamata et al. 2006). Expression of CaMKIIα in dopaminergic 
brainstem nuclei regions as a whole is high (Erondu and Kennedy 1985; Ochiishi et al. 1998), 
consistent with the strong expression that I have seen, but my results suggest that either 
the particular vector I was using was ineffectual or that dopaminergic neurons are not 
amenable to transfection. 
Had the transfection worked, it would still have been non-specific: any light flash to 
a slice with transfected VTA afferents would have stimulated both glutamate and dopamine 
release. Recently, a transgenic, tyrosine hydroxylase::Cre rat has been created in which 
transgenes can be expressed selectively and reliably in dopaminergic neurons (Witten et al. 
2011) and has already been used to study learning (Steinberg et al. 2013) and depression 
(Chaudhury et al. 2013; Tye et al. 2013). Were I to try this experimental method again, I 
would choose this elegant system or, if possible, the TH-promotor AAV system (Oh et al. 
2009) to transfect dopaminergic neurons. 
 
7.5 Conclusion 
Hippocampal afferents from the ventral tegmental area can be specifically 
transfected by midbrain viral injection – but these projections were not dopaminergic. 
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Chapter 8: General Discussion 
 
In this final chapter I will discuss the overall findings from this thesis, the questions 
yet unanswered and possible ways to tackle them. I will then consider some 
methodological issues and discuss the physiological relevance of the effects of dopamine on 
astrocytes and other possible areas of astrocyte-dopamine interaction. 
 
8.1 Dopamine triggers astrocyte calcium increases  
 The first, most consistent and least controversial observation made in this thesis is 
that dopamine can stimulate increased astrocyte calcium (Ca2+) activity in situ (chapters 3, 
4, 5), in agreement with the culture literature also describing such an increase (Parpura and 
Haydon 2000; Liu et al. 2009a; Vaarmann et al. 2010; Requardt et al. 2012). In probing the 
mechanisms of this Ca2+ increase, it becomes apparent how varied the potential routes of 
dopamine action on astrocytes are – a problem I believe underlies much of the dopamine 
literature in neurons as well. I have provided evidence for D1-type receptor, D2-type 
receptor and IP3 receptor control of dopamine-induced astrocytic Ca
2+ increase, as well is 
modulation through monoamine oxidase and purinergic receptor activity. One explanation 
is activation of an astrocytic D1-D2 heteromer (figure 8.1), a receptor type that is known to 
exist on neurons (Hasbi et al. 2011), that exerts its effects through PLC activation and IP3 
release. The best test for this hypothesis would be to image astrocyte Ca2+ upon challenge 
with SKF83959, the specific D1-D2 heterooligomer agonist used by the group championing 
this research (Hasbi et al. 2009), with a large Ca2+ increase (and no decrease) predicted.  
How do my results compare to the literature? The most reliable of the myriad 
results reported in cultures is that stimulation of astrocytes with dopamine itself produces  
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Figure 8.1 Possible dopaminergic signalling pathways in astrocytes 
Heteromeric dopamine receptors activate PLC which produces IP3 and facilitates release of Ca
2+ 
from 
intracellular stores; DA breakdown by monoamine oxidase amplifies the PLC response through lipid 
peroxidation; activation of the D2-type receptor can decrease resting calcium levels, possibly 
through voltage-gated calcium channel or TRPA1 channel inhibition. 
 
 
overall cytosolic Ca2+ concentration increase. Unfortunately, the pharmacology reported 
here is inconclusive, although a potential unifying mechanism based on my results is 
described in figure 8.1. The unusual sensitivity of the dopaminergic increase to both D1 and 
D2-type receptor blockers (chapter 4) has not been reported in the previous culture 
studies. It is possible that culture conditions known to change expression profiles of 
another monoamine receptor, the 5-HT receptor (Kimelberg et al. 1997), could be having 
similar, unique, actions on astrocytes cultured in different labs. An interesting result 
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reported here that could shed light on this culture/slice difference, was the striking 
response difference between astrocytes of the SR and the SLM. Not only is the functional 
relevance of this worth investigating, but if such differences are visible between two very 
similar populations of astrocytes, the massive differences seen in culture studies could be 
explained by slight differences in astrocyte harvesting or culturing technique.  
An interesting result in the light of recent reports is the inhibitory effect of MAOb 
blockade on the dopamine-induced Ca2+ increase, as reported first by Vaarmann et al. 
(2010). This, coupled to reports of astrocytic D1-mediated control of NAD+/NADH ratio 
(Requardt et al. 2012), is compatible with an important role for reactive oxygen species 
(ROS) in the amplification of intracellular Ca2+ signals. Lipid peroxidation activates PLC and 
triggers intracellular IP3 increase, a previously reported route of ROS-mediated astrocytic 
Ca2+ increase (Vaarmann et al. 2010) that is consistent with selegline sensitivity and 
possible 2-APB sensitivity of the dopamine-induced astrocye Ca2+ increase reported here 
(chapter 3). But another, as yet unexplored mechanism of ROS induced Ca2+ signalling in 
astrocytes, is through TRP channel activation. TRPA1 (Shigetomi et al. 2011) and TRPV4 
(Dunn et al. 2013) activation has been shown to mediated astrocyte calcium increase, and 
TRP channels are sensitive to oxidative stress (Naziroglu 2012). As a further experiment, 
imaging astrocyte Ca2+ and selective blockade of either of these TRP channel types during 
dopaminergic stimulation could reveal a new, ROS-mediated form of astrocyte calcium 
signalling. 
 
8.2 Dopamine triggers astrocyte calcium decreases 
 The second major finding, one that I believe is the most interesting and most 
worthy of further investigation, is that dopamine can reliably induce decreases in astrocytic 
cytosolic Ca2+ concentration. There has been only one other report in the literature of a 
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pharmacologically tractable astrocyte Ca2+ decrease (Shigetomi et al. 2011) and no report of 
a dopamine-mediated Ca2+ decrease – the question is: what is the function of this Ca2+ 
drop? A tantalizing prospect comes from the methods of this thesis: the Ca2+-clamp 
protocol (chapters 2, 6) was found to block specifically dopamine-induced Ca2+ decreases, 
but not increases. I found no effect of the clamp on dopaminergic inhibition of SLM 
synapses, but the clamp is capable of inhibiting both LTP (Henneberger et al. 2010) and LTD 
(Min and Nevian 2012). Given dopamine’s well publicised involvement in LTP induction and 
maintenance in the hippocampus (Frey et al. 1990; Li et al. 2003), it is exciting to speculate 
that clamp of a dopamine-induced Ca2+ decrease (dopamine released from the LTP-inducing 
HFS) that appears concomitantly with the observed HFS-induced Ca2+ increase could play a 
part in the Ca2+-mediated inhibition of LTP. TRPA1 blockade decreases astrocyte basal 
calcium levels and HFS-induced LTP in CA1 of the hippocampus (Shigetomi et al. 2013); I 
have shown that blockade of D1/5 receptors also decreases basal calcium – in the presence 
of dopamine (chapter 4) – could this be an explanation for the inhibitory effects of D1/5 
receptor blockade on LTP induction (Frey et al. 1991)? If so, one might expect selective 
inhibition of the astrocytic dopamine-induced Ca2+ decrease, but not the Ca2+ increase, seen 
upon Ca2+-clamp, to paradoxically preserve LTP in the presence of simultaneous dopamine 
and Ca2+-clamp. That said, the multiple possible forms of calcium signalling in astrocytes 
(spatially and temporally – Rusakov et al. 2014) may indicate that simply raising global Ca2+ 
(as dopamine has been shown to do) does not activate the correct Ca2+-sensitive astrocytic 
machinery, as in the case of Fiacco et al. (2007). This could be easily tested by attempting to 
rescue LTP induction during Ca2+-clamp with dopamine application. Apomorphine has 
recently been shown to inhibit TRPA1 channels in high concentrations (Schulze et al. 2013), 
hence another prediction would be that apomorphine dose dependently inhibits 
hippocampal LTP through decrease of astrocyte basal calcium levels – a theory that would 
be relatively simple to test. 
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8.3 Dopamine, astrocytes and LTP. 
 In the hippocampus, dopamine is most often linked to LTP induction and 
maintenance (Frey et al. 1991; Matthies et al. 1997; Li et al. 2003). Similarly, astrocytes 
have been convincingly shown to mediate LTP induction (Henneberger et al. 2010). 
Therefore it is my lasting regret that I have not managed to test for a possible interaction 
between the two in this process. To do so one would have to be able to manipulate 
dopaminergic signalling in astrocytes without interfering with the internal Ca2+ state that 
allows them to gate LTP. The most elegant solution would be astrocyte-specific knockout 
(or viral knockdown) of either D1 or D2 receptors. This would block the dopamine induced 
Ca2+ increase, but leave the decrease intact in a D2-KO sensitive fashion – dopaminergic LTP 
modulation could then be probed between control and knockout animals. Such animals 
could also be used to probe known dopamine-sensitive behaviours. Failing these, 
admittedly fancy, techniques, one could replace the astrocytically-derived d-serine (release 
of which allows LTP induction) with bath applied d-serine, clamp astrocytic Ca2+ (or use FAC) 
and probe LTP-induction between healthy astrocyte and clamped/poisoned astrocyte slices. 
There are some potential problems with this approach: the correct concentration of D-
serine to add to the perfusion solution to provide adequate NMDAR co-agonism without 
complete saturation (and hence overstimulation) of the receptor is not known; it may also 
be the case that an astrocytic role in dopaminergic modulation of LTP works through 
modulation of d-serine release.  
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8.4 Tonic dopamine action in the hippocampus 
An intriguing, unexpected result of chapter 6 is the astrocyte-modulated inhibition 
of baseline synaptic transmission. This result has not been previously documented in the 
literature, although potential mechanisms for it have (Hsu 1996; Otmakhova and Lisman 
1999). One possible reason for this information blackspot could be that an increase requires 
dual blockade of both D1/5 and D2/3 receptors; if true, the culprit could be a dopamine 
receptor heteroligomer – although these receptors have yet to be described and 
characterized in the hippocampus. Two simple experiments could shed light on the DR-
blockade induced baseline release probability increase: addition of SCH23390 and sulpiride 
without prior TBS, to ensure no complicating interaction and addition of SKF83959 to 
baseline Schaffer collateral responses to witness an increase in fEPSP slope. I saw no clear 
effect of blockade of tonic dopaminergic signalling on astrocyte calcium activity (See 
chapters 3 and 4), although a may have had I used a calcium indicator more sensitive in the 
resting calcium range (e.g. OGB-1). If astrocytes are involved in tonic dopaminergic 
modulation of synaptic transmission, one would expect some sort of intracellular signalling 
linking sensation of dopamine to release of inhibitory gliotransmitter. It is possible that this 
is not Ca2+ or that it works through a different intracellular signalling cascade (e.g. cAMP 
signalling). I would also be interested to see the effect of simultaneous application of both 
DR blockers on NMDAR-mediated currents – any effect could indicate a role for astrocytes 
in baseline NMDAR modulation through dopamine. 
 
8.5 Imaging astrocytic Ca2+ signals. 
This thesis makes use of two popular Ca2+-imaging techniques: bulk AM-dye loading 
and cell-impermeable dye loading through a patch-pipette: I will now briefly discuss the 
merits and drawbacks of each technique. AM-dyes have many advantages: they have a 
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simple loading protocol (see chapter 2); the technique is high-throughput – multiple cells 
can be imaged at a time and viable cells can be identified quickly. Perhaps the greatest 
advantage of bulk-loading is that cells can be imaged with no physical interference – 
although this is a weakness in another sense: it offers no specific control over the 
intracellular milieu (unlike whole-cell patch-clamp). There are, however some serious 
drawbacks: the signal to noise ratio drastically decreases as AM-dyes load non-specifically: 
astrocytes, neurons and other glial cells will take up the dye. This necessitates addition of 
astrocyte-specific markers to ensure data is gathered from the correct cell population. Such 
cell type-specific staining can be achieved with genetically encoded fluorescent proteins 
under the control of astrocyte-specific promoters (e.g. GFAP, S100β), fluorescent dyes that 
label astrocytes specifically (Nimmerjahn et al. 2004) or with post-hoc 
immuncytochemsitry. The necessity of labelling cells is problematic – genetic labelling can 
only be done in certain transgenic animals (mice are the only mammals for which these 
methods are widespread, although some transgenic rats are starting to be used (Witten et 
al. 2011)), or over a small area when virally transfecting non-transgenic animals (the act of 
injection can also cause gliosis, changing the nature of astrocytic physiology). SR101 is the 
most commonly used astrocyte-specific fluorescent dye, but it can induce neuronal 
plasticity change (Kang et al. 2010). Simply being able to identify cells post-hoc is clearly 
suboptimal. But perhaps most importantly when considering the use of AM-dyes, 
astrocytes in situ have huge numbers of very fine processes that make up most of their 
volume (Bushong et al. 2002; Halassa et al. 2007) and display great variety and number of 
Ca2+ events that are uncoupled from the soma (Di Castro et al. 2011) – but these fine 
processes cannot be resolved with AM-dyes (figure 2c). Studies using these dyes can often 
report Ca2+ activity only from the soma and the very large adjacent primary processes (e.g. 
Porter and McCarthy, 1996) (see chapter 2): but it is vital to understand the Ca2+ activity in 
the fine processes, as it is at the fine processes, enwrapping individual synapses, that local 
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release of neurotransmitter is most likely to trigger a Ca2+ response (Rusakov et al. 2011) 
and indeed local calcium signalling may form a parallel information processing pathway 
(Rusakov et al. 2014).  
Whole-cell patch clamp offers a clear solution to this problem. This technique 
greatly increases the signal to noise ratio and allows imaging of the free Ca2+ activity in the 
finer processes. However this method can also lead to artefacts in ascertaining intracellular 
free Ca2+ concentration – mechanical stimulation from the pipette tip can cause Ca2+ 
transients (Charles et al. 1991), the intracellular milieu is dialysed (an effect that the Ca2+-
clamp takes advantage of) and the widely used 2-photon excitation imaging systems used 
for intact tissue still cannot image the smallest astrocytic compartments – although new 
fluorescent techniques, PALM, STORM and STED, can provide increased spatial resolution at 
the cost of temporal resolution and laser light intensity increase, respectively. Genetically 
encoded Ca2+ indicators may soon become the Ca2+ reporter of choice (Shigetomi et al. 
2011; Tong et al. 2013) given that no patch-clamping is necessary – and they are of clear 
use for in vivo studies (Atkin et al. 2009) and TIRF studies of Ca2+ microactivity in cultured 
astrocytes (Shigetomi et al. 2011) – but their current lack of temporal sensitivity (Yamada 
and Mikoshiba 2012) and heterogenous subcellular expression of the proteins 
(concentrated in organelles) makes their current incarnation suboptimal for slice work. 
 
8.6 Analysis of astrocyte Ca2+ Signals 
 A major challenge in understanding astrocyte Ca2+ signalling lies in the huge variety 
of Ca2+ activity they can display and in the heterogeneity of their response to a given 
stimulus (Bernardinelli et al. 2011). Unlike neurons, whose stereotyped output – the action 
potential – is a physiological reference point to judge the efficacy of a given stimulation, 
astrocytes have no clear ‘spike’-like signal. Hence judging the purpose, relative magnitude 
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or physiological relevance of a stimulus by its Ca2+ response is challenging and this has led 
to confusion in the literature. Figure 1.3 shows some examples of the astrocytic Ca2+ signals 
that have been published: clearly there is great spatial, temporal and magnitudal variety, 
even between neighbouring astrocytes in the same preparation, and there is no consensus 
as to either what constitutes a stereotypical astrocytic Ca2+ signal, or what is a 
physiologically relevant Ca2+ increase to experimentally evoke when attempting to 
stimulate a change in neuronal activity.  
In vivo recording of spontaneous (Hirase et al. 2004; Takata and Hirase 2008; 
Kuchibhotla et al. 2009; Sasaki et al. 2011) and evoked astrocyte Ca2+ activity (Gourine et al. 
2010; Takata et al. 2011) have shed some light on physiologically relevant astrocytic Ca2+ 
signals, although spontaneous activity is still highly variable and difficult to quantify (but see 
Sasaki et al. and Takata and Hirase). Two caveats of the current in vivo literature: firstly, all 
studies have been done under anaesthetic and secondly, current imaging technology only 
allows accurate fluorescent measurement from astrocyte somata in vivo and at with low 
temporal resolution (seconds). Not only do astrocytes display large amounts of Ca2+ activity 
in their finer processes – which may have more relevance to synaptic physiology (Rusakov 
et al. 2014) –  but also that their Ca2+ activity can occur on a timescale of hundreds of 
milliseconds and less. 
These difficulties have led many studies to simply describe astrocytic Ca2+ 
qualitatively – as stimulation of an obvious change in Ca2+ concentration or dynamics. 
Attempts in the literature to apply a rigorous quantification of Ca2+ activity are always 
reliant on either an arbitrary numerical definition of an ‘event’, or manual selection of 
‘events’, which amounts to the same thing: Takata et al. (2012) quantify their evoked Ca2+ 
‘surges’ as beginning when change in fluorescence (ΔF/F0) exceeds 50% increase from a 
baseline (defined, arbitrarily, as the mean of the lower 2/3s of the fluorescence intensity 
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histogram) and ending when ΔF/F0 drops beneath 2SD of the baseline – again an arbitrary 
value; di Castro et al. (2011) quantify their spontaneous activity by frequency, rise time and 
duration of events – but the threshold for classification of an event in the fluorescence 
signal is ‘operator’ chosen; Tanaka et al. (2013) compare the integral and duration of ΔF/F0 
over time of each event, after a DHPG (mGluR1 agonist) puff, but again the events 
measured are manually selected.  
 The highly non-stereotyped responses to stimulation often recorded in this thesis 
have led to my choice of simple, impartial forms of fluorescence analysis: average ΔF/F0 
over a given time; relative ‘oscillatory activity’ change from baseline; differences in ΔF/F0 
frequency distribution between baseline and presence-of-dopamine epochs. Although this 
risks losing some detail of the signal and possibly some biological effect that could be found 
in individual event analysis (Tanaka et al. 2013), it provides a solid, quantitative base upon 
which to report any overall change in astrocytic free Ca2+ concentration. 
 
8.7 Caveats of studying dopaminergic activity in slice 
A serious problem facing all previous in vitro studies, and the experiments from this 
thesis, is the nature of the dopaminergic stimulation. Topical application of dopamine, or 
dopamine agonists, is by far the most commonly used way of stimulating cells 
dopaminergically in vitro: this is because dopaminergic innervation of forebrain regions is 
sparse so electrically stimulated release is not possible without resorting to overly powerful 
stimulation protocols (Frey et al. 1989). Unfortunately, my brief foray into optogentics, with 
the aim of overcoming this problem, was fruitless, preventing me from solving the problem. 
Dopamine is released phasically in response to environmental stimulus, but it also 
maintains a tonus throughout brain tissue (consistent with my results in chapter 6) – the 
prolonged addition of dopamine, or dopamine agonists, to the slice (or culture) perfusion 
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solution creates a kind of ‘dopamine clamp’ on the recorded cellular activity. Whereas this 
would not be a great problem if the pharmacology was simple, given the antagonistic 
nature of the two dopamine receptor types and the non-receptor-mediated effects of 
dopamine, the summation of all of these activities that occurs over this prolonged 
stimulation time makes untangling the causes especially hard. Coupled to this, we cannot 
be sure of the physiological concentration of dopamine reached at any time in living brain 
tissue – as dopamine receptors have different affinities, this would drastically alter the 
overall effect of dopamine in the extracellular space (given all of these potential problems, 
it is interesting that application of only D1 or D2 antagonists can fully block the powerful 
Ca2+ response to dopamine – this suggests that dopamine receptors are strongly linked to 
the workings of astrocytic Ca2+). The most pressing of all further experiments on this subject 
would be the recording of astrocytic Ca2+ response to optogenetic stimulation of the 
dopaminergic innervating input, using TH-CRE rats, or the AAV TH-promoter described by 
Oh et al. (2009). Without these tools, it would also be possible to use high-frequency 
stimulation (HFS) protocols (such as used by Frey et al. 1989) during the blockade of 
ionotropic and metabotropic glutamate, GABA, endocannabinoid, serotonin, acetylcholine 
and adrenergic receptors to record only the dopamine receptor mediated response to a 
more physiological release of dopamine. 
Another factor to take into account is the age of animals used in this thesis – 
animals were sacrificed at post-natal day 21-25: there is some evidence to suggest that (in 
the prefrontal cortex) dopamine changes its effects throughout development – at p12-20, 
dopamine triggers a D2R-dependent inhibition, one which is smaller at p30-40 and gone at 
p70-100 (Paul and Cox 2013). Hence it is possible that astrocytes also exhibit 
developmental changes in dopamine sensitivity or involvement in dopaminergic function –
repetition of the above experiments in adult slices would address this. 
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8.8 Physiological relevance 
 There is a body of evidence that questions the relevance of astrocytic Ca2+ 
transients, such as the ones I have catalogued here in response to dopamine, to astrocyte-
neuron communication (Fiacco et al. 2007; Agulhon et al. 2010). Given the large, complex 
and long-lasting nature of the astrocyte Ca2+ responses to dopamine, the total lack of 
observed effect on neurons (both in this thesis and the literature) begs the question: how 
can astrocyte Ca2+ activity be so radically changed and yet there be no visible effect on 
neuronal activity? Previous studies have reported LTP induction (Perea and Araque 2007) 
and glutamate release (Wang et al. 2013a) upon triggering of similar levels of Ca2+ increase 
– where was this in my recordings, or throughout the hippocampal dopamine literature? It 
could possibly be due to activation of separate Ca2+ signalling pathways, perhaps it was 
overstimulation of intracellular Ca2+ activity. But the results best fit with the observations 
that Ca2+ increases in astrocytes are not necessarily a marker for neuron-glia interaction or 
necessarily mediate any effect on local neuronal activity. A conceptual difference is 
evolving in the literature between widespread, whole-cell astrocyte Ca2+ increases and 
localized Ca2+ dynamics (Rusakov et al. 2014). It is clearly possible to stimulate widespread  
Ca2+ increase in astrocytes with dopamine – the challenge is now to modulate localized 
calcium dynamics; the limiting factor here (as mentioned in section 8.7) is the method of 
dopaminergic stimulation. This is not to say that large-scale Ca2+ transients have no effect 
on astrocyte dynamics – there are many physiological pathways not investigated in this 
thesis – i.e. the possibility of longer term change of their Ca2+ oscillation dynamics.  
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8.9 Astrocytes and dopamine: Unexplored avenues 
Dopamine has actions on astrocytes that are not mediated by intracellular Ca2+ – 
and these alternative signalling cascades could prove more important in dopaminergic 
modulation of astrocyte activity (and hence potentially neuronal activity). Classically, 
dopamine receptors are defined by their control of the cAMP signalling pathway, control 
which they exert in astrocytes (Zanassi et al. 1999; Li et al. 2006), and this could be a fruitful 
area of investigation, given that cAMP can control capacitative Ca2+ entry in astrocytes (Wu 
et al. 1999), change aquaporin expression (through PKA activation)(Yamamoto et al. 2002) 
and has been reported to control astrocytic membrane potential (Bolton et al. 2006) – 
although if this happened upon dopamine stimulation I would expect to have seen it in the 
astrocytes I patched and I did not. Consistent with a role for astrocytic cAMP activity, 
fluorocitrate poisoning has been shown to decrease overall cAMP levels in cortex (Stone 
and John 1991). Other dopamine signalling pathways that have been found in astrocytes – 
αβcrystallin (Shao et al. 2013), FGF-2 (Reuss and Unsicker 2001) – would also be interesting 
to study. The dopaminergic agonist apomorphine has been reported to decrease S100β 
secretion from astrocytes (Nardin et al. 2011) and increased metabolic stress has been 
reported to increase S100β secretion (Gerlach et al. 2006) – could this be a TRP channel 
mediated effect as discussed above? Also, as S100β is Ca2+ buffer there may be effects of 
dopamine on astrocyte control of extracellular Ca2+ concentrations (or longer term 
intracellular astrocyte Ca2+ buffering) which, given the recent description of extracellular 
Ca2+ as a signalling molecule (Torres et al. 2012), is an exciting potential area for research. 
Another fascinating question is whether astrocytes play a role in the release of 
dopamine. In the striatum, astrocytes have been reported to control dopamine release 
through their release of (release inhibiting) kynurenic acid (Wu et al. 2007). In the 
hippocampus, NMDAR activity modulates extracellular dopamine concentration (Schroder 
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and Reymann 1990; Whitton et al. 1994; Chaki et al. 1998) and astrocytes modulate 
NMDAR activity (Henneberger et al. 2010) through d-serine release – d-serine has been 
shown to be important in some dopamine-mediated behaviour (Horio et al. 2012; 
Hammond et al. 2013). Hence it seems likely that astrocytes exert some level of control 
over the concentration of dopamine in the hippocampus. One could use cyclic voltammetry 
to compare hippocampal dopamine levels in astrocyte-IP3 KO mice with wild types. 
Another, unusual, possibility is that astrocytes could produce dopamine themselves – d-
amino oxidase, expressed in astrocytes (Urai et al. 2002), can break down D-DOPA to form 
dopamine (Kawazoe et al. 2007), although this would presuppose the presence of D-DOPA 
in hippocampal astrocytes. 
A final unexplored area in this thesis is the prefrontal cortex (PFC): there is plenty of 
research showing an important role for astrocytes in the cortex (Reyes and Parpura 2008; 
Perea et al. 2014) and dopamine exerts strong modulation of neuronal activity in the PFC 
(Schultz 2001) – given the difference in dopamine response in astrocytes from the same 
hippocampal zone (chapter 4, 5), one could surely expect some novel and exciting 
dopamine response from PFC astrocytes. 
 
8.10 Conclusion 
This thesis adds to the expanding literature detailing astrocytic calcium increases in 
response to dopamine. It details a dopamine receptor mediated increase in astrocytic 
calcium in situ, and reveals a novel D2-type receptor mediated astrocytic calcium response 
– a cytosolic concentration decrease. However it can provide little evidence to suggest that 
astrocytic dopaminergic signalling is involved in hippocampal synaptic transmission. 
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Chapter 9: Supplementary figures 
9.1 Supplementary figures 
 
Figure S1    Gaussian fits for 100μM dopamine application in Figure 2 
ai) Baseline ΔF/F0 proportional distribution and fitted single Gaussian curve in AC processes; grey 
circles indicate recorded data, red line indicates modelled data. aii) as in ai) but in dopamine. aiii) 
double Gaussian fit of dopamine proportional ΔF/F0 distribution; grey circles indicate recorded data, 
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red line indicates 1
st
 of 2 modelled gaussian curves, green line indicates 2
nd
 of 2, blue line indicates 
sum of 1
st
 and 2
nd
 Gaussians, giving modelled distribution. b) As in a) but recordings from GJC 
somata. Data taken from figure 2c, d. 
 
 
 
Figure S2    Gaussian fits for 10μM dopamine application in Figure 3a 
ai) Baseline ΔF/F0 proportional distribution and fitted single Gaussian curve in AC processes; grey 
circles indicate recorded data, red line indicates modelled data. aii) as in ai) but in dopamine. b) As in 
a) but recordings from GJC somata. Data taken from figure 3a. 
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Figure S3    Gaussian fits for 20μM dopamine application in Figure 3b 
ai) Baseline ΔF/F0 proportional distribution and fitted single Gaussian curve in AC processes; grey 
circles indicate recorded data, red line indicates modelled data. aii) as in ai) but in dopamine. aiii) 
double Gaussian fit of dopamine proportional ΔF/F0 distribution; grey circles indicate recorded data, 
red line indicates 1
st
 of 2 modelled gaussian curves, green line indicates 2
nd
 of 2, blue line indicates 
sum of 1
st
 and 2
nd
 Gaussians, giving modelled distribution. b) As in a) but recordings from GJC 
somata. Data taken from figure 3b. 
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 circles indicate recorded data, red line indicates 1st of 2 modelled gaussian curves, green line indicates 2nd of 2, 
blue line indicates sum of 1
st
 and 2
nd
 Gaussians, giving modelled distribution. b) As in a) but recordings from GJC 
somata. biv) triple Gaussian fit of dopamine proportional ΔF/F0 distribution; magenta line indicates 3
rd
 modelled 
gaussian curve. Data taken from figure 3c. 
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Figure S5   Gaussian fits for 100μM dopamine application during neuronal 
blocker cocktail in Figure 4a 
ai) Baseline ΔF/F0 proportional distribution and fitted single Gaussian curve in AC processes; grey 
circles indicate recorded data, red line indicates modelled data. aii) as in ai) but in dopamine. aiii) 
double Gaussian fit of dopamine proportional ΔF/F0 distribution; grey circles indicate recorded data, 
red line indicates 1
st
 of 2 modelled gaussian curves, green line indicates 2
nd
 of 2, blue line indicates 
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sum of 1
st
 and 2
nd
 Gaussians, giving modelled distribution. b) As in a) but recordings from GJC 
somata. Data taken from figure 4a. 
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Figure S7    Gaussian fits for 100μM dopamine application during dopamine 
receptor blockerade in Figure 4c 
ai) Baseline ΔF/F0 proportional distribution and fitted single Gaussian curve in AC processes; grey 
circles indicate recorded data, red line indicates modelled data. aii) as in ai) but in dopamine. b) As in 
a) but recordings from GJC somata. Data taken from figure 4c. 
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Figure S8  Gaussian fits for 100μM dopamine application in the presence of 
10μM SCH23390 Figure 5a 
ai) Baseline ΔF/F0 proportional distribution and fitted single Gaussian curve in AC processes; grey 
circles indicate recorded data, red line indicates modelled data. aii) as in ai) but in dopamine. b) As in 
a) but recordings from GJC somata. Data taken from figure 5a. 
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Figure S9    Gaussian fits for 100μM dopamine application during 5μM SCH 
23390 in Figure 5b 
ai) Baseline ΔF/F0 proportional distribution and fitted single Gaussian curve in AC processes; grey 
circles indicate recorded data, red line indicates modelled data. aii) as in ai) but in dopamine. aiii) 
double Gaussian fit of dopamine proportional ΔF/F0 distribution; grey circles indicate recorded data, 
red line indicates 1
st
 of 2 modelled gaussian curves, green line indicates 2
nd
 of 2, blue line indicates 
sum of 1
st
 and 2
nd
 Gaussians, giving modelled distribution. b) As in a) but recordings from GJC 
somata. Data taken from figure 5b. 
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Figure S10    Gaussian fits for 100μM dopamine application during 50μM 
sulpiride in Figure 6a. 
ai) Baseline ΔF/F0 proportional distribution and fitted single Gaussian curve in AC processes; grey 
circles indicate recorded data, red line indicates modelled data. aii) as in ai) but in dopamine. aiii) 
double Gaussian fit of dopamine proportional ΔF/F0 distribution; grey circles indicate recorded data, 
red line indicates 1
st
 of 2 modelled gaussian curves, green line indicates 2
nd
 of 2, blue line indicates 
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sum of 1
st
 and 2
nd
 Gaussians, giving modelled distribution. b) As in a) but recordings from GJC 
somata. Data taken from figure 6a. 
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Figure S12    Gaussian fits for simultaneous 100μM SKF38390 and 100μM 
quinpirole application in Figure 7a. 
ai) Baseline ΔF/F0 proportional distribution and fitted single Gaussian curve in AC processes; grey 
circles indicate recorded data, red line indicates modelled data. aii) as in ai) but in dopamine. aiii) 
double Gaussian fit of dopamine proportional ΔF/F0 distribution; grey circles indicate recorded data, 
red line indicates 1
st
 of 2 modelled gaussian curves, green line indicates 2
nd
 of 2, blue line indicates 
sum of 1
st
 and 2
nd
 Gaussians, giving modelled distribution. b) As in a) but recordings from GJC 
somata. Data taken from figure 7a. 
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ai) Baseline ΔF/F0 proportional distribution and 
fitted single Gaussian curve in AC processes; 
grey circles indicate recorded data, red line 
indicates modelled data. aii) double Gaussian 
fit of baseline proportional ΔF/F0 distribution; 
grey circles indicate recorded data, red line 
indicates 1
st
 of 2 modelled gaussian curves, 
green line indicates 2
nd
 of 2, blue line indicates 
sum of 1
st
 and 2
nd
 Gaussians, giving modelled 
distribution. as in ai) but in dopamine. aiii) as in  
 
Figure S13    Gaussian fits for 
simultaneous 100μM 
SKF38390 and 100μM 
quinpirole application 
in Figure 7a. 
 
ai) but in dopamine. aiv) double Gaussian fit of dopamine proportional ΔF/F0 distribution; grey circles 
indicate recorded data, red line indicates 1
st
 of 2 modelled gaussian curves, green line indicates 2
nd
 of 
2, blue line indicates sum of 1
st
 and 2
nd
 Gaussians, giving modelled distribution. bi) As in ai) but 
recordings from GJC somata. bii) as in aiii) but recordings from GJC somata. Data taken from figure 7b. 
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9.2 Supplementary tables 
 
Time 
(s) 
Mean 
Dif. 
Std. 
Error DF |t|value Prob>|t| Sig. 95% LCL 
95% 
UCL 
5 -0.01898 0.0407 171 0.46633 0.64157 
 
-
0.09933 0.06136 
20 0.17186 0.0407 171 4.22222 3.92E-05 * 0.09151 0.2522 
35 0.14187 0.0407 171 3.48557 6.24E-04 * 0.06153 0.22222 
50 0.14859 0.0407 171 3.65055 3.47E-04 * 0.06824 0.22893 
65 0.11506 0.0407 171 2.82681 0.00526 * 0.03471 0.1954 
80 0.14851 0.0407 171 3.64853 3.50E-04 * 0.06816 0.22885 
95 0.17309 0.0407 171 4.25258 3.47E-05 * 0.09275 0.25344 
110 0.10042 0.0407 171 2.46727 0.0146 * 0.02008 0.18077 
125 0.12242 0.0407 171 3.00763 0.00303 * 0.04207 0.20276 
140 0.14539 0.0407 171 3.57202 4.60E-04 * 0.06505 0.22574 
155 0.07096 0.0407 171 1.74327 0.08308 
 
-
0.00939 0.1513 
170 0.06337 0.0407 171 1.55693 0.12134 
 
-
0.01697 0.14372 
185 0.12222 0.0407 171 3.00285 0.00308 * 0.04188 0.20257 
200 0.129 0.0407 171 3.16929 0.00181 * 0.04865 0.20934 
215 0.07428 0.0407 171 1.82483 0.06977 
 
-
0.00607 0.15462 
230 0.08482 0.0407 171 2.08389 0.03866 * 0.00448 0.16516 
245 0.07565 0.0407 171 1.85869 0.06479 
 
-
0.00469 0.156 
260 0.04704 0.0407 171 1.1558 0.24938 
 
-0.0333 0.12739 
275 0.10457 0.0407 171 2.56915 0.01105 * 0.02423 0.18492 
290 0.03656 0.0407 171 0.8983 0.37029 
 
-
0.04378 0.11691 
 
Table S1 ANOVA for post-TBS fEPSP amplitudes in control and dopamine 
conditions. 
Time - seconds post-TBS stimulus; Mean Dif. – dopamine fEPSP amplitude subtracted from control 
fEPSP amplitude; std. error – standard error; DF – degrees of freedom; t value – statistical t-value; 
prob>t – probability that t value is the same as expected; Sig. – does prob>t reach a significance of 
<0.05; 95% LCL – 95% lower confidence interval; 95% UCL – 95% upper confidence interval. 
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Time 
Mean 
Dif. 
Std. 
Error DF |t|value Prob>|t| Sig. 95% LCL 95% UCL 
5 -0.07132 0.03438 171 2.07419 0.03956 * -0.13919 -0.00345 
20 -0.10373 0.03438 171 3.01679 2.94E-03 * -0.17159 -0.03586 
35 -0.06564 0.03438 171 1.90922 5.79E-02 
 
-0.13351 0.00223 
50 -0.12416 0.03438 171 3.61102 4.01E-04 * -0.19203 -0.05629 
65 -0.11968 0.03438 171 3.48095 6.34E-04 * -0.18755 -0.05182 
80 -0.12352 0.03438 171 3.59257 4.28E-04 * -0.19139 -0.05565 
95 -0.10971 0.03438 171 3.19075 1.69E-03 * -0.17758 -0.04184 
110 -0.05315 0.03438 171 1.54578 0.12401 
 
-0.12102 0.01472 
125 -0.06723 0.03438 171 1.9553 0.05218 
 
-0.1351 6.41E-04 
140 -0.05972 0.03438 171 1.73705 8.42E-02 
 
-0.12759 0.00814 
155 -0.0463 0.03438 171 1.34672 0.17985  -0.11417 0.02157 
170 -0.05523 0.03438 171 1.60629 0.11005  -0.1231 0.01264 
185 -0.047 0.03438 171 1.36685 0.17347 
 
-0.11487 0.02087 
200 -0.09716 0.03438 171 2.82594 0.00528 * -0.16503 -0.02929 
215 -0.02584 0.03438 171 0.7516 0.45333  -0.09371 0.04203 
230 -0.0432 0.03438 171 1.25653 0.21064  -0.11107 0.02467 
245 -0.02472 0.03438 171 0.71893 0.47316  -0.09259 0.04315 
260 0.02661 0.03438 171 0.77398 0.44001  -0.04126 0.09448 
275 -0.07641 0.03438 171 2.2223 0.02757 * -0.14428 -0.00854 
290 0.01177 0.03438 171 0.34234 0.73251 
 
-0.0561 0.07964 
 
Table S2 ANOVA for post-TBS PPR in control and dopamine conditions. 
Time - seconds post-TBS stimulus; Mean Dif. – dopamine PPR subtracted from control PPR; std. error 
– standard error; DF – degrees of freedom; t value – statistical t-value; prob>t – probability that t 
value is the same as expected; Sig. – does prob>t reach a significance of <0.05; 95% LCL – 95% lower 
confidence interval; 95% UCL – 95% upper confidence interval. 
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Time 
Mean 
Dif. 
Std. 
Error DF |t|value Prob>|t| Sig. 95% LCL 95% UCL 
5 0.05358 0.0486 133 1.10255 0.27221 
 
-0.04254 0.14971 
20 0.04528 0.0486 133 0.93171 3.53E-01 
 
-0.05085 0.14141 
35 0.03391 0.0486 133 0.69771 4.87E-01 
 
-0.06222 0.13004 
50 0.01523 0.0486 133 0.31341 7.54E-01 
 
-0.0809 0.11136 
65 -0.00501 0.0486 133 0.10303 9.18E-01 
 
-0.10114 0.09112 
80 0.03638 0.0486 133 0.74863 4.55E-01 
 
-0.05975 0.13251 
95 0.0444 0.0486 133 0.91367 3.63E-01 
 
-0.05172 0.14053 
110 0.02866 0.0486 133 0.5898 0.55632 
 
-0.06746 0.12479 
125 0.05251 0.0486 133 1.08037 0.28193 
 
-0.04362 1.49E-01 
140 0.02712 0.0486 133 0.5581 5.78E-01 
 
-0.06901 0.12325 
155 0.03991 0.0486 133 0.8212 0.413 
 
-0.05622 0.13604 
170 0.0465 0.0486 133 0.95685 0.34038 
 
-0.04963 0.14263 
185 0.12085 0.0486 133 2.48661 0.01414 * 0.02472 0.21698 
200 0.0474 0.0486 133 0.97538 0.33114 
 
-0.04873 0.14353 
215 0.1075 0.0486 133 2.21193 0.02868 * 0.01137 0.20363 
230 0.11239 0.0486 133 2.3125 0.02229 * 0.01626 0.20852 
245 0.07251 0.0486 133 1.49192 0.13809 
 
-0.02362 0.16864 
260 0.04151 0.0486 133 0.8542 0.39453 
 
-0.05462 0.13764 
275 0.06144 0.0486 133 1.26426 0.20835 
 
-0.03469 0.15757 
290 0.08426 0.0486 133 1.73382 0.08527 
 
-0.01187 0.18039 
 
Table S3 ANOVA for post-TBS fEPSPs in control and FAC conditions. 
Time - seconds post-TBS stimulus; Mean Dif. – FAC fEPSP subtracted from control fEPSP; std. error – 
standard error; DF – degrees of freedom; t value – statistical t-value; prob>t – probability that t value 
is the same as expected; Sig. – does prob>t reach a significance of <0.05; 95% LCL – 95% lower 
confidence interval; 95% UCL – 95% upper confidence interval. 
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Time Mean Dif. 
Std. 
Error DF |t|value Prob>|t| Sig. 95% LCL 95% UCL 
5 -0.07146 0.03539 133 2.0193 0.04547 * -0.14146 -0.00146 
20 -0.07304 0.03539 133 2.06387 4.10E-02 * -0.14303 -0.00304 
35 -0.07675 0.03539 133 2.16881 3.19E-02 * -0.14675 -0.00675 
50 -0.06078 0.03539 133 1.71757 8.82E-02 
 
-0.13078 0.00921 
65 -0.01936 0.03539 133 0.54708 5.85E-01 
 
-0.08936 0.05064 
80 -0.05792 0.03539 133 1.63657 1.04E-01 
 
-0.12791 0.01208 
95 -0.0087 0.03539 133 0.24571 8.06E-01 
 
-0.07869 0.0613 
110 -0.04842 0.03539 133 1.36822 0.17355 
 
-0.11842 0.02158 
125 0.01209 0.03539 133 0.34167 0.73314 
 
-0.05791 8.21E-02 
140 -0.01775 0.03539 133 0.50172 6.17E-01 
 
-0.08775 0.05224 
155 -0.00399 0.03539 133 0.11268 0.91045 
 
-0.07398 0.06601 
170 -0.03229 0.03539 133 0.91244 0.36319 
 
-0.10229 0.03771 
185 -0.08629 0.03539 133 2.43836 0.01607 * -0.15629 -0.01629 
200 -0.0297 0.03539 133 0.83936 0.40277 
 
-0.0997 0.04029 
215 -0.07181 0.03539 133 2.02913 0.04444 * -0.1418 -0.00181 
230 -0.08075 0.03539 133 2.2817 0.0241 * -0.15074 -0.01075 
245 -0.0033 0.03539 133 0.09334 0.92578 
 
-0.0733 0.06669 
260 0.00309 0.03539 133 0.08725 0.93061 
 
-0.06691 0.07308 
275 -0.01447 0.03539 133 0.40903 0.68317 
 
-0.08447 0.05552 
290 -0.03461 0.03539 133 0.97797 0.32987 
 
-0.10461 0.03539 
 
Table S4 ANOVA for post-TBS PPR in control and FAC conditions. 
Time - seconds post-TBS stimulus; Mean Dif. – FAC PPR subtracted from control PPR; std. error – 
standard error; DF – degrees of freedom; t value – statistical t-value; prob>t – probability that t value 
is the same as expected; Sig. – does prob>t reach a significance of <0.05; 95% LCL – 95% lower 
confidence interval; 95% UCL – 95% upper confidence interval. 
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Time 
Mean 
Dif. 
Std. 
Error DF |t|value Prob>|t| Sig. 95% LCL 95% UCL 
5 0.08104 0.05773 133 1.40371 0.16274 
 
-0.03315 0.19524 
20 0.14563 0.05773 133 2.52232 1.28E-02 * 0.03143 0.25982 
35 0.12048 0.05773 133 2.08684 3.88E-02 * 0.00629 0.23468 
50 0.07865 0.05773 133 1.36229 1.75E-01 
 
-0.03555 0.19285 
65 0.12313 0.05773 133 2.13264 3.48E-02 * 0.00893 0.23732 
80 0.07102 0.05773 133 1.2301 2.21E-01 
 
-0.04318 0.18522 
95 -0.01796 0.05773 133 0.31101 7.56E-01 
 
-0.13215 0.09624 
110 0.0697 0.05773 133 1.20726 0.22947 
 
-0.0445 0.1839 
125 0.04866 0.05773 133 0.84287 0.40082 
 
-0.06553 1.63E-01 
140 -0.06232 0.05773 133 1.07949 2.82E-01 
 
-0.17652 0.05187 
155 -0.05533 0.05773 133 0.95841 0.3396 
 
-0.16953 0.05886 
170 0.03064 0.05773 133 0.53068 0.59653 
 
-0.08356 0.14484 
185 -0.02049 0.05773 133 0.35495 0.72319 
 
-0.13469 0.0937 
200 0.03737 0.05773 133 0.64732 0.51854 
 
-0.07682 0.15157 
215 0.03743 0.05773 133 0.64828 0.51792 
 
-0.07677 0.15163 
230 0.08312 0.05773 133 1.43969 0.1523 
 
-0.03108 0.19732 
245 0.09787 0.05773 133 1.69509 0.0924 
 
-0.01633 0.21206 
260 -0.02529 0.05773 133 0.43808 0.66204 
 
-0.13949 0.0889 
275 -0.01246 0.05773 133 0.21576 0.8295 
 
-0.12665 0.10174 
290 -0.05355 0.05773 133 0.92756 0.35532 
 
-0.16775 0.06064 
 
Table S5 ANOVA for post-TBS fEPSP in dopamine and dopamine + FAC 
conditions. 
Time - seconds post-TBS stimulus; Mean Dif. – dopamine fEPSP subtracted from dopamine + FAC 
fEPSP; std. error – standard error; DF – degrees of freedom; t value – statistical t-value; prob>t – 
probability that t value is the same as expected; Sig. – does prob>t reach a significance of <0.05; 95% 
LCL – 95% lower confidence interval; 95% UCL – 95% upper confidence interval. 
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Time 
Mean 
Dif. 
Std. 
Error DF |t|value Prob>|t| Sig. 95% LCL 95% UCL 
5 -0.05856 0.05536 133 1.05778 0.29207 
 
-0.16805 0.05094 
20 -0.06643 0.05536 133 1.20007 2.32E-01 
 
-0.17593 0.04306 
35 -0.02107 0.05536 133 0.38063 7.04E-01 
 
-0.13057 0.08842 
50 -0.01771 0.05536 133 0.31994 7.50E-01 
 
-0.12721 0.09178 
65 0.08006 0.05536 133 1.44631 1.50E-01 
 
-0.02943 0.18956 
80 -0.02927 0.05536 133 0.52866 5.98E-01 
 
-0.13876 0.08023 
95 -0.00883 0.05536 133 0.15954 8.73E-01 
 
-0.11833 0.10066 
110 -0.04745 0.05536 133 0.85711 0.39292 
 
-0.15694 0.06205 
125 0.02055 0.05536 133 0.37125 0.71105 
 
-0.08894 1.30E-01 
140 0.0309 0.05536 133 0.55817 5.78E-01 
 
-0.0786 0.14039 
155 0.04279 0.05536 133 0.77303 0.44088 
 
-0.0667 0.15229 
170 0.01043 0.05536 133 0.1884 0.85085 
 
-0.09907 0.11992 
185 0.01043 0.05536 133 0.1884 0.85085 
 
-0.09907 0.11992 
200 0.02923 0.05536 133 0.52808 0.59832 
 
-0.08026 0.13873 
215 -0.04227 0.05536 133 0.76363 0.44644 
 
-0.15177 0.06722 
230 -0.06558 0.05536 133 1.1847 0.23825 
 
-0.17508 0.04391 
245 -0.0236 0.05536 133 0.42624 0.67062 
 
-0.13309 0.0859 
260 0.03809 0.05536 133 0.68799 0.49266 
 
-0.07141 0.14758 
275 -0.0041 0.05536 133 0.074 0.94112 
 
-0.11359 0.1054 
290 0.02844 0.05536 133 0.51371 0.60831 
 
-0.08106 0.13793 
 
Table S6 ANOVA for post-TBS PPR in dopamine and dopamine + FAC 
conditions. 
Time - seconds post-TBS stimulus; Mean Dif. – dopamine fEPSP subtracted from dopamine + FAC 
fEPSP; std. error – standard error; DF – degrees of freedom; t value – statistical t-value; prob>t – 
probability that t value is the same as expected; Sig. – does prob>t reach a significance of <0.05; 95% 
LCL – 95% lower confidence interval; 95% UCL – 95% upper confidence interval. 
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Time Mean Dif. 
Std. 
Error DF |t|value Prob>|t| Sig. 95% LCL 95% UCL 
15 -0.13597 0.12896 133 1.05433 0.29364 
 
-0.39105 0.11911 
30 -0.11814 0.12896 133 0.91611 0.36127 
 
-0.37322 0.13694 
45 -0.04044 0.12896 133 0.31355 0.75436 
 
-0.29552 0.21464 
60 -0.16477 0.12896 133 1.27766 0.2036 
 
-0.41985 0.09031 
75 -0.16395 0.12896 133 1.27134 0.20583 
 
-0.41903 0.09113 
90 0.1423 0.12896 133 1.10341 0.27184 
 
-0.11278 0.39738 
105 -0.15233 0.12896 133 1.1812 0.23963 
 
-0.40741 0.10275 
120 -0.09656 0.12896 133 0.74872 0.45535 
 
-0.35164 0.15852 
135 0.00102 0.12896 133 0.00793 0.99368 
 
-0.25406 0.2561 
150 0.06915 0.12896 133 0.53621 0.59271 
 
-0.18593 0.32423 
165 -0.04562 0.12896 133 0.35371 0.72411 
 
-0.30069 0.20946 
180 -0.0841 0.12896 133 0.6521 0.51546 
 
-0.33918 0.17098 
195 -0.01264 0.12896 133 0.098 0.92208 
 
-0.26772 0.24244 
210 -0.14197 0.12896 133 1.10089 0.27293 
 
-0.39705 0.11311 
225 2.81E-04 0.12896 133 0.00218 0.99826 
 
-0.2548 0.25536 
240 -0.00169 0.12896 133 0.01308 0.98959 
 
-0.25677 0.25339 
255 0.05133 0.12896 133 0.398 0.69127 
 
-0.20375 0.30641 
270 -0.12275 0.12896 133 0.95186 0.34289 
 
-0.37783 0.13233 
285 -0.08625 0.12896 133 0.6688 0.50478 
 
-0.34133 0.16883 
300 -0.07914 0.12896 133 0.6137 0.54046 
 
-0.33422 0.17594 
 
Table S7 ANOVA for PTP fEPSP amplitudes comparing post 1st and 2nd TBS. 
Time - seconds post-TBS; Mean Dif. – 1
st
 TBS fEPSP amplitude subtracted from 2
nd
 TBS fEPSP 
amplitude; std. error – standard error; DF – degrees of freedom; t value – statistical t-value; prob>t – 
probability that t value is the same as expected; Sig. – does prob>t reach a significance of <0.05; 95% 
LCL – 95% lower confidence interval; 95% UCL – 95% upper confidence interval. 
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Time 
Mean 
Dif. 
Std. 
Error DF |t|value Prob>|t| Sig. 95% LCL 95% UCL 
15 0.08618 0.08935 133 0.96446 0.33657 
 
-0.09056 0.26291 
30 0.00926 0.08935 133 0.10368 0.91758 
 
-0.16747 0.186 
45 -0.08585 0.08935 133 0.96081 0.33839 
 
-0.26258 0.09088 
60 0.07486 0.08935 133 0.83778 0.40365 
 
-0.10188 0.25159 
75 0.10474 0.08935 133 1.17227 0.24318 
 
-0.07199 0.28148 
90 -0.15199 0.08935 133 1.70104 0.09127 
 
-0.32872 0.02474 
105 0.01603 0.08935 133 0.17945 0.85785 
 
-0.1607 0.19277 
120 0.05883 0.08935 133 0.65845 0.51139 
 
-0.1179 0.23557 
135 -0.0033 0.08935 133 0.03694 0.97059 
 
-0.18003 0.17343 
150 -0.07009 0.08935 133 0.78444 0.43418 
 
-0.24682 0.10664 
165 0.01456 0.08935 133 0.16301 0.87076 
 
-0.16217 0.1913 
180 -0.0191 0.08935 133 0.21377 0.83105 
 
-0.19583 0.15763 
195 -0.02904 0.08935 133 0.325 0.74569 
 
-0.20577 0.14769 
210 0.05918 0.08935 133 0.66231 0.50892 
 
-0.11755 0.23591 
225 -0.05844 0.08935 133 0.65401 0.51423 
 
-0.23517 0.1183 
240 -0.05688 0.08935 133 0.63658 0.52549 
 
-0.23361 0.11985 
255 -0.03533 0.08935 133 0.39545 0.69315 
 
-0.21207 0.1414 
270 0.0824 0.08935 133 0.92226 0.35806 
 
-0.09433 0.25914 
285 -0.03464 0.08935 133 0.38767 0.69888 
 
-0.21137 0.14209 
300 0.08513 0.08935 133 0.95271 0.34247 
 
-0.09161 0.26186 
 
Table S8 ANOVA for PTP PPR amplitudes comparing post 1st and 2nd TBS. 
Time - seconds post-TBS; Mean Dif. – 1
st
 TBS PPR amplitude subtracted from 2
nd
 TBS PPR amplitude; 
std. error – standard error; DF – degrees of freedom; t value – statistical t-value; prob>t – probability 
that t value is the same as expected; Sig. – does prob>t reach a significance of <0.05; 95% LCL – 95% 
lower confidence interval; 95% UCL – 95% upper confidence interval. 
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Time 
Mean 
Dif. 
Std. 
Error DF |t|value Prob>|t| Sig. 95% LCL 95% UCL 
15 -0.02294 0.08317 152 0.27579 0.78308 
 
-0.18727 0.14139 
30 -0.12277 0.08317 152 1.47603 0.142 
 
-0.28709 0.04156 
45 -0.07287 0.08317 152 0.87606 0.38238 
 
-0.23719 0.09146 
60 -0.18289 0.08317 152 2.19883 0.0294 * -0.34721 -0.01856 
75 -0.07179 0.08317 152 0.86312 0.38943 
 
-0.23612 0.09254 
90 -0.13062 0.08317 152 1.57041 0.1184 
 
-0.29494 0.03371 
105 -0.20294 0.08317 152 2.43994 0.01584 * -0.36727 -0.03861 
120 -0.12389 0.08317 152 1.48956 0.13841 
 
-0.28822 0.04043 
135 -0.14576 0.08317 152 1.75248 0.08171 
 
-0.31009 0.01857 
150 -0.16336 0.08317 152 1.96408 0.05134 
 
-0.32769 9.66E-04 
165 -0.1187 0.08317 152 1.42707 0.15561 
 
-0.28302 0.04563 
180 -0.24727 0.08317 152 2.97297 0.00343 * -0.4116 -0.08295 
195 -0.16634 0.08317 152 1.99986 0.0473 * -0.33066 -0.00201 
210 -0.20582 0.08317 152 2.47458 0.01444 * -0.37015 -0.04149 
225 -0.2014 0.08317 152 2.42143 0.01664 * -0.36573 -0.03707 
240 -0.13791 0.08317 152 1.65812 0.09936 
 
-0.30224 0.02641 
255 -0.12792 0.08317 152 1.53796 0.12614 
 
-0.29224 0.03641 
270 -0.26298 0.08317 152 3.16181 0.00189 * -0.42731 -0.09865 
285 -0.1255 0.08317 152 1.50882 0.13342 
 
-0.28982 0.03883 
300 -0.18405 0.08317 152 2.21283 0.0284 * -0.34838 -0.01972 
 
Table S9 ANOVA for PTP fEPSP amplitudes comparing post 1st and 2nd TBS in 
control vs. SCH23390 and Sulpiride – both normalized to 1st 
baseline. 
Time - seconds post-TBS; Mean Dif. – 1
st
 TBS fEPSP amplitude subtracted from 2
nd
 TBS fEPSP 
amplitude; std. error – standard error; DF – degrees of freedom; t value – statistical t-value; prob>t – 
probability that t value is the same as expected; Sig. – does prob>t reach a significance of <0.05; 95% 
LCL – 95% lower confidence interval; 95% UCL – 95% upper confidence interval. 
  
243 
 
Time 
Mean 
Dif. 
Std. 
Error DF |t|value Prob>|t| Sig. 95% LCL 95% UCL 
15 0.17179 0.06186 152 2.77722 0.00617 * 0.04958 0.294 
30 0.06062 0.06186 152 0.98007 0.32861 
 
-0.06159 0.18283 
45 0.11209 0.06186 152 1.81215 0.07194 
 
-0.01012 0.2343 
60 -0.01016 0.06186 152 0.16426 0.86975 
 
-0.13237 0.11205 
75 0.09752 0.06186 152 1.57649 0.11699 
 
-0.02469 0.21973 
90 0.03944 0.06186 152 0.63753 0.52474 
 
-0.08277 0.16164 
105 -0.01555 0.06186 152 0.25145 0.8018 
 
-0.13776 0.10666 
120 0.04692 0.06186 152 0.75845 0.44936 
 
-0.07529 0.16912 
135 0.02756 0.06186 152 0.44558 0.65654 
 
-0.09465 0.14977 
150 0.00925 0.06186 152 0.14957 0.8813 
 
-0.11296 0.13146 
165 0.03949 0.06186 152 0.63837 0.52419 
 
-0.08272 0.1617 
180 -0.09422 0.06186 152 1.52323 0.12978 
 
-0.21643 0.02799 
195 -0.00756 0.06186 152 0.12215 0.90294 
 
-0.12977 0.11465 
210 -0.0438 0.06186 152 0.70808 0.47998 
 
-0.16601 0.07841 
225 -0.04146 0.06186 152 0.67024 0.50372 
 
-0.16367 0.08075 
240 0.01863 0.06186 152 0.30125 0.76363 
 
-0.10358 0.14084 
255 0.02759 0.06186 152 0.44604 0.6562 
 
-0.09462 0.1498 
270 -0.10583 0.06186 152 1.71086 0.08915 
 
-0.22804 0.01638 
285 0.0262 0.06186 152 0.42351 0.67252 
 
-0.09601 0.14841 
300 -0.03787 0.06186 152 0.61219 0.54133 
 
-0.16008 0.08434 
 
Table S10 ANOVA for PTP fEPSP amplitudes comparing post 1st and 2nd TBS in 
control vs. SCH23390 and Sulpiride – renormalized. 
Time - seconds post-TBS; Mean Dif. – 1
st
 TBS fEPSP amplitude subtracted from 2
nd
 TBS fEPSP 
amplitude; std. error – standard error; DF – degrees of freedom; t value – statistical t-value; prob>t – 
probability that t value is the same as expected; Sig. – does prob>t reach a significance of <0.05; 95% 
LCL – 95% lower confidence interval; 95% UCL – 95% upper confidence interval. 
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Time 
Mean 
Dif. 
Std. 
Error DF |t|value Prob>|t| Sig. 95% LCL 95% UCL 
15 -0.00841 0.03489 152 0.24115 0.80977 
 
-0.07734 0.06052 
30 0.01819 0.03489 152 0.52135 0.60288 
 
-0.05074 0.08712 
45 0.03199 0.03489 152 0.9169 0.36065 
 
-0.03694 0.10092 
60 0.04872 0.03489 152 1.39644 0.16462 
 
-0.02021 0.11765 
75 0.01134 0.03489 152 0.3251 0.74555 
 
-0.05759 0.08027 
90 0.05283 0.03489 152 1.51413 0.13207 
 
-0.0161 0.12176 
105 0.07994 0.03489 152 2.29138 0.02332 * 0.01101 0.14887 
120 0.02237 0.03489 152 0.64127 0.52231 
 
-0.04656 0.0913 
135 0.0669 0.03489 152 1.91761 0.05704 
 
-0.00203 0.13583 
150 0.04459 0.03489 152 1.27816 0.20314 
 
-0.02434 0.11352 
165 0.02687 0.03489 152 0.77021 0.44237 
 
-0.04206 0.0958 
180 0.10431 0.03489 152 2.98989 0.00326 * 0.03538 0.17324 
195 0.05455 0.03489 152 1.56362 0.11999 
 
-0.01438 0.12348 
210 0.09301 0.03489 152 2.66575 0.00851 * 0.02408 0.16194 
225 0.05761 0.03489 152 1.65113 0.10078 
 
-0.01132 0.12654 
240 0.05943 0.03489 152 1.70329 0.09056 
 
-0.0095 0.12836 
255 0.06206 0.03489 152 1.77892 0.07725 
 
-0.00687 0.13099 
270 0.18683 0.03489 152 5.35492 3.10E-07 * 0.1179 0.25576 
285 0.06068 0.03489 152 1.73912 0.08404 
 
-0.00825 0.12961 
300 0.0453 0.03489 152 1.29843 0.19611 
 
-0.02363 0.11423 
 
Table S11 ANOVA for PTP PPR amplitudes comparing post 1st and 2nd TBS in 
control vs. SCH23390 and Sulpiride – both normalized to 1st 
baseline. 
Time - seconds post-TBS; Mean Dif. – 1
st
 TBS PPR amplitude subtracted from 2
nd
 TBS PPR amplitude; 
std. error – standard error; DF – degrees of freedom; t value – statistical t-value; prob>t – probability 
that t value is the same as expected; Sig. – does prob>t reach a significance of <0.05; 95% LCL – 95% 
lower confidence interval; 95% UCL – 95% upper confidence interval. 
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Time 
Mean 
Dif. Std. Error DF |t|value Prob>|t| Sig. 95% LCL 95% UCL 
15 -0.0554 0.03597 152 1.54005 0.12563 
 
-0.12646 0.01567 
30 -0.0307 0.03597 152 0.85334 0.39482 
 
-0.10176 0.04037 
45 -0.01692 0.03597 152 0.4703 0.63882 
 
-0.08798 0.05415 
60 -0.00108 0.03597 152 0.0301 0.97603 
 
-0.07215 0.06998 
75 -0.03983 0.03597 152 1.10723 0.26994 
 
-0.1109 0.03124 
90 8.84E-04 0.03597 152 0.02457 0.98043 
 
-0.07018 0.07195 
105 0.03246 0.03597 152 0.90237 0.36829 
 
-0.03861 0.10353 
120 -0.02884 0.03597 152 0.80179 0.42393 
 
-0.09991 0.04223 
135 0.01868 0.03597 152 0.51924 0.60435 
 
-0.05239 0.08975 
150 -0.00412 0.03597 152 0.11447 0.90901 
 
-0.07519 0.06695 
165 -0.02248 0.03597 152 0.62507 0.53286 
 
-0.09355 0.04858 
180 0.05166 0.03597 152 1.43614 0.15302 
 
-0.01941 0.12273 
195 0.00269 0.03597 152 0.07473 0.94053 
 
-0.06838 0.07376 
210 0.04383 0.03597 152 1.21859 0.22489 
 
-0.02723 0.1149 
225 0.00811 0.03597 152 0.22543 0.82194 
 
-0.06296 0.07918 
240 0.0095 0.03597 152 0.26407 0.79208 
 
-0.06157 0.08057 
255 0.01053 0.03597 152 0.29276 0.77011 
 
-0.06054 0.0816 
270 0.13827 0.03597 152 3.84403 1.77E-04 * 0.06721 0.20934 
285 0.00919 0.03597 152 0.25555 0.79864 
 
-0.06188 0.08026 
300 -0.00792 0.03597 152 0.22021 0.826 
 
-0.07899 0.06315 
 
Table S12 ANOVA for PTP PPR amplitudes comparing post 1st and 2nd TBS in 
control vs. SCH23390 and Sulpiride – renormalized. 
Time - seconds post-TBS; Mean Dif. – 1
st
 TBS PPR amplitude subtracted from 2
nd
 TBS PPR amplitude; 
std. error – standard error; DF – degrees of freedom; t value – statistical t-value; prob>t – probability 
that t value is the same as expected; Sig. – does prob>t reach a significance of <0.05; 95% LCL – 95% 
lower confidence interval; 95% UCL – 95% upper confidence interval. 
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Time 
Mean 
Dif. Std. Error DF |t|value Prob>|t| 
Sig. 
95% LCL 95% UCL 
15 -0.0485 0.14875 57 0.32603 0.7456 
 
-0.34636 0.24937 
30 -0.16108 0.14875 57 1.0829 0.28341 
 
-0.45894 0.13678 
45 -0.12328 0.14875 57 0.82875 0.4107 
 
-0.42114 0.17459 
60 -0.2247 0.14875 57 1.5106 0.13641 
 
-0.52256 0.07316 
75 -0.12522 0.14875 57 0.84181 0.40341 
 
-0.42308 0.17265 
90 -0.13604 0.14875 57 0.91454 0.36428 
 
-0.4339 0.16183 
105 -0.14408 0.14875 57 0.96863 0.33682 
 
-0.44195 0.15378 
120 -0.08912 0.14875 57 0.59911 0.55147 
 
-0.38698 0.20875 
135 -0.34667 0.14875 57 2.3306 0.02334 * -0.64454 -0.04881 
150 -0.22685 0.14875 57 1.52504 0.13278 
 
-0.52471 0.07102 
165 -0.12941 0.14875 57 0.87002 0.38794 
 
-0.42728 0.16845 
180 -0.24559 0.14875 57 1.65105 0.10423 
 
-0.54346 0.05227 
195 -0.13077 0.14875 57 0.87914 0.38302 
 
-0.42863 0.16709 
210 -0.15522 0.14875 57 1.04348 0.30113 
 
-0.45308 0.14265 
225 -0.0916 0.14875 57 0.61581 0.54047 
 
-0.38947 0.20626 
240 -0.0916 0.14875 57 0.61581 0.54047 
 
-0.38947 0.20626 
255 -0.10632 0.14875 57 0.71473 0.47769 
 
-0.40418 0.19155 
270 -0.08151 0.14875 57 0.54799 0.58584 
 
-0.37938 0.21635 
285 -0.2553 0.14875 57 1.71631 0.09154 
 
-0.55316 0.04257 
300 -0.07661 0.14875 57 0.51505 0.60851 
 
-0.37448 0.22125 
 
Table S13 ANOVA for PTP fEPSP amplitudes comparing post 1st and 2nd TBS in 
control and FAC – renormalized. 
Time - seconds post-TBS; Mean Dif. – 1
st
 TBS fEPSP amplitude subtracted from 2
nd
 TBS fEPSP 
amplitude; std. error – standard error; DF – degrees of freedom; t value – statistical t-value; prob>t – 
probability that t value is the same as expected; Sig. – does prob>t reach a significance of <0.05; 95% 
LCL – 95% lower confidence interval; 95% UCL – 95% upper confidence interval. 
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Time 
Mean 
Dif. Std. Error DF |t|value Prob>|t| 
Sig. 
95% LCL 95% UCL 
15 0.02018 0.059 57 0.34197 0.73363 
 
-0.09797 0.13833 
30 0.07188 0.059 57 1.21825 0.22815 
 
-0.04627 0.19003 
45 -0.0198 0.059 57 0.33554 0.73845 
 
-0.13795 0.09835 
60 0.09063 0.059 57 1.53596 0.13008 
 
-0.02753 0.20878 
75 0.03591 0.059 57 0.60854 0.54525 
 
-0.08225 0.15406 
90 0.04923 0.059 57 0.83442 0.40753 
 
-0.06892 0.16739 
105 0.07759 0.059 57 1.31508 0.19375 
 
-0.04056 0.19575 
120 0.04635 0.059 57 0.78557 0.43537 
 
-0.0718 0.1645 
135 0.09182 0.059 57 1.55615 0.12521 
 
-0.02633 0.20997 
150 0.12395 0.059 57 2.10068 0.0401 * 0.00579 0.2421 
165 0.03855 0.059 57 0.65329 0.5162 
 
-0.07961 0.1567 
180 0.12722 0.059 57 2.15612 0.03531 * 0.00907 0.24537 
195 0.12172 0.059 57 2.06293 0.04369 * 0.00357 0.23987 
210 0.05788 0.059 57 0.98099 0.33074 
 
-0.06027 0.17603 
225 0.05134 0.059 57 0.87005 0.38792 
 
-0.06682 0.16949 
240 0.02352 0.059 57 0.39864 0.69165 
 
-0.09463 0.14167 
255 0.04714 0.059 57 0.79886 0.42769 
 
-0.07102 0.16529 
270 0.0074 0.059 57 0.1254 0.90065 
 
-0.11075 0.12555 
285 0.14168 0.059 57 2.40117 0.01963 * 0.02352 0.25983 
300 -0.04216 0.059 57 0.71459 0.47778 
 
-0.16031 0.07599 
 
Table S14 ANOVA for PTP PPR amplitudes comparing post 1st and 2nd TBS in 
control and FAC – renormalized. 
Time - seconds post-TBS; Mean Dif. – 1
st
 TBS PPR amplitude subtracted from 2
nd
 TBS PPR amplitude; 
std. error – standard error; DF – degrees of freedom; t value – statistical t-value; prob>t – probability 
that t value is the same as expected; Sig. – does prob>t reach a significance of <0.05; 95% LCL – 95% 
lower confidence interval; 95% UCL – 95% upper confidence interval. 
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Time 
Mean 
Dif. 
Std. 
Error DF |t|value Prob>|t| 
Sig. 
95% LCL 95% UCL 
15 -0.13196 0.12461 171 1.05894 0.29112 
 
-0.37793 0.11402 
30 -0.19996 0.12461 171 1.60463 0.11042 
 
-0.44594 0.04602 
45 -0.15296 0.12461 171 1.22752 0.22131 
 
-0.39894 0.09301 
60 -0.13137 0.12461 171 1.05421 0.29327 
 
-0.37735 0.11461 
75 -0.19823 0.12461 171 1.59077 0.11351 
 
-0.44421 0.04775 
90 -0.2592 0.12461 171 2.08007 0.03901 * -0.50518 -0.01323 
105 -0.18885 0.12461 171 1.51553 0.13148 
 
-0.43483 0.05712 
120 -0.14988 0.12461 171 1.20277 0.23073 
 
-0.39586 0.0961 
135 -0.26707 0.12461 171 2.14324 0.03351 * -0.51305 -0.0211 
150 -0.05826 0.12461 171 0.4675 0.64074 
 
-0.30423 0.18772 
165 -0.09429 0.12461 171 0.75663 0.45032 
 
-0.34026 0.15169 
180 -0.24776 0.12461 171 1.98827 0.04838 * -0.49374 -0.00179 
195 -0.16825 0.12461 171 1.35022 0.17873 
 
-0.41423 0.07772 
210 -0.39978 0.12461 171 3.20815 0.0016 * -0.64575 -0.1538 
225 -0.16387 0.12461 171 1.31504 0.19026 
 
-0.40985 0.08211 
240 -0.10341 0.12461 171 0.82983 0.40779 
 
-0.34938 0.14257 
255 0.15832 0.12461 171 1.27048 0.20564 
 
-0.08766 0.4043 
270 -0.14643 0.12461 171 1.17504 0.24161 
 
-0.3924 0.09955 
285 -0.24678 0.12461 171 1.98037 0.04927 * -0.49276 
-8.02E-
04 
300 -0.05861 0.12461 171 0.47035 0.63871 
 
-0.30459 0.18737 
 
Table S15 ANOVA for PTP fEPSP amplitudes, preincubated in FAC, comparing 
post 1st and 2nd TBS in control vs. SCH23390 and Sulpiride – both 
normalized to 1st baseline. 
Time - seconds post-TBS; Mean Dif. – 1
st
 TBS fEPSP amplitude subtracted from 2
nd
 TBS fEPSP 
amplitude; std. error – standard error; DF – degrees of freedom; t value – statistical t-value; prob>t – 
probability that t value is the same as expected; Sig. – does prob>t reach a significance of <0.05; 95% 
LCL – 95% lower confidence interval; 95% UCL – 95% upper confidence interval. 
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Time 
Mean 
Dif. Std. Error DF |t|value Prob>|t| 
Sig. 
95% LCL 95% UCL 
15 0.20473 0.12592 171 1.62588 0.10582 
 
-0.04383 0.45328 
30 0.14305 0.12592 171 1.13606 0.25752 
 
-0.1055 0.3916 
45 0.16544 0.12592 171 1.31386 0.19065 
 
-0.08311 0.41399 
60 0.16741 0.12592 171 1.3295 0.18545 
 
-0.08115 0.41596 
75 0.10029 0.12592 171 0.7965 0.42684 
 
-0.14826 0.34885 
90 0.01883 0.12592 171 0.14956 0.88129 
 
-0.22972 0.26738 
105 0.08053 0.12592 171 0.63953 0.52334 
 
-0.16802 0.32908 
120 0.1069 0.12592 171 0.84898 0.39708 
 
-0.14165 0.35545 
135 -0.0062 0.12592 171 0.04926 0.96077 
 
-0.25476 0.24235 
150 0.19919 0.12592 171 1.5819 0.11552 
 
-0.04936 0.44774 
165 0.15694 0.12592 171 1.24636 0.21434 
 
-0.09161 0.40549 
180 0.02195 0.12592 171 0.17435 0.8618 
 
-0.2266 0.27051 
195 0.08182 0.12592 171 0.64978 0.5167 
 
-0.16673 0.33037 
210 -0.12752 0.12592 171 1.01276 0.31261 
 
-0.37608 0.12103 
225 0.09703 0.12592 171 0.7706 0.44201 
 
-0.15152 0.34558 
240 0.15474 0.12592 171 1.22888 0.2208 
 
-0.09381 0.40329 
255 0.40265 0.12592 171 3.19774 0.00165 * 0.1541 0.6512 
270 0.10928 0.12592 171 0.86785 0.38669 
 
-0.13927 0.35783 
285 0.00645 0.12592 171 0.05124 0.95919 
 
-0.2421 0.255 
300 0.18474 0.12592 171 1.46713 0.14418 
 
-0.06381 0.43329 
 
Table S16 ANOVA for PTP fEPSP amplitudes, preincubated in FAC, comparing 
post 1st and 2nd TBS in control vs. SCH23390 and Sulpiride – 
renormalized. 
Time - seconds post-TBS; Mean Dif. – 1
st
 TBS fEPSP amplitude subtracted from 2
nd
 TBS fEPSP 
amplitude; std. error – standard error; DF – degrees of freedom; t value – statistical t-value; prob>t – 
probability that t value is the same as expected; Sig. – does prob>t reach a significance of <0.05; 95% 
LCL – 95% lower confidence interval; 95% UCL – 95% upper confidence interval. 
  
250 
 
Time 
Mean 
Dif. 
Std. 
Error DF |t|value Prob>|t| 
Sig. 
95% LCL 95% UCL 
15 0.00133 0.06294 171 0.02111 0.98319 
 
-0.12291 0.12556 
30 -0.01074 0.06294 171 0.17057 0.86476 
 
-0.13497 0.1135 
45 -0.02116 0.06294 171 0.33626 0.73709 
 
-0.1454 0.10307 
60 0.06636 0.06294 171 1.05443 0.29317 
 
-0.05787 0.1906 
75 0.0763 0.06294 171 1.21233 0.22706 
 
-0.04793 0.20054 
90 0.0209 0.06294 171 0.332 0.74029 
 
-0.10334 0.14513 
105 0.04991 0.06294 171 0.79306 0.42884 
 
-0.07432 0.17415 
120 0.06067 0.06294 171 0.96398 0.33642 
 
-0.06356 0.18491 
135 0.03808 0.06294 171 0.60506 0.54594 
 
-0.08615 0.16232 
150 0.0286 0.06294 171 0.45441 0.65011 
 
-0.09564 0.15283 
165 -0.01999 0.06294 171 0.31768 0.75112 
 
-0.14423 0.10424 
180 0.11851 0.06294 171 1.88299 0.0614 
 
-0.00572 0.24275 
195 0.14559 0.06294 171 2.3133 0.0219 * 0.02136 0.26983 
210 0.18162 0.06294 171 2.88567 0.00441 * 0.05738 0.30585 
225 0.11363 0.06294 171 1.80535 0.07278 
 
-0.01061 0.23786 
240 -0.01016 0.06294 171 0.1615 0.87189 
 
-0.1344 0.11407 
255 -0.0403 0.06294 171 0.64037 0.52279 
 
-0.16454 0.08393 
270 0.0449 0.06294 171 0.71336 0.47659 
 
-0.07934 0.16913 
285 0.13119 0.06294 171 2.08439 0.03861 * 0.00695 0.25542 
300 -0.02058 0.06294 171 0.32691 0.74413 
 
-0.14481 0.10366 
 
Table S17 ANOVA for PTP PPR amplitudes, preincubated in FAC, comparing 
post 1st and 2nd TBS in control vs. SCH23390 and Sulpiride – both 
normalized to 1st baseline. 
Time - seconds post-TBS; Mean Dif. – 1
st
 TBS PPR amplitude subtracted from 2
nd
 TBS PPR amplitude; 
std. error – standard error; DF – degrees of freedom; t value – statistical t-value; prob>t – probability 
that t value is the same as expected; Sig. – does prob>t reach a significance of <0.05; 95% LCL – 95% 
lower confidence interval; 95% UCL – 95% upper confidence interval. 
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Time 
Mean 
Dif. 
Std. 
Error DF |t|value Prob>|t| 
Sig. 
95% LCL 95% UCL 
15 -0.0627 0.07202 171 0.87054 0.38522 
 
-0.20486 0.07947 
30 -0.08991 0.07202 171 1.24838 0.2136 
 
-0.23207 0.05225 
45 -0.09373 0.07202 171 1.30137 0.19488 
 
-0.23589 0.04844 
60 -0.01124 0.07202 171 0.15613 0.87612 
 
-0.15341 0.13092 
75 0.00624 0.07202 171 0.08661 0.93108 
 
-0.13593 0.1484 
90 -0.06335 0.07202 171 0.87956 0.38033 
 
-0.20551 0.07882 
105 -0.0263 0.07202 171 0.36517 0.71544 
 
-0.16846 0.11586 
120 -0.02538 0.07202 171 0.35245 0.72494 
 
-0.16755 0.11678 
135 -0.04519 0.07202 171 0.62747 0.53119 
 
-0.18735 0.09697 
150 -0.04333 0.07202 171 0.6016 0.54824 
 
-0.18549 0.09884 
165 -0.1122 0.07202 171 1.5579 0.1211 
 
-0.25436 0.02996 
180 0.0454 0.07202 171 0.63041 0.52927 
 
-0.09676 0.18757 
195 0.07932 0.07202 171 1.10138 0.27228 
 
-0.06284 0.22148 
210 0.12125 0.07202 171 1.68355 0.09409 
 
-0.02091 0.26341 
225 0.03836 0.07202 171 0.53257 0.59502 
 
-0.10381 0.18052 
240 -0.10483 0.07202 171 1.45556 0.14735 
 
-0.24699 0.03733 
255 -0.11984 0.07202 171 1.66404 0.09794 
 
-0.26201 0.02232 
270 -0.04578 0.07202 171 0.63569 0.52583 
 
-0.18795 0.09638 
285 0.0569 0.07202 171 0.79004 0.4306 
 
-0.08526 0.19906 
300 -0.09922 0.07202 171 1.37761 0.17013 
 
-0.24138 0.04295 
 
Table S18 ANOVA for PTP PPR amplitudes, preincubated in FAC, comparing 
post 1st and 2nd TBS in control vs. SCH23390 and Sulpiride – 
renormalized. 
Time - seconds post-TBS; Mean Dif. – 1
st
 TBS PPR amplitude subtracted from 2
nd
 TBS PPR amplitude; 
std. error – standard error; DF – degrees of freedom; t value – statistical t-value; prob>t – probability 
that t value is the same as expected; Sig. – does prob>t reach a significance of <0.05; 95% LCL – 95% 
lower confidence interval; 95% UCL – 95% upper confidence interval. 
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